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BRIEF REPORT
16th SNIP Conference, April 13–17, 2010
SNIP Administrative Meetings
Tuesday, April 13, 2010
1:00 PM Opening of Conference Office
3:00–4:00 PM SNIP Executive Committee Meeting (President’s Suite)
4:00–6:30 PM SNIP Meetings Committee
7:30 PM SNIP Council Dinner
Conference Scientific Program
Wednesday, April 14, 2010
8:30–9:00 AM Awards Committee
9:00–10:00 AM Finance Committee
10:00–11:00 AM Communications Committee
11:00 AM–Noon Membership Committee
Noon–1:15 PM Lunch
1:15–3:00 PM Council Meeting and Committee Reports
2:00 PM Conference Office opens
3:00–6:00 PM Registration Opens—Put up Posters for Session1
5:00–7:00 PM Opening Reception
5:00–7:00 PM POSTER SESSION I—Young Investigators Session
Please have ALL posters mounted on the poster boards BEFORE 5:00PM.
Odd numbered posters are to be presented from 5–6P M
Even numbered posters are to be presented from 6–7PM
Please remove posters at end of this session.
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DOI 10.1007/s11481-010-9196-97:15–9:15 PM Meet the Mentors Dinner: Hosted by Gayle Baldwin, Ph.D. (David Geffen School of Medicine at
UCLA) and the Young Investigator Travel Award Committee
Restricted to Young Investigators Who are Presenting Their Work at the Conference and Who Have a
Confirmed Reservation
Thursday, April 15, 2010
7:30–8:30 AM Continental Breakfast for Conference Registrants
Put up Posters for Poster Session II
8:30–8:40 AM INTRODUCTION TO THE MEETING
Welcome from the Society on NeuroImmune Pharmacology
Yuri Persidsky, M.D., Ph.D.—SNIP President
(Temple University School of Medicine, Philadelphia, PA)
–Acknowledgement of NIH Staff and Officials
–Acknowledgement of Key Sponsors, Committees and Chairs
Guy A. Cabral, Ph.D., Chairman, SNIP Meetings Committee (Virginia Commonwealth
University School of Medicine, Richmond, VA)
–Conference Overview & Business
8:45–9:25 AM PLENARY LECTURE I: Stuart Lipton, M.D., Ph.D.—Scientific Director, Burnham Center for
Neuroscience, Aging, and Stem Cell Research
8:45–8:50 Introduction by Yuri Persidsky, M.D., Ph.D.—SNIP President
(Temple University School of Medicine, Philadelphia, PA)
8:50–9:25 Lecture: “Molecular Mechanism of Decreased Adult Neurogenesis in the HIV-Infected Brain”
9:30 AM–12:00 SYMPOSIUM #1: Effects of HIV-1 in Promoting Alcohol Addiction and Mechanisms of Associated
Neurodegeneration
Session Co-Chairs: Yuri Persidsky, M.D., Ph.D.—Temple University School of Medicine,
Philadelphia, PA
He Li, Ph.D.—Tongji Medical College, Huazhong University of Science and
Technology, Wuhan, Hubei, People’s Republic of China
9:30–10:00 Symposium Lecture: Fulton T. Crews, Ph.D.—Director: Bowles Center for Alcohol Studies,
Pharmacology and Psychiatry, University of North Carolina–Chapel Hill
“Synergistic Effects of Alcohol and TLR Agonists in Neuroinflammation and Neurodegeneration”
10:00–10:25 Lecture 1: Kathleen A. Grant, Ph.D.—Senior Scientist, Oregon National Primate Research Center,
Portland, OR
“Longitudinal Analysis of Circulating Cytokines in a Monkey Model of Alcohol Self-Administration”
10:25–10:45 Coffee Break
S4 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S5910:45–11:10 Lecture 2: Consuelo Guerri, Ph.D.—Department of Cell Pathology, Centro de Investigacion Principe
Felipe, Valencia, Spain
“Critical Role of TLR4 Response in Ethanol-induced Microglia Activation and Neuroinflammation”
11:10–11:35 Lecture 3: Yuri Blednov, M.D., Ph.D.—Research Scientist, University of Texas in Austin
“Excessive Alcohol Consumption: An Inflammatory Disease? Lessons Learned from Mouse Models”
11:35–12:00 Lecture 4: Yuri Persidsky, M.D., Ph.D.—Temple University School of Medicine, Philadelphia, PA
“How HIV-1 CNS Infection Can Promote Alcohol Addiction”
12:00–1:00 PM Lunch on your own
1:00–2:00 PM SNIP Annual Business Meeting
All Society Members Welcome
2:00–4:00 PM POSTER SESSION II (Video Conference Room)
GENERAL POSTER SESSION
PROGRAM NOTE: Presenting authors for “odd-numbered” posters (T-1, T-3, T-5, etc.) should be at their posters
from 2:00–3:00P.M. to present their work and presenting authors for “even-numbered” posters (T-2, T-4, T-6, etc.)
should be at their posters from 3:00–4:00P.M. to present their work.
Please have ALL posters mounted on the poster boards BEFORE 2:00PM.
Coffee Break at 3:30 PM During Poster Session
Remove all posters at the end of the session.
4:00–6:00 PM SYMPOSIUM #2: Opiates, Other Drugs of Abuse and Co-Infections
Session Co-Chairs: Ing-Kang Ho, Ph.D.—National Health Research Institutes, Taiwan, R. O. C.
Kurt Hauser, Ph.D.—Virginia Commonwealth University, School of Medicine,
Richmond, VA
Symposium Talks:
4:00–4:25 Lecture 1: Kurt Hauser, Ph.D.—Department of Pharmacology and Toxicology, Virginia
Commonwealth University School of Medicine, Richmond, VA
“Coordinated Astroglial and Microglial Actions Mediate the Synergistic Inflammatory and
Neurodegenerative Effects of Opioids in HIV-1 Encephalitis”
4:25–4:50 Lecture 2: Joan Berman, Ph.D.—Departments of Pathology and of Microbiology and Immunology,
Albert Einstein College of Medicine, Bronx, NY
“Dopamine Exacerbates CNS Inflammation and HIV Infection”
4:50–5:15 Lecture 3: Jian-Guo Wu, Ph.D.—Director, State Key Laboratory of Virology, College of Life
Sciences, Wuhan University, Wuhan People’s Republic of China
“Inputs on Co-Infection of HIV and HCV”
5:15–5:40 Lecture 4: Zhengrong Wang, M.D.—Sichuan University, West China Medical College, Sichuan
Center for Disease Control, People’s Republic of China.
“HIV Infection and Drug Abuse in the Yi Ethnic Chinese of Sichuan”
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S56:00–7:00 PM Tacos and Beer—Sponsored by the UCLA Center for AIDS Research and UCLA AIDS Institute
7:00–9:05 PM UCLA CENTER FOR AIDS RESEARCH AND UCLA AIDS INSTITUTE SYMPOSIUM: HIV
and Host Immunity in the Design of Novel Therapeutic Approaches
Session Co–Chairs: Gayle Baldwin, Ph.D.—David Geffen School of Medicine at UCLA
Michael Roth, M.D.—David Geffen School of Medicine at UCLA
7:00–7:25 PM Lecture 1: Otto Yang, M.D., Ph.D.—“Obstacles to an HIV Vaccine”
7:25–7:50 PM Lecture 2: Christel H. Uittenbogaart, M.D.—“Impact of the Innate Immune Response on HIV
Infection
7:50–8:15 PM Lecture 3: Dung Sung An, M.D., Ph.D.—“Gene Therapy: A Potential Approach to Eradicate HIV–1
Infection”
8:15–8:40 PM Lecture 4: Scott Kitchen, Ph.D.—“Engineering HIV-specific T Cell Immunity”
8:40–9:05 PM Lecture 5: Raphael J. Landovitz, M.D.—“A Combined Biobehavioral Intervention for HIV
Prevention in Methamphetamine-using Men who have Sex
with Men”
Friday, April 16, 2010
7:30–9:00 AM Continental Breakfast for Conference Registrants
9:00–11:30 AM SYMPOSIUM #3: Nanomedicine and Drug Delivery
Session Co-Chairs: Howard E. Gendelman, M.D.—Chair, Department of Pharmacology and
Experimental Neuroscience, University of
Nebraska Medical Center, Omaha, NE
Philip S. Low, Ph.D.—Ralph C. Corley Distinguished Professor–Biochemistry,
Purdue University, West Lafayette, IN
9:00–9:45 Symposium Lecture: Andre Nel, Ph.D.—Chief, Division of Nanomedicine, UCLA David Geffen
School of Medicine UCLA, Los Angeles, CA
“An Overview of Nanomedicine”
9:45–10:05 Lecture 1: Alexander V. Kabanov, Ph.D., Dr. Sc.—Director, Center for Drug Discovery and
Nanomedicine, University of Nebraska Medical Center, Omaha, NE
“Nanomedicines for Polypeptide Delivery to the CNS”
10:05–10:25 Lecture 2: Philip S. Low, Ph.D.—Ralph C. Corley Distinguished Professor–Biochemistry, Purdue
University, West Lafayette, IN
“Use of Targeting Ligands to Deliver Therapeutic Agents to Pathologic Cells”
10:25–10:45 Coffee Break
10:45–11:05 Lecture 3: Madhavan Nair, Ph.D.—Director, Center for Neuroimmune Pharmacology, College of
Medicine, Florida International University, Miami, FL
“Multifunctional Magnetic Nanocarrier for Drug Targeting of Brain”
S6 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S5911:05–11:25 Lecture 4: Howard E. Gendelman, M.D.—Chair, Department of Pharmacology and Experimental
Neuroscience, University of Nebraska Medical Center,
Omaha, NE
“NanoArt”
11:30–Noon PICK UP LUNCHES
12:00–1:00 PM TECHNICAL WORKSHOP: New NIH Initiatives, Grant Writing & Review Process
Session Co-Chairs: David Shurtleff, Ph.D. (NIDA/NIH)/Abraham Bautista, Ph.D. (NIAAA/NIH)
David Shurtleff, Ph.D.—Division of Basic Neuroscience and Behavioral Research/(NIDA/NIH)
Abraham Bautista, Ph.D.—Director, Office of Extramural Activities/ (NIAAA/NIH)
Srinivas Ranga, Ph.D.—Extramural Project Review Br./(NIAAA/NIH)
1:00–2:05 PM YOUNG INVESTIGATOR’S SYMPOSIUM
Session Co-Chairs:
Gayle Baldwin, Ph.D.—David Geffen School of Medicine at UCLA
Albert Avila, Ph.D.—Division of Basic Neuroscience and Behavioral Research/NIDA
1:00–1:05 Introduction to the YITA Symposium
Pre–Doctoral Presentations:
1:05–1:20 Xiuyan Huang—Department of Pharmacology and Experimental Neuroscience, University
of Nebraska Medical Center, Omaha, NE
“Functional Proteomic Analyses of CD4
+ T Lymphocyte Surveillance of the HIV-1 Infected
Macrophage”
1:20–1:35 Sody Mweetwa Munsaka—Neuroscience and MR Research Program, University of Hawaii,
John A. Burns School of Medicine, Honolulu, HI
“Marijuana Use Worsens Cognitive Function but Does Not Change CSF Immune Markers in
Subjects without HIV Associated Neurocognitive Disorder (HAND)”
Post-Doctoral Presentations:
1:35–1:50 Ming Zhang, M.D., Ph.D.—Department of Physiology, Temple University School of Medicine,
Philadelphia, PA
“A Cannabinoid CB2 Agonist Attenuated Leukocyte-Brain Endothelial Interaction and Blood–
Brain Barrier Dysfunction Under Inflammatory Conditions”
1:50–2:05 P. J. Gaskill, Ph.D.—Departments of Pathology and of Microbiology and Immunology, Albert
Einstein College of Medicine, Bronx, NY
“Mechanisms of Dopamine-Mediated Increase in HIV Infection of Human Macrophages”
2:15–7:00 PM Free Time or Trip to Getty Museum
7:00–9:30 PM Journal of Neuroimmune Pharmacology Editorial Board Meeting
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7:30–9:00 AM Continental Breakfast for Conference registrants
9:00–9:55 AM PLENARY LECTURE II: Vincenzo Di Marzo, Ph.D.—Istituto di Chimica Biomolecolare,
Consiglio Nazionale delle Ricerche, Pozzuoli, Italy
9:05–9:10 Introduction by Guy Cabral
9:10–9:50 “Endocannabinoids and Related Lipid Mediators: A General Introduction and Emerging
Role in Neuroinflammatory Disorders”
10:00–12:00 AM SYMPOSIUM #4: Neuroimmunopharmacology and the Cannabinoid System
Session Co-Chairs: Martin Adler, Ph.D.—Temple University School of Medicine, Philadelphia, PA
Guy A. Cabral, Ph.D.—Department of Microbiology and Immunology,
Virginia Commonwealth University, School of Medicine,
Richmond, VA
10:00–10:20 Lecture 1: R. Bryan Rock, M.D.—Department of Medicine, University of Minnesota Medical Center,
Minneapolis, MN
“Protective Role of Synthetic Cannabinoids in gp120-induced Neurotoxicity”
10:20–10:40 Coffee Break
10:40–11:00 Lecture 2: Aron Lichtman, Ph.D.—Virginia Commonwealth University School of Medicine,
Richmond, VA
“Targeting Endocannabinoid Catabolic Enzymes to Treat Inflammatory Pain”
11:00–11:20 Lecture 3: Norbert Kaminski, Ph.D.—Department of Pharmacology and Toxicology, Michigan State
University, East Lansing, MI
“Enhanced Anti-influenza Immune Responses Are Associated with Targeted Deletion of both
Cannabinoid Receptors, CB1 and CB2”
11:20–11:40 Lecture 4: Ronald Tuma, Ph.D.—Temple University School of Medicine, Philadelphia, PA
“SR141716A, Unexpected Actions”
11:45–12:45 AM Pick-up box lunches
12:45–2:30 PM SYMPOSIUM #5: Recent Advances in the Activities of Tobacco Smoke
Session Co-Chairs: Thomas Rogers, Ph.D.—Temple University School of Medicine,
Philadelphia, PA
Mohan Sopori, Ph.D.—Lovelace Respiratory Research Institute,
Albuquerque, NM
Symposium Talks:
12:45–1:05 PM Lecture 1: Thomas Rogers, Ph.D.—Temple University School of Medicine, Philadelphia, PA
“The Immunopathology Associated with Cigarette Smoking: It May Be Worse than you Think”
1:05–1:55 Lecture 2: Nancy Kerkvliet, Ph.D.—Oregon State University, Corvallis, Oregon
“Immunoregulation by the Aryl Hydrocarbon Receptor (AHR)”
S8 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S591:55–2:15 Lecture 3: Imad Damaj, Ph.D.—Department of Pharmacology and Toxicology, Virginia
Commonwealth University, Richmond, VA
“Differential Contribution of Neuronal Nicotinic Acetycholine Receptors to Nicotine Dependence:
Recent Progress and Emerging Opportunities”
2:15–2:35 Lecture 4: Mohan Sopori, Ph.D.—Lovelace Respiratory Research Institute, Albuquerque, NM
“Role of GABA Receptors in Cigarette Smoke/Nicotine-induced Chronic Bronchitis”
2:35–3:00 Coffee/Tea Break
3:00–4:40 PM SYMPOSIUM #6: Epigenomic Regulation in Neuroscience and HIV Infection
Session Co-Chairs: Diane Lawrence, Ph.D.—National Institute on Drug Abuse, National Institutes
of Health
Howard Fox, Ph.D., M.D.—University of Nebraska Medical Center, Omaha, NE
Symposium Talks:
3:00–3:20 Lecture 1: Yi Sun, Ph.D.—Associate Academic Director, Broad Center for Stem Cell Research,
Molecular and Medical Pharmacology, UCLA
“DNA Methylation and Neuronal Differentiation”
3:20–3:40 Lecture 2: Lisa Monteggia, Ph.D.—Department of Psychiatry, UT Southwestern Medical Center
at Dallas
“Role of Histone Deacetylases (HDACS) in Regulating Synapse Function“
3:40–4:00 Lecture 3: Melanie Ott, M.D., Ph.D.—Gladstone Institute of Virology and Immunology, University
of California, San Francisco
“Regulation of HIV Transcription by Tat Methylation”
4:00–4:20 Lecture 4: Sowmya V. Yelamanchili, Ph.D.—University of Nebraska Medical Center, Omaha, NE
“Dysregulation of Neuronal MicroRNA Expression in SIV/HIV Associated Neurological Disease”
4:20–4:40 Lecture 5: Kenneth Witwer—Molecular and Comparative Pathobiology, The Johns Hopkins
University, Baltimore, MD
“IFNβ-modulating MicroRNAs in Lentivirus-associated CNS Disease”
7:00–10:00 PM EVENING BANQUET AND AWARDS CEREMONY
Hosted by Toby Eisenstein, Ph.D.—incoming SNIP President
Special Dinner Presentation: Patricia Molina, M.D., Ph.D.—Louisiana State University Health
Science Center, New Orleans, LA
“Alcohol, Drugs of Abuse, and HIV: Beyond Risk Factors”
Meeting Adjourned!
Sunday, April 18, 2010—Departure Day
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Gene Therapy: A Potential Approach to Eradicate HIV
Infection. DA n
1, S Shimizu
1, P Hong
1, B Arumugam
1,
L Pokomo
1, J Boyer
1, N Koizumi
1, K Kittipongdaja
1,
A Chen
1, G Bristol
1, Z Galic
1, J Zack
1, O Yang
1, I Chen
1,
B Lee
1;
1UCLA AIDS Institute, University of California at
Los Angeles, Los Angeles, CA 90095
Stable inhibition of the HIV-1 co-receptor CCR5 expression
holds great promise for controlling and potentially eradi-
cating HIV-1 infection in patients. We succeeded in stably
knocking down human CCR5 cell surface expression by a
short hairpin RNA (shRNA) in a human bone marrow/liver/
thymus (BLT) transplanted mouse model. We delivered a
potent shRNA against CCR5 into human CD34
+ hemato-
poietic progenitor/stem cells (HPSCs) by lentiviral vector
transduction. We transplanted vector-transduced human
HPSCs solidified with matrigel and a thymus segment
under the mouse kidney capsule. Vector-transduced autol-
ogous CD34
+ cells were subsequently injected in the
irradiated mouse intended to create systemic reconstitution.
CCR5 expression was down-regulated in human T cells and
monocytes/macrophages in systemic lymphoid tissues,
including gut associated lymphoid tissue, the major site of
HIV-1 replication. The shRNA-mediated CCR5 knockdown
had no apparent adverse effects on T cell development as
assessed by polyclonal T cell receptor V? family develop-
ment and naïve/memory T cell differentiation. CCR5
knockdown in the secondary transplanted mice suggested
the potential of long-term hematopoietic reconstitution by
the shRNA-transduced HSPCs. CCR5 tropic HIV-1 infec-
tion was effectively inhibited in mouse-derived human
splenocytes ex vivo. These results demonstrate that lenti-
viral vector delivery of shRNA into human HPSCs could
stably down-regulate CCR5 in systemic lymphoid organs in
vivo. Supported by NHLBI 1R01HL086409, NCI
CA086306, UCLA CFAR NIAID AI028697
Dopamine Exacerbates CNS Inflammation and HIV
Infection. JW Berman
1;
1Departments of Pathology,
Microbiology & Immunology, Albert Einstein College of
Medicine, Bronx, NY 10461
Many HIV-infected substance abusers have exacerbated and
accelerated CNS disease and subsequent dysfunction.
Drugs of abuse, including cocaine and methamphetamine,
cause increased levels of extracellular dopamine. Thus, we
examined dopamine-mediated alterations in CNS functions
that could contribute to the neuropathology characteristic of
HIV-infected drug abusers. We demonstrate that dopamine
significantly increases chemokine-mediated T cell transmi-
gration across our tissue culture model of the blood–brain
barrier (BBB) and that dopamine alters BBB tight junction
proteins that could result in increased CNS inflammation.
Several other genes whose products participate in barrier
function and inflammation were altered by dopamine, as
demonstrated by gene arrays. Additionally, we show that
dopamine increases HIV infection of human macrophages,
the major cell target of HIV in the brain, through activation,
in part, of the D2 receptor This results in an increased
number of HIV-infected cells. Preliminary data indicate that
one of the mechanisms by which dopamine increases
infection is by increased viral entry. Dopamine alters
several signaling molecules in macrophages, including
MAP kinase pathways, which also may mediate macro-
phage dysfunction in the HIV-infected brain. Thus, we
demonstrate several mechanisms by which elevated levels
of extracellular dopamine in the CNS in the context of HIV
infection contribute to the exacerbated neuropathogenesis
and subsequent cognitive impairment in the drug-abusing,
HIV-infected population. Supported by NIDA
Excessive Alcohol Consumption: An Inflammatory
Disease? YA Blednov
1, RA Harris
1;
1Waggoner Center for
Alcohol and Addiction Research, University of Texas,
Austin, TX 78712
Genes classified as “immune/stress response” form one of
the most prominent functional groups with differential
expression in frontal cortex of alcoholics in comparison to
non-alcoholics (Liu et al. 2006). In addition, our ongoing
analysis of brain gene expression in mice that are
genetically predisposed to high alcohol consumption
indicates an important role for pro-inflammatory mediators
in regulating alcohol intake (Mulligan et al. 2006). We
hypothesized that the normal functioning of the immune
system maintains drinking at “social” levels, whereas
activation of the immune system promotes excessive
alcohol consumption. This is based on our new findings
that null mutant mice with impaired immunity drink less
alcohol (Blednov et al., RSA poster 2009). Our initial
studies with C57Bl/6 inbred mice have shown that injection
of lipopolysaccharide (LPS, 1 mg/kg, i.p.) promotes alcohol
consumption. Such effect on alcohol consumption was
long-lasting and was observed at least 3 month after LPS
treatment. This increase of alcohol intake could not be
explained by changes in taste (sweet or bitter) perception or
olfactory recognition of ethanol. However, the lack of
CD14, a key component of the TLR4 signaling pathway
(CD14 knockout mice), completely prevented the increase
of alcohol intake after treatment with LPS. Our results show
that activation of an immune response, via TLR4, produces
a long-lasting increase in voluntary alcohol intake even in a
strain of mice with genetically elevated alcohol intake.
S10 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59Supported by NIAAA/AA U01 13520-INIA Project;
AA06399
Ethanol-TLR Synergistic Induction of Innate Immune
Responses Leads to Persistent Brain Neuroinflammatory
Gene Induction, Oxidative Stress, and Neurodegeneration.
FT Crews
1;
1Bowles Center for Alcohol Studies, University
of North Carolina School of Medicine, Chapel Hill, NC
27599-7178
Alcoholic pathology includes liver disease, neurodegenera-
tion, and dysfunctional cytokine cascades. Ethanol (5 g/kg,
i.g., daily for 10 days) pretreatment followed by LPS, a TLR4
agonist, increases liver, serum, and brain levels of TNF-alpha,
MCP-1, IL-6, as well as other protease and oxidase innate
immune genes and microglial markers. Similarly, ethanol
pretreatment preceding poly I:C, TLR3 viral mimetic,
increases TNF-alpha (345%), IL-1-beta (331%), IL-6
(167%), and MCP-1(190%) compared with poly I:C alone
treatment. Brain innate immune gene induction persists long
after systemic levels decline. A component of the brain innate
immune response involves NOX, an enzyme that produces
reactive oxygen species (ROS). Ethanol-LPS or poly I:C
increasesNOX,productionofROS,microglialactivation,and
neurodegeneration as shown by caspase-3 activation and
Fluoro-Jade B staining. ROS in neurons showing neurotox-
icity are blocked by diphenyleneiodonium, a non-specific
NOX inhibitor. Dopamine neurons are followed over long
periods. Persistent brain ROS following transient systemic
insults show no marked change until at 7 months, a 23%
decrease progresses to 47% by 10 months. Motor deficits at
10 months are reversed by L-DOPA. NOX-deficient (NOX
−/−)
mice do not show TH neuron loss. Markers of neuro-
inflammation are broadly reduced, including Iba1-activated
microglial morphology, levels of TNF-alpha, and other pro-
inflammatory genes. Together, these results suggest that
ethanol induction of innate immune genes, particularly
NOX, leads to ROS and neurotoxicity. Supported by NIAAA
Differential Contribution of Neuronal Nicotinic
Acetylcholine Receptors to Nicotine Dependence:
Recent Progress and Emerging Opportunities. MI
Damaj
1;
1Pharmacology, Virginia Commonwealth
University, Richmond, VA 23298
Nicotine dependence (ND), a major public health challenge,
is a complex and multifactorial behavior. Neuronal nicotin-
ic acetylcholine receptors (nAChRs) can regulate the
activity of many neurotransmitter pathways throughout the
central nervous system and are considered to the primary
site of action in the brain for nicotine, the major addictive
component of tobacco smoke. nAChRs consist of five
membrane-spanning subunits (alpha and beta isoforms) that
can associate in various combinations to form functional
nAChR ion channels. Until recently, most research on the
role of nAChRs in ND has focused on alpha4 beta2*, and
not much attention has been paid to the possible contribu-
tion of the other brain nAChR subunits. This situation has
changed dramatically in the last several years during which
intensive research using the genetically modified mice and
human genetics analysis have addressed the issue. In this
presentation, we highlight recent findings regarding the
contribution of non-alpha4/beta2-subunit containing
nAChRs to ND based on several lines of evidence: (1)
human genetics studies, (2) differential pharmacological
and biochemical properties of receptors containing these
subunits, and (3) evidence from genetically manipulated
mice. Combining neurobiological genetic and behavioral
perspectives, we suggest that ND is not linked to one or
two specific nAChR subtypes but to several. In particular,
the alpha3, alpha5-6, and beta3-4 nAChR subunits may
play a much more pivotal role in the neurobiology of ND
than was appreciated earlier. Supported by NIH
Endocannabinoids and Related Lipid Mediators: A General
Introduction and Emerging Role in Neuroinflammatory
Disorders. V Di Marzo
1;
1Institute of Biomolecular Chemistry,
Consiglio Nazionale delle Ricerche, Pozzuoli, 80078
The identification of the psychoactive constituent of
Cannabis, delta9-tetrahydrocannabinol, led to the cloning
of the G-protein-coupled cannabinoid CB1 and CB2
receptors for this compound and to the isolation and
characterization of their endogenous agonists, the endocan-
nabinoids (eCBs), of which anandamide and 2-
arachidonoylglycerol (2-AG) are the two most studied
representatives. CB receptors, eCBs, and enzymes control-
ling eCB levels constitute the eCB system (eCBS). CB1
receptors are very abundant in neurons, whereas CB2
receptors are mostly found in immune cells and become
over-expressed in the brain during neuroinflammatory
disorders. The eCBs, and 2-AG in particular, act via CB1
as local neuromodulators and participate in the retrograde
control of synaptic activity. On the other hand, CB2
receptors modulate microglia and astrocyte migration and
the release of pro- and anti-inflammatory cytokines. The
eCBS plays a major and possibly dual role in neuro-
inflammatory disorders. They first become activated fol-
lowing excitotoxicity and neuronal damage in an attempt to
exert a pro-homeostatic, neuroprotective function and possi-
bly regulate microglial and astrocyte activity in a site- and
time-specific manner. However, during neurodegenerative
disorders with self-feeding inflammatory responses, as in the
latephasesofAlzheimer’san dParki ns on’s diseases, the eCBS
becomes dysregulated and start contributing to the symptoms.
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S11These observations might open the way to the therapeutic use
of both “enhancers” and “curbers” of eCB levelsand action in
these disorders.
NanoART Manufacture, Delivery, and Pharmacokinetics
for Optimizing Drug Adherence. HE Gendelman
1,A V
Kabanov
2,H SF o x
1, C Fletcher
2, Y Alnouti
1, S Swindells
1,
RL Mosley
1, G Kanmogne
1, L Poluektova
1,MB o s k a
1,
A Anderson
1,AN o w a c e k
1,JM c M i l l a n
1;
1Colleges of
Medicine and
2Pharmacy, University of Nebraska Medical
Center, Omaha, NE 68198-5880
While antiretroviral therapy (ART) leads to improved
morbidity and reduced mortality for HIV-1-infected people,
a major limitation rests in the need for lifelong daily
regimens. Suboptimal adherence causes increased risk of
treatment failure. Drug abuse disorders correlate with such
sporadic adherences commonly resulting in accelerated
HIV disease progression. Providers are often reluctant to
prescribe ART to patients who abuse or are addicted to
drugs because of concerns about the promotion of virologic
resistance. These risk factors often result in poor treatment
outcomes. The advent of slow-release ART (ritonavir,
indinavir, efavirenz, atazanovir, and efavirenz) will posi-
tively impact these concerns. Thus, our laboratories are
developing antiretroviral nanoparticles (nanoART) that are
carried within circulating immunocytes and delivered to
virus target tissues. Cell-based nanoART can travel to sites
of inflammation and release drug slowly with limited tissue
toxicities. We posit that such a drug delivery system, if
realized, can revolutionize ART treatment outcomes partic-
ularly those within the nervous system. This lecture
describes works conducted in our laboratories demonstrat-
ing “proof of concept” in that a single nanoART dose can
elicit high-sustained tissue and plasma drug levels in the
reticuloenthelial system and brain. NanoART can be taken
up within minutes by circulating monocytes and released in
tissues for more than 2 weeks. This process is monitored by
cell biologic, pharmacologic, virologic, and molecular
testing and shows potential for human use. Supported by
NINDS, NIDA, and NIMH
Longitudinal Analysis of Circulating Cytokines in a Monkey
Model of Chronic Alcohol Self-Administration. KA Grant
1,
WM Freeman
2,K EV r a n a
2;
1Oregon National Primate Research
Center, Oregon Health & Sciences University, Portland, OR
97006,
2Department of Pharmacology, Penn State College of
Medicine, Hershey, PA 17033
Alcohol abuse and alcoholism is the third major cause of
preventable death in the USA. Heavy alcohol consumption
alters immune system function, but a complete character-
ization of these changes is not yet known. Studies with
human subjects are limited due to an unknown pre-alcohol
state and quantifying total alcohol consumption. Animal
models help bridge this gap. Here, we report on ten adult
male cynomolgus monkeys that were induced to drink
ethanol with a standard procedure and given over 12 months
of daily sessions with the choice of drinking ethanol (4%,
w/v, in water) or water for 22 h/day. Daily mean intakes
were 2.8 g/kg (about 12 drinks/day), and mean blood
ethanol levels 7 h after the onset of the session was 102 mg/
dl. In a directed proteomic screening approach, Luminex
technology was used to query 90 different protein and
peptides, including cytokines (Rules Based Medicine,
Austin TX). Sixty of the 90 proteins were detected using
the human assay. Of these, 15 cytokines changed signifi-
cantly over the course of drinking, measured at baseline,
post-induction, 6 months, and 12 months of 22 h/day access
to ethanol. Some, such as IL-7 and IL-13, were increased,
whereas most were decreased. Furthermore, cytokines had
different “threshold doses” for change, with some altered
during the low doses consumed during induction and others
requiring 12 months of heavy drinking to be significantly
changed. Overall, the data suggest a complex effect of
chronic alcohol drinking on circulating cytokines, most
likely involving pathological changes in liver, heart, bone,
and brain. Supported by National Institute on Alcohol
Abuse and Alcoholism AA 13510, 13641, 16613
Critical Role of TLR4 Response in Ethanol-Induced
Microglia Activation and Neuroinflammation. C Guerri
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Toll-like receptors (TLRs) play an important role in the
innate immune response. Activation of TLRs triggers the
stimulation of glia, production of inflammatory mediators,
neuroinflammatory damage, and neurodegeneration. Alco-
hol abuse induces brain damage and can sometimes lead to
neurodegeneration. We recently found that ethanol induces
microglia activation and phagocytosis to trigger the
production of inflammatory mediators which cause neuro-
nal death. We showed that TLR4 is critical for ethanol-
induced inflammatory signaling in microglial cells since
knockdown of TLR4 by either using siRNA or by using
cells from TLR4-deficient mice abolished the activation of
MAPKs and NFkappaB pathways and the production of
inflammatory mediators by microglia. Our recent results in
mice show that chronic ethanol intake by wild-type mice
up-regulates CD11b (microglial marker) and glial fibrillary
S12 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59acidic protein (astrocyte marker) and increases caspase-3
activity, iNOS, COX-2, and several cytokines in cerebral
cortex. The deficiency of TLR4 (TLR4
−/− mice) protects
against ethanol-induced glial activation, hampering the
induction of inflammatory mediators and of apoptosis.
These findings not only provide the first evidence for the
critical role of the TLR4 response in ethanol-induced
neuroinflammation but also new insight into the mecha-
nisms participating in ethanol-induced brain injury and
possible neurodegeneration. Supported by MCI, SAF 2006-
02178 and SAF 2009-07503
Coordinated Astroglial and Microglial Actions Mediate
the Synergistic Inflammatory and Neurodegenerative
Effects of Opioids in HIV-1 Encephalitis. KF Hauser
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Opioids reportedly exacerbate HIV encephalitis (HIVE).
We find that morphine enhances the neurotoxicity of Tat
and gp120 in vitro and observe that this relates to the
presence of glia. Opioids can exacerbate viral protein-
induced cytokine and/or oxyradical production uniquely in
glia (astroglia and microglia). To assess the role of glia in
mediating the interactive neurotoxicity, neurons were
cultured alone or with glia enriched in astrocytes from
wild-type or mu opioid receptor (MOPr) null mice. Cell
culture paradigms included (1) transwell cultures with glia
physically separated from neurons; (2) neurons and glia
physically separated by specific distances; and (3) co-
cultures with neurons and glia in contact. Results showed
that (1) HIV Tat or gp120 were intrinsically neurotoxic
irrespective of glial proximity, while (2) morphine-
enhanced Tat/gp120 neurotoxicity was entirely dependent
on proximity to glia, and (3) the synergistic neurotoxicity
was abolished when neurons were cultured with MOPr null
glia. Thus, morphine’s ability to potentiate Tat or gp120-
induced neurotoxicity seems completely dependent upon
the presence of MOPr
+ glia. We propose that opioids and
HIV-1 Tat/gp120 act synergistically to directly destabilize
glial function and that aberrant glia-neuron signaling causes
neuron injury and dysfunction. Our results provide insight
into the cellular basis by which opioids exacerbate HIVE.
MOPr-expressing glia, and not neurons, may be the most
logical targets for therapeutic intervention for HIV–opioid
abuse comorbidity. Supported by NIH NIDA DA19398,
DA18633
Functional Proteomic Analyses of Cd4
+ T Lymphocyte
Surveillance of the HIV-1 Infected Macrophage. XY
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Macrophages orchestrate immune responses that include
microbial clearance, presentation of antigens, and secretion
of bioactive molecules. Paradoxically, they also act as
reservoirs and vehicles for microbial pathogen dissemina-
tion including HIV. Moreover, macrophages, as biological
response modifiers, influence disease progression. We
demonstrated that both effector T cells (Teff) and regulatory
T cells (Treg) affect neuroAIDS. Treg inhibits macrophage
activation, enhances apoptosis, and reduces viral produc-
tion. Teff showed contrary effects except for killing infected
macrophage. To elucidate the molecular mechanisms for
these effects, we used iTRAQ to study quantitative changes
in the proteome of virus-infected macrophages during cell–
cell interactions with Teff or Treg. In these studies, HIV-1/
VSV pseudotypes were used to infect murine bone marrow
macrophages. Expectedly, both Teff and Treg modulated
virus-infected macrophage proteins associated with cell
structure, metabolism, and redox biology. Surprisingly, they
enhanced virus-specific immune response by upregulation
of interferon-inducible proteins (GBP2, STAT1, and
ISG15). HIV-1 infection triggered caspase-1 activation.
This response was enhanced by Teff and attenuated by
Treg, resulting in pyroptosis and apoptosis, respectively.
Taken together, we posit that Treg possess regulatory and
effector functions for virus-infected macrophages. Our
results challenge the dogma that Treg functions exclusively
as suppressor and provide undisclosed mechanisms of
adaptive immune surveillance during HIV-1 infection.
Nanomedicines for Polypeptide Delivery to CNS. AV
Kabanov
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Polypeptides can positively affect outcomes of central
nervous system (CNS)-related diseases, but their entry into
the brain is commonly restricted. One example is leptin, a
candidate for treatment of epidemic obesity that has failed.
A major cause of its failure is unfavorable pharmacokinet-
ics and peripheral resistance—loss of leptin ability to cross
the blood–brain barrier (BBB) and so reach its receptors in
the arcuate nucleus of the hypothalamus. We produced a
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S13conjugate of leptin with Pluronic P85 (P85-LepA) that has
a long half-life, is enzymatically resistant in blood and
brain, and retains biological activity. The P85-LepA crosses
the BBB by a mechanism independent of the leptin
transporter and was shown to be effective in the ob/ob
mouse and mice with diet-induced obesity. Therefore, P85-
LepA may be effective when normal transport of leptin
across BBB is impaired. Another example is RedOx
enzymes, such as Cu/Zn superoxide dismutase (SOD1),
which have potential to mitigate oxidative stress in CNS.
We incorporated SOD1 into polyion complexes with
cationic block copolymers. Such complexes (nanozymes)
were shown to increase stability, circulation half-life, and
brain delivery of active SOD1 after peripheral administra-
tion. The intracarotid injection of SOD1 nanozyme greatly
attenuates AngII pressor response in conscious rabbits after
chronic heart failure. Therefore, SOD1 nanozymes have
potential for the treatment of cardiovascular diseases
associated with the dysregulation of brain angiotensinergic
signaling, particularly hypertension and chronic heart
failure. Supported by National Institutes of Heath (RO1
NS051335, 1P20RR021937)
Enhanced Anti-influenza Immune Responses are Associated
with Targeted Deletion of Both Cannabinoid Receptors,
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The focus of these studies was to ascertain the role of
cannabinoid receptors (CB) in the antiviral immune
response to a single non-lethal challenge with A/PR8/34,
an H1N1 strain of influenza, by comparing mice null for
both CB1 and CB2 (KO) to wild-type (WT) C57Bl/6. KO
mice infected with PR8 exhibited markedly less viral H1
mRNA in lungs compared to WT, suggesting more rapid
clearance of virus in KO mice. Flow cytometric analysis of
BALF on day7 also showed significantly greater numbers
of CD8
+ T cells in PR8-infected KO versus WT mice.
Based on these observations, times earlier than 7 days post-
infection were investigated. Consistent with preliminary
observations, bronchoalveolar lavage fluid (BALF)
contained a greater immune cell infiltrate in KO mice
compared to WT, with the highest magnitude at day3 post-
challenge. Differential staining of BALF showed an
increase in both macrophages and neutrophils, with the
latter being statistically significant in KO compared to WT.
In lung tissue, CD69 surface expression and IFN-gamma
intracellular staining was increased in CD4
+ T cells from
KO as compared to WT on day3. In addition, the CD8
+ T
cell response was more rapid as determined by the presence
of CD8
+ IFN-gamma
+ as early as day3 in KO versus day7
in WT post-influenza challenge. In conclusion, the magni-
tude of CD4
+ T cell and inflammatory responses was
greater and CD8
+ T cell response was accelerated in KO
compared to WT mice. Supported by NIH DA07908 and
NIH DA12740
Immunoregulation by the Aryl Hydrocarbon Receptor
(AHR). NI Kerkvliet
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AhR is a cytoplasmic ligand-binding protein that partners
with nuclear ARNT (Hif1b) to function as a transcription
factor regulating gene expression. Activation of the AhR by
its most potent ligand, TCDD, results in severe immune
suppression in mice that has recently been associated with
the induction of regulatory T cells (Treg). AHR-induced
Tregs appear to underlie the potent suppression of the graft
vs. host (GVH) response in TCDD-treated mice as well as
suppression of autoimmune diseases such as type 1 diabetes
in NOD mice and EAE. Current studies are focused on
identifying the genes that are regulated by AhR activation
in CD4
+ T cells treated with TCDD that drive the Treg
pathway. A genetic fingerprint of this pathway will provide
mechanistic insight into the signaling pathways that
underlie the potent immunosuppressive activity of TCDD
and related chemicals of concern due to environmental
exposure. This fingerprint will also be useful for identifying
alternative AHR ligands that might find clinical application
in the treatment of immune-mediated diseases. Supported
by NIH/NIEHS
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The human immunodeficiency virus (HIV) has a profound
effect on lymphoid cells in an infected individual. A
therapeutic strategy that contributes to the antiviral immune
response and allows protection and reconstitution of these
cells could have important implications in the treatment and
clinical prognosis of an infected individual. We seek to
genetically manipulate human hematopoietic stem cells to
target HIV-infected cells following their differentiation into
mature CTL. To perform this, we have examined the ability
of human stem cells to generate mature CD8
+ cytotoxic T
lymphocytes (CTLs) that express an anti-HIV T cell
receptor (TCR). We have utilized a TCR specific for the
SL9 peptide, a conserved region in the HIV gag protein
sequence. To demonstrate that a “transgenic” TCR can
function in the context of human cells, CD34
+ human
S14 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59hematopoietic progenitor cells were genetically modified
and allowed to develop in humanized mice. We determined
that the expression of the anti-HIV TCR allows gag-
specific tetramer binding and induces preferential lineage
commitment towards CD8
+ mature thymocytes. In addition,
we demonstrate that these cells can functionally respond to
SL9 peptide stimulation. This system has demonstrated that
a human transgenic TCR can undergo T lineage develop-
ment and produce an antigen-specific, functional CTL.
These results have strong implications in the use of this
technology to engineer the human immune response to
combat viral infections and suggest that genetic engineering
via stem cells may allow tailoring of the immune response.
Supported by CIRM, NIH
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Background: In Los Angeles, methamphetamine (MA)-
using men who have sex with men (MSM) are 2.4 times
more likely to acquire HIV infection (8%) than non-using
MSM (3%). Post-exposure prophylaxis (PEP) after sexual
exposure to HIV has not been studied among MA-using
MSM due to historically poor medical adherence. This
study provided a drug reduction intervention for MA-using
MSM at high risk for HIV infection to facilitate adherence
to PEP following exposure to HIV. A prospective single-
arm, open-label, pilot safety and feasibility study using
contingency management (CM, voucher-based incentives to
support MA abstinence) with PEP to prevent seroconver-
sion among MA-using MSM. Between March 2009 and
January 2010, 32 participants enrolled. Mean age was 35
(SD 7.7), race/ethnicity was mostly Caucasian/White
(60%), or Latino (30%), the majority identified as gay
(87%), most had a high school diploma or bachelor’s
degree (90%), and most earned less than $15,000 per year
(57%). Participants reported elevated historical rates of
chlamydia (33%), gonorrhea (40%), and syphilis (20%). At
baseline, participants had high rates of chronic hepatitis B
(7%), syphilis (7%), gonorrhea (7% pharyngeal; 3% rectal),
and chlamydia (7% rectal; 3% urethral). Twenty-one of the
32 participants (66%) initiated PEP. Median time from
high-risk exposure to PEP initiation was 37 h (range, 14–
68). Among evaluable participants (n=19), mean medica-
tion adherence was 75% (SD 37.7). Although a small
sample size, no incidence seroconversions were observed.
Supported by Los Angeles County Office of AIDS
Programs and Policy/NIDA K23DA026308
Targeting Endocannabinoid Catabolic Enzymes to Treat
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The endocannabinoid system consists of the naturally occur-
ring ligands anandamide (AEA) and 2-arachidonylglycerol (2-
AG), enzymes regulating endocannabinoid biosynthesis
and catabolism, and CB1 and CB2 cannabinoid receptors.
Inhibition of fatty acid amide hydrolase (FAAH) or
monoacylglycerol lipase (MAGL) leads to increased levels
of AEA and 2-AG, respectively, and concomitant reduc-
tions of nociception in a variety of pain models (e.g.,
neuropathic and visceral). Here, I will present new research
testing the hypothesis that FAAH and MAGL can also be
targeted to reduce nociceptive responses in an inflammatory
pain model in which LPS is administered into the mouse
hind paw. Genetic or pharmacological blockade of FAAH
dampened nociception to thermal or mechanical stimulation
of the inflamed paw. These anti-hyperalgesic actions
required the activation of cannabinoid receptors, strongly
suggesting an important role of AEA in reducing inflam-
matory nociception. Surprisingly, inhibition of MAGL
failed to reduce LPS-induced nociceptive behavior despite
the fact that 2-AG brain levels were elevated approximately
tenfold. These results contrast with previous research
implicating the involvement of both endogenous cannabi-
noids in dampening nociceptive responses in other pain
assays. Accordingly, this is the first evidence suggesting
that anandamide and 2-AG play distinct roles in reducing
inflammatory pain. More generally, these findings suggest
that FAAH represents a more viable target than MAGL for
developing endocannabinoid-based medications to treat
inflammatory pain. Supported by NIDA P01DA009789,
P01DA017259, P50DA005274, R01DA015197, and
T32DA007027
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HIV-1 or gp120 can activate microglia/macrophages in the
brain. These monocytoid cells then release molecules that
contribute to neuronal apoptosis via an NMDA receptor-
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S15mediated pathway. Additionally, we recently found that
gp120 can impair neuronal stem/progenitor cells in the
brain. Impaired neurogenesis has been observed in the adult
human brain in several neurodegenerative diseases, includ-
ing HIV-associated dementia (HAD). Similarly, we found
decreased proliferation of adult neural progenitor cells
(aNPCs) in the hippocampus of gp120-transgenic mice,
thus inhibiting generation of new neurons. We demonstrat-
ed that gp120 arrests cell cycle progression of aNPCs at the
G1 phase via a molecular cascade mediated by a cell cycle
checkpoint kinase. Prior work had shown that checkpoint
kinases were involved in the DNA damage response; in a
completely unexpected manner, we found that checkpoint
kinases can also inhibit stem cell proliferation, importantly,
in the absence of overt DNA damage. The detailed
signaling pathway consists of: gp120/CXCR4 receptor
interaction; p38 mitogen-activated protein kinase (MAPK);
MAPK-activated protein kinase 2 (a cell cycle checkpoint
kinase); and Cdc25B/C. Our findings define a molecular
mechanism that compromises adult neurogenesis in neuro-
degenerative disorders. Additionally, this pathway may
provide drug targets to treat neurodegenerative diseases,
including HAD. Recently, we developed novel agents,
termed synthetically and modularly modified (SMM)-
chemokine analogs. SMM-chemokines can abrogate the
gp120-induced proliferation deficit of aNPCs. Supported by
NIH R01 EY09024
Use of Targeting Ligands to Deliver Therapeutic Agents
to Pathologic Cells. PS Low
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We have developed methods to target drugs specifically to
pathologic cells, thereby avoiding collateral toxicity to
healthy cells. To achieve this specificity, we have searched
for ligands that bind selectively to diseased cells and have
linked these ligands to therapeutic agents to promote their
selective uptake by the pathologic cells. In the case of
cancer, we have exploited up-regulation of the folate
receptor on many malignant cells to target the following
pharmaceuticals to cancer tissue: (1) protein toxins, (2)
chemotherapeutic agents, (3) gene therapy vectors, (4)
siRNAs, (5) radioimaging agents, (6) MRI contrast agents,
(7) liposomes with entrapped drugs, (8) radiotherapeutic
agents, (9) immunotherapeutic agents, and (9) enzyme
constructs for prodrug therapy. Current clinical trials of
four of our folate-linked drugs demonstrate that the folate
receptor targeting strategy holds great promise for increas-
ing drug potency while reducing drug toxicity. We have
also developed imaging and therapeutic agents that target
prostate-specific membrane antigen in prostate cancer. A
brief summary of laboratory, preclinical, and clinical results
with these targeted agents will be presented. In other areas
of medicine, we have developed drug targeting strategies
for the imaging and therapy of rheumatoid arthritis, Crohn’s
disease, atherosclerosis, diabetes and ischemia reperfusion
injury, etc. Finally, we are beginning to explore uses of
similar ligand targeting methods to deliver drugs selectively
into pathogenic microbes. Several examples of these will be
discussed. Supported by DOD, Endocyte Inc.
Role of HDACs in Regulating Synapse Function. LM
Monteggia
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Histone deacetylases (HDACs) are nuclear enzymes that
trigger long-term changes in gene expression by removing
acetyl groups from key histone residues, thus promoting an
inactive chromatin state. HDACs also regulate several
developmental processes as well as plasticities in mature
tissue and are widely expressed in the brain, although the
role of individual HDACs in the CNS is largely unknown.
In the last decade, several studies have shown that the
structural assembly of synapses can be accomplished in a
rapid time frame. Nevertheless, there is also ample evidence
that most nascent synapses formed during early develop-
ment are not fully functional and respond poorly to
presynaptic action potentials. In this presentation, we will
discuss our recent findings that the activity of HDACs
underlies this commonly observed delay in functional
maturation of excitatory synapses during development.
Our results show that pharmacological inhibition of
HDACs, as well as genetic knockdown of HDACs1&2,
during early synaptic development results in a robust
facilitation of excitatory synapse maturation and a modest
increase in synapse numbers. Furthermore, these findings
pinpoint class I HDACs (HDACs1&2) as the primary
players in this suppression of synaptic function. In contrast,
we also found that this inhibitory role of HDACs in
synapse regulation was restricted to early development as in
mature neurons, a specific decrease in HDAC2 levels alone
attenuated basal excitatory neurotransmission without a
significant change in the numbers of detectable nerve
terminals. Supported by NIMH
Marijuana Use Worsens Cognitive Function But Does Not
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Marijuana is the leading drug abused by HIV-infected
individuals and is often prescribed to them for medical
S16 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59reasons. Tetrahydrocannabinol (THC), the major psychoac-
tiveingredientinmarijuana,mayleadtocognitivedeficitsand
may shift the balance of cytokine or chemokine expression
from TH1 to TH2. We studied 20 HIV subjects with normal
cognition and had current (within last 6 months) or without
current (last use >1 year) daily marijuana use. Each was
administered a battery of neuropsychological tests that had
been used in numerous HIV studies, localized brain proton
MR spectroscopy in four brain regions, and had lumbar
punctures to collect cerebrospinal fluid (CSF) for measure-
ments of a set of cytokines using Luminex. No significant
group difference was observed between HIV current and
non-current marijuana smokers in the 11 measurable
cytokines and chemokines (IL-1beta, IL-6, IL-8, FLT-3L,
IP-10, MCP-1, MDC, PDGF-AA, TGF-alpha) in their CSF.
Yet, current HIV+ marijuana users had significantly lower
z-scores in cognitive domains for learning (p=0.040),
memory (p=0.050), and motor function (p=0.023), as well
as lower glutamate in the basal ganglia (p=0.05) and higher
glutamate+glutamine in frontal white matter (p=0.03). These
findings suggest that poorer cognitive functions in the HIV+
marijuana users is not related to the THC-mediated alteration
of expression of these cytokines and chemokines, but may be
due to other mechanisms such as oxidative stress or changes
in neurotransmitter function. Supported by NIMH (R01
MH61427); NIDA (K24-DA16170); NINDS and NIDA
(U54NS56883)
Multifunctional Magnetic Nanocarrier for Drug Targeting
to Brain. MN Nair
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Opiates act synergistically with HIV-1 proteins to potentiate
the HIV-related neurotoxicity that leads to the development
of NeuroAIDS. Currently, no effective treatment exists for
NeuroAIDS, which is mainly attributed to the impenetra-
bility of therapeutic molecules across the blood–brain
barrier (BBB). We herein report the development of a
magnetic nanocarrier of AZT 5′-triphosphate (active form
of AZT) and CTOP (a potent mu-opioid receptor antago-
nist) to deliver drugs across the BBB under the influence of
an external magnetic field. The proposed nanocarrier is
anticipated to simultaneously reduce NeuroAIDS and
opiate addiction in HIV-1 infected subjects who are opiate
users. Supported by NIDA
The Promise, Prospects, and Impact of Nanomedicine.
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NanoMedicine is the science and technology of diagnosing,
treating, alleviating, and preventing disease and traumatic
injury through the use of nanoscale operations in the human
body. Operations at the nanoscale (one billionth of a meter)
are incredibly powerful because all the interactive compo-
nents and energy are concentrated on the surface of the
material and therefore strengthen its interactivity. If an
engineered nanomaterial is placed in juxtaposition with a
biological component (which often assumes nanoscale
dimensions, e.g., proteins and cellular organelles), new
interactions are created wherein the inorganic nanomaterial
can communicate with the biological substrate to influence
the function of the protein or the cellular organelle. For
instance, the engineered material could interrogate the
biological substrate to find out if it is damaged and then
relay that information to a remote sensor via an optical or
magnetic signal on the nanomaterial surface. This could
allow the physician to diagnose a disease while it is still at
the molecular level and to send a nanomaterial delivery
device back into the body to fix the damage or to deliver a
drug that can assist in healing. Thus, the foundations of
NanoMedicine include the use of nanomaterials and nano-
devices to perform nano-imaging, early disease diagnosis,
and delivery of therapeutic agents. I will illustrate this
aspect by describing some of the research in the UCLA
Nanomachine Center where we are developing nanovalve-
controlled mesoporous silica nanoparticles for cancer drug
delivery. Supported by NCI, NIEHS
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Posttranslational modifications of the HIV-1 Tat protein
have emerged as critical regulatory mechanisms that fine-
tune interactions of the viral transactivator with TAR RNA
and cellular cofactors. We recently identified the lysine
methyltransferase Set7/9 (recently renamed KMT7) as a
novel co-activator of HIV transcription. Set7/9-KMT7
associates with the HIV promoter in vivo and monomethy-
lates lysine 51, a highly conserved residue located in the
RNA-binding domain of Tat. Knockdown of Set7/9-KMT7
suppresses Tat transactivation of the HIV promoter, but
does not affect the transcriptional activity of methylation-
deficient Tat (K51A). Set7/9-KMT7 itself binds TAR RNA
and forms a complex with Tat and the positive transcription
elongation factor P-TEFb. Our findings uncover novel
RNA-binding properties of Set7/9-KMT7 and demonstrate
a positive role of Tat methylation in the early steps of the
Tat transactivation cycle.
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Our previous works demonstrated molecular mechanisms
of blood–brain barrier (BBB) disruption by alcohol in
pathophysiologically relevant concentrations. Such mecha-
nisms included alcohol metabolism in BMVEC causing
oxidative stress, Ca
2+ release, activation of myosin light
chain kinase, and phosphorylation of tight junction pro-
teins, activation of phospholipase A2 (PLA2) and cyclo-
oxygenase (COX-2), and secretion of prostaglandin E2
(PGE2). These changes increased BBB permeability in
vitro and in vivo and enhanced monocyte migration across
BBB, events enhancing neurotoxicity associated with HIV-
1 CNS infection. Ethanol metabolism in human astrocytes
enhanced generation of reactive oxygen species land
secretion of prostaglandin PGE2 due to the induction of
PLA2 and COX-2. Alcohol metabolism in human neurons
resulted in oxidative stress and activation of NADPH/
xanthine oxidase, leading to neuronal injury. Overall,
alcohol promoted pro-inflammatory phenotype in different
types of CNS cells. Using small animal model for HIV-1
encephalitis, we found that alcohol exposure caused
significant increase in neuroinflammation and decreased
antiviral responses, leading to increased viral load in the
brain. Recent findings in humans and animal models
suggest that alcohol induces inflammatory processes in
the brain, leading to neurodegeneration. Neuroinflammation
appears to promote alcohol addiction, making this finding
very relevant for HIV-1 brain infection associated with
chronic inflammation. Therefore, HIV-1 infection increas-
ing neuroinflammatory responses could promote excessive
drinking. Supported by NIAAA/ AA017398, AA015913
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Despite the therapeutic impact of anti-retroviral therapy
(ART), HIV-1-associated dementia (HAD) remains a
serious threat to AIDS patients, and there currently remains
no specific therapy for the neurological manifestations of
HIV-1. Based upon recent work that the nigrostriatal
dopaminergic area is a critical brain region for the neuronal
dysfunction and death seen in HAD, that synthetic
cannabinoids inhibit HIV-1 expression in human microglia
and suppress production of inflammatory mediators in
human astrocytes, as well as a substantial literature
demonstrating neuroprotective properties of cannabinoids
in other systems, we tested the hypothesis that synthetic
cannabinoids will protect dopaminergic neurons against the
toxic effects of the HIV-1 protein gp120. Using a human
midbrain cell culture model, we were able to identify the
relative sensitivity of dopaminergic neurons to gp120-
induced damage, evaluate the extent of neuronal damage,
demonstrate the role of gp120-induced oxidative damage in
this process, and also show that CB1/CB2 agonist
WIN55,212-2 blunts the gp120-induced neuronal damage.
Pretreatment with WIN55,212-2 also inhibited the migra-
tion of human microglial cells toward CCL2. Furthermore,
in the presence of glutamate, gp120 pretreatment potenti-
ated neurotoxicity of human cortical neuronal cultures and
pretreatment with WIN55,212-2 down-regulated gp120-
induced glutamate receptor activity. These results support
the concept that synthetic cannabinoids are potential
neuroprotective agents that may prove useful for the
treatment of HIV-1-related brain disease. Supported by
NIH/NIDA DA025525
The Immunopathology Associated with Cigarette
Smoking: It May Be Worse Than You Think.TR o g e r s
1,
1Temple University School of Medicine, Philadelphia, PA
19140
Long-term inhalation of tobacco smoke can result in the
development of a number of disease states, including chronic
obstructive pulmonary disease (COPD). This disease is
characterized by remodeling and destruction of lung tissue
and a significant reduction of lung function. Some of these
patients experience periods of acute exacerbation in which
lung function is further reduced and hospitalization may be
required.Iwillpresentresultswhichshowthatexacerbationin
these patients is accompanied by a substantial alteration in
systemic immune competence. Results from our studies
suggest that the exacerbation process is associated with
immune processes which may promote a profibrotic inflam-
matory response. These studies support the notion that the
development of acute exacerbation of COPD involves a
significant change in the composition of the circulating
immune system, and this may contribute to the ongoing
immunopathology in the lung.
Role of GABAA Receptors in Cigarette Smoke/Nicotine-
Induced Chronic Bronchitis. M Sopori
1, S Gundavarapu
1,
JA Wilder
1, HC Mishra
1,JR i r - s i m - a h
1,SB u c h
2,S PS i n g h
1,
R Jaramillo
1, KS Harrod
1, Y Tesfaigzi
1;
1Immunology
Division , Lovelace Respiratory Research Institute , Albu-
querque, NM 87108,
2Pharmacology and Experimental
Neuroscience, University of Nebraska Medical Center,
Omaha, NE 68198
Mucous overproduction is associated with chronic airway
inflammatory diseases such as asthma, chronic obstructive
S18 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59pulmonary disease (COPD), and cystic fibrosis. Moreover,
HIV-positive smokers have a much higher incidence and
early onset of COPD than HIV-negative smokers. We have
shown that nicotine inhibits allergen-induced Th2 inflam-
mation in the lung; surprisingly, however, nicotine upregu-
lated mucous cell metaplasia. Recent reports suggest that
GABAA receptors (GABAAR) regulate mucous production
by airway epithelial cells. In the CNS, nicotine is
GABAergic, and to explain the paradox of increased mucus
formation under low Th2 response, we hypothesized that
nicotine promoted mucus formation through upregulated
expression of GABAAR, and the expression is further
increased by HIV infection. To test this hypothesis, we
examined the expression of GABAAR and mucus forma-
tion in normal human bronchial epithelium (NHBE) cells
grown at the air–liquid interphase and exposed to nicotine
and/or gp120/tat. Expression of GABAAR and mucous
formation was also determined in Balb/c mice exposed to
secondhand smoke (SS). Results suggest that: (a) while
control mice had very low or undetectable expression of
GABAAR in lung, lungs from animals exposed to
secondhand cigarette smoke exhibited significantly higher
expression of GABAAR and mucous formation that was
further increased after allergic sensitization. (b) NHBE cells
express alpha-7-, alpha-9-, and alpha-10-nicotinic acetyl-
choline receptors, and nicotine treatment increased
GABAAR-alpha2 expression in these cells. The expression
of GABAAR-alpha2 was casually related to elevated
mucous cell metaplasia after IL-13 or LPS treatment and
blocked by nicotinic receptor or GABAAR antagonists. (c)
gp120 and tat induced GABAAR-alpha2 receptor expres-
sions and IL-13/LPS-stimulated mucous formation in
NHBEC; this response was increased further in the
presence of nicotine. Thus, nicotine in cigarette smoke
and HIV proteins may affect mucus formation through the
upregulation of GABAARα2 receptors on the epithelial
cells. Dysregulated expression of GABAAR-alpha2 recep-
tors may influence the development of mucus-related
diseases in smokers. Supported by NIDA, DOD, and
Lovelace Respiratory Research Institute
SR141716A, Unexpected Actions. RF Tuma
1, M Zhang
1,
MW Adler,
1;
1Center for Substance Abuse Research, Temple
University School of Medicine, Philadelphia, PA 19140.
The CB1 receptor antagonist SR141716A is perhaps the
most commonly used antagonist for the CB1 receptor.
SR141716A has very high affinity for the CB1 receptor and
very low affinity for the CB2 receptor. Therefore, because
of the differences in affinity between these two well-
characterized receptors, alterations in outcome following
administration of SR141716A have often been interpreted
as evidence of the contributions of the CB1 receptor to
neuroprotective effects. However, SR141716A may modu-
late other receptors within the brain. Therefore, the
assumption that changes seen following administrations of
SR141716A are just the result of alterations in the activity
of the CB1 receptor may lead to serious misinterpretations
of the actions of the CB1 receptors and be the cause of
numerous conflicting reports concerning the activity of this
receptor. This conclusion is supported by recent studies in
our laboratory indicating that SR141716A may act upon
receptors other than CB1 and CB2 within the central
nervous system. Results from our laboratory also provide
evidence that the combined administration of SR141716A
with a selective CB2 agonist may result in unique changes
in vascular function following ischemia. Supported by
Crain H. Neilsen Foundation #82412, NIH 1 RO1
A1084065-01A209, DA P30 13429
Impact of the Innate Immune Response on HIV-1
Infection. CH Uittenbogaart
1;
1Department of Pediatrics
and Microbiology, Immunology and Molecular Genetics,
UCLA, Los Angeles, CA 90095
Interferon-alpha (IFN-alpha) is a cytokine known for its
antiviral effects and has been shown to decrease HIV viral
replication in vitro. Based on its antiviral effects, it has been
used for the treatment of HIV infection alone or in
combination with antiretroviral drugs, with mixed results.
Nonetheless, a wave of IFN-alpha observed in acute
infection may initially suppress viral replication, yet
persistent high levels may cause pathogenesis. In addition
to antiviral effects, IFN-alpha which is mainly produced by
plasmacytoid dendritic cells (pDC) links the innate and
adaptive immunity and is known to have immunoregulatory
activities. Our hypothesis is that IFN-alpha may be
important for normal functioning of the adaptive and innate
immune system at low, physiologic concentrations, while it
is immunosuppressive at high concentrations. Indeed, we
discovered that IFN-alpha is expressed in normal thymus
tissue where T cell development takes place, but that high
concentrations of IFN-alpha, comparable with plasma
levels in HIV-infected individuals, are indeed immunosup-
pressive for T cells and inhibit early steps of T cell
development in the human thymus. HIV infection impairs
thymic output of naïve T cells and depletes developing T
cells in the thymus. A potential unifying hypothesis is that
HIV-1 induces high and persistent levels of IFN-alpha
which impair human T cell development and consequently
peripheral T cell reconstitution. Thus, elevated levels of
IFN-alpha are not correlated with control of HIV-1
infection but are likely a sign of immune activation that
contributes to HIV pathogenesis. Supported by NIH/NIAID
R01 AI080564
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S19HIV Infection and Drug Abuse in the YI Ethnic Chinese
of Sichuan. Z Wang
1,
1Sichuan University, West China
Medical College, Sichuan Center for Disease Control,
People’s Republic of China. [Abstract not available at time
of publication]
IFN-Beta-modulating micro-RNA in Lentivirus-
Associated CNS Disease. KW Witwer
1,J MS i s k
1,JL i u
1,
L Gama
1, JE Clements
1;
1Molecular and Comparative
Pathobiology, The Johns Hopkins University School of
Medicine, Baltimore, MD 21205
Interferon beta (IFN-beta) production is an early innate
immune response to lentiviral infection of the CNS. In our
rapid and consistent SIV/macaque model of HIV encepha-
litis, SIV enters the CNS within 4 days of infection,
accompanied by a marked IFN-beta response. IFN-beta
levels then decline when SIV enters its latent phase. The
critical role of IFN-beta in the CNS antiviral response,
combined with the potential for inflammatory damage
associated with long-term activation, suggests that IFN-
beta is subject to multiple levels of regulation. Adding to
known regulatory mechanisms, we present evidence that
IFN-beta expression may be tuned posttranscriptionally by
microRNAs (miRNAs). We identified miRNAs with po-
tential recognition elements in the 3′ UTR of the IFN-beta
transcript using target recognition algorithms. Three
macrophage-expressed miRNAs, -26a,-34a, and let-7b,
appear to exert direct effects on the IFN-beta 3′ UTR in
reporter assays and to modulate the levels of IFN-beta
protein in primary macrophages, while miR-145 may have
indirect effects. In vivo relevance is supported by differen-
tial expression of these miRNAs during the course of SIV
infection and by IFN-beta-mediated upregulation of several
IFN-beta-targeting miRNAs. We further describe the
localization of miRNAs and IFN-beta mRNA in macro-
phages/microglia, astrocytes, and neurons during SIV
infection, discussing the implications of these expression
patterns for miRNA-mediated control of IFN-beta. Our
results suggest the regulation of IFN-beta by miRNAs and
show that miRNAs may influence HIV-associated CNS
disease progression. Supported by NIH/NS055648
Inputs on Co-infection of HIVand HCV. JG Wu
1,LK a n g
1,
XS Xia
2;
1State Key Laboratory of Virology and College of
Li, Wuhan University, Wuhan, P.R. China 430072,
2College
of Life Science and Technology, Kunming University of
Science and Technology, Kunming, P.R. China 650093
Both human immunodeficiency virus type 1 (HIV-1) and
hepatitis C virus (HCV) are deadly pathogens to human
health. Due to shared routes of transmission, co-infection is
common that is unfortunately a scenario because of high
risk factors of the viruses. Here, we studied the molecular
mechanism involved in HIV-1/HCV co-infection with
emphasis on the effect of HCV on HIV-1 replication. To
gain a clinical implication for HIV-1/HCV co-infection, we
analyzed 149 blood specimens derived from co-infected
intravenous drug users which revealed that there was a
correlation between HCV and HIV-1 viral loads (spear-
man’s ρ=0.200, p<0.05). Such correlation was confirmed
by infecting pNL4-3-transfected Huh7 cells with HCV1b
(R=0.978, p<0.05), which showed that HCV significantly
enhanced HIV-1 replication in vitro. We further demon-
strated that HCV NS3/4A complex stimulated HIV-1
replication through NF-KB pathway. In addition, we
showed that HIV-1 Vpu protein was required for the NS3/
4A-mediated activation of NF-KB. In conclusion, we
demonstrated that HCV stimulates HIV-1 replication
through the interaction between HCV NS3/4A complex
and HIV-1 Vpu protein. Our results provided new insight in
understanding the molecular mechanism of HIV-1/HCV co-
infection.
Obstacles to an HIV Vaccine. OO Yang
1;
1Division of
Infectious Diseases, University of California Los Angeles,
Los Angeles, CA 90095
More than 25 years after HIV was isolated as the causative
agent of AIDS, a vaccine remains elusive. Despite
increasing knowledge about the immunopathogenesis of
HIV infection and multiple vaccine trials in humans, the
field has been fraught with disappointment. This presenta-
tion will review the principles of immunity and likely
reasons for failure of vaccine attempts and review recent
vaccine trial results. Supported by NIH AI043203 and
AI051970
Dysregulation of Neuronal Micro-RNA Expression in SIV/
HIV-Associated Neurological Disease. SV Yelamanchili
1,
CL i - n a
1,HX i o n g
1,H SF o x
1;
1Dept of Pharmacology and
Experimental Neuroscience, University Of Nebraska Medical
Center, Omaha, NE 68198
Many facets of transcriptional and translation regulation
contribute to the proper functioning of the nervous system.
miRNAs are small RNA molecules that serve as check-
points in transcription and translation processes. However,
the molecular basis for neuronal dysfunction found in the
HIV-associated neurocognitive disorder (HAND) and its
associated neuropathology, HIV encephalitis (HIVE),
remains unknown. This study focused on identifying the
regulation of miRNAs in the brains of monkeys and
humans with SIVE/HIVE. Strikingly, a number of miRNAs
S20 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59were significantly increased in the infected brains and,
when assessed by in situ hybridization, were abnormally
expressed in neurons. Given the ability of miRNAs to
modulate cellular mRNAs and proteins and thus cellular
physiology, we identified for the first time that a critical
neuronal transcription factor is a target of one of these
miRNAs, miR-21. Functionally, miR-21 expression in
neurons prolongs the opening of voltage-gated K
+ chan-
nels. These findings further underscore the regulatory loop
in which miRNAs function and highlight their importance
in neurodegenerative research. Supported by NIH grants
P30 MH062261 and R01 MH073490 in addition to
Nebraska Tobacco Settlement Biomedical Research
A Cannabinoid CB2 Agonist Attenuated Leukocyte–
Brain Endothelial Interaction and Blood–Brain Barrier
Dysfunction Under Inflammatory Conditions. MZ h a n g
1,
SR a m i r e z
2, Y Persidsky
2, RF Tuma
1;
1Department of
Physiology, Temple University School of Medicine,
Philadelphia, PA 19140,
2Deparment of Pathology and
Laboratory Medicine, Temple University School of
Medicine, Philadelphia, PA 19140
Lipopolysaccharide (LPS), released from Gram-negative
bacteria, induces an inflammation-mediated endothelial and
vascular dysfunction in various organs. Our previous
studies indicated that selective CB2 receptor activation
was neuroprotective through its anti-inflammatory proper-
ties. In this study, the role of a selective CB2 receptor
agonist (O-1966) in LPS-induced cerebral microvascular
inflammation and blood–brain barrier (BBB) function was
investigated. Cranial window and intravital microscopy
were used to directly observe leukocyte/endothelial inter-
actions in mouse brain after LPS (6 mg/kg) injection. O-
1966 (5 mg/kg) was given at the same time as LPS. BBB
function was tested by Evans blue extravasations in vivo.
Transendothelial electrical resistance (TEER) was used to
test the effects of O-1966 on compromised barrier integrity
of human brain endothelial cells (BMVEC) after LPS
stimulation in vitro. The results showed that LPS induced
a dramatic increase in leukocyte rolling and adhesion (p<
0.05) on brain microvascular endothelial cells after LPS
inoculation, which were significantly reduced by O-1966 (p
<0.05). Permeability of BBB (measured by Evans blue
extravasations) was increased at 24 h after LPS injection (p
<0.05), and these changes were prevented by treatment
with O-1966. Our preliminary data also indicate that O-
1966 enhances and protects barrier function when the
TEER is monitored on BMVEC. Our studies demonstrated
that selective CB2 activation diminished leukocyte engage-
ment by brain endothelium under inflammatory conditions
and protected BBB.
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Morphine Induces Tubular Cell Autophagy Through
Reactive Oxygen Species (ROS) Generation. SA r o r a
1,
D Salhan
2,PT a n d o n
2, PC Singhal
2;
1Division of Internal
Medicine, Wyckoff Heights Medical Center, Brooklyn, NY
11237-0000,
2Immunology, Feinstein Institute for Medical
Research, Manhasset, NY 11030
Background: Morphine is a known immune modulator and
has been reported to stimulate the generation of ROS in a
variety of cells. ROS-induced oxidative stress leads to the
accumulation of damaged organelles and proteins that, if
not degraded, may injure the cell and may activate cell
death pathway. We asked whether morphine promotes
oxidative stress in tubular cells and, if so, whether it is
associated with enhanced autophagic process. The effect of
morphine on the generation of reactive oxygen species
(ROS) by cultured mouse proximal tubular cell
(MRPTECs) was determined by the trafficking of redox
sensor CC-1 and Mitotracker green. The kinetics of ROS
metabolism was determined by measuring the intensity of
the fluorescent signal from the redox-sensitive fluoroprobe
(DCFDA) at multiple time points. Control and morphine-
treated cells in the presence or absence of antioxidants (DPI
and N-acetyl cysteine) were evaluated for the development
of autophagy by staining with Monodansylcadaverine and
electron microscopic studies. Cells treated under the same
conditions were also evaluated for the expression of genes
(beclin-1, LC3-2) associated with the induction of autophagy.
Morphine stimulated tubular cell ROS generation in a dose-
and time-dependent manner. Morphine not only promoted
tubular cell accumulation of autophagic vacuoles but also
enhanced the expression of beclin-1 and LC-3-2. Antioxidants
such as DPI and N-acetyl cysteine inhibited morphine-induced
tubular cell autophagy as well as the expression of the genes
associated with the induction of autophagy.
HIV-1 Tat and Cocaine Cooperatively Disrupt
the Neurovascular Unit: Role of PDGF/PDGF-SS
Receptor Axis. C Bethel-Brown
1,HY a o
1,S JB u c h
1;
1Department of Pharmacology & Experimental Neurosci-
ence, University of Nebraska Medical Center, Omaha, NE
68137
Cocaine, abused by HIV+ patients, worsens HIV-associated
neurological disease (HAND) that is accompanied by
astrogliosis, BBB disruption, and neuronal degeneration.
Among the various cytokines implicated in HAND, the role
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S21of platelet-derived growth factor (PDGF) remains elusive.
This factor is critical in various pathological syndromes. We
have demonstrated upregulation of PDGF in perivascular
macrophages in the brains of SIV-infected macaques. Since
thesecellsenterthebrainviadisruptedBBB,wehypothesized
that PDGF/PDGF-beta-R may play a role in HIV-1- and
cocaine-mediatedcompromiseoftheneurovascularunitofthe
BBB. Astrocyte foot processes in close proximity of the
endothelial cells are critical in maintaining the integrity of the
barrier. To explore the role of PDGF/PDGF-beta-R axis in
astroglial–endothelial interaction, astrocytes were treated with
HIV-1 Tat. Exposure with Tat induced the expression of
PDGF RNA and protein. Reciprocally, exposure of brain
endothelial cells to cocaine resulted in sigma receptor-
mediated phosphorylation of PDGF-beta-R. Engagement of
PDGF-beta-R, in turn, resulted in the disruption of tight
junction proteins of the barrier. Signaling pathways involved
in PDGF-beta-R phosphorylation include MAPK and FAK/
Rho/PKC kinases. In conclusion, HIV-1 Tat and cocaine
complementarily disrupt the neurovascular unit leading to
enhanced transmigration of monocytes into the CNS. Sup-
ported by grants RO1 DA020392, RO1 DA027729 &
Nebraska Tobacco Settlement Biomedical Research
CXCR4/DOR Interactions in the Brain of MOR-Deficient
Mice. S Burbassi
1,OM e u c c i
1;
1Department of
Pharmacology & Physiology, Drexel University College of
Medicine, Philadelphia, PA 19102-0000,
2Microbiology
and Immunology, Drexel University College of Medicine,
Philadelphia, PA 19102
Growing evidence suggests a reciprocal cross talk between
chemokine and opioid receptors. Our previous data show that
in vitro or in vivo treatments with mu-opioid receptor (MOR)
agonists increase intracellular levels of ferritin heavy chain in
neurons, which inhibits CXCR4 function. To further charac-
terize the interaction between opioid receptors and CXCR4 in
brain cells, we investigated the effect of CXCL12 in tissue/
cells from MOR-deficient (MOR
−/−) mice. Surprisingly, our
data show a significant reduction in CXCL12/CXCR4
signaling in MOR
−/− mice despite apparent increase in
CXCR4 mRNA and total protein in the MOR
−/− and similar
surface expression of CXCR4 in WT and MOR
−/− animals.
As expected, very low levels of FHC were observed in
MOR
−/−. Interestingly, co-immunoprecipitation studies show
increased association of CXCR4 with delta opioid receptors
(DOR) in MOR
−/−-derived brain tissue (and cultured cells),
suggesting that the two receptors may form heterodimers. In
line with this hypothesis, co-treatment of WT neuronal
cultures or brain homogenates with CXCL12 and the DOR
selective agonist SNC80 prevents CXCR4 activation by
CXCL12. Moreover, pretreatment with Naltrindole (a DOR
antagonist) before addition of CXCL12 restores CXCL12-
induced stimulation in brain homogenates from MOR
−/−
animals. We conclude that in the absence of MOR, CXCR4
may form silent dimers with DOR. Overall, these findings
indicate that opioid receptors play an important role in the
regulation of CXCR4 via multiple mechanisms converging
on inhibition of CXCR4 signaling. Supported by NIH
DA15014, DA19808
Increased Brain Levels of Amyloid Beta Enhance HIV
Tat Protein-Induced Blood–Brain Barrier Disruption
and Transcapillary Migration of Leukocytes. L Chen
1,
YJ Choi
1, M Toborek
1;
1University of Kentucky,
Neurosurgery, Lexington, KY 40536
The widespread use of anti-retroviral therapy in Western
countries transformed HIV infection into a chronic disease.
Because HIV-infected patients live longer, an emerging
development is an increase in the older population infected
with HIV. HIV-infected brains are characterized by elevated
depositions of amyloid beta (A-beta); however, the inter-
actions between A-beta and viral factors are poorly
understood. The present study is based on a model of
HIV protein Tat injections into double transgenic mice that
express a chimeric mouse/human amyloid precursor protein
(Mo/HuAPP695swe) and a mutant human presenilin 1
(PS1-dE9) and are characterized by increased A-beta
deposition in the brain. Tat was administered via a vessel
microport directed into the internal carotid artery. Twenty-
four hours after Tat treatment, we evaluated vascular
permeability, tight junction protein expression, and matrix
metalloproteinase-9 (MMP-9) activity. In addition, we
monitored endothelial attachment of leukocytes through a
cranial window in live animals. Tat injections resulted in
increased permeability across cerebral capillaries, elevated
MMP-9 activity, and enhanced disruption of tight junctions
in transgenic mice as compared to littermate controls. These
changes were associated with increased leukocyte attach-
ment and their transcapillary migration, the effects that
were attenuated by a specific Rho inhibitor hydroxyfasudil.
These results indicate that increased brain levels of A-beta
can enhance vascular toxicity and pro-inflammatory
responses induced by Tat. Supported by MH63022,
MH072567, NS39254
Suppressive Effect of Nicotine on the Toll-Like Receptor
Signaling Pathway in Macrophages. WC u i
1,S LC h a n g
2,
ML i
1;
1Department of Psychiatry & Neurobehavioral
Science, University of Virginia, Charlottesville, VA 22911-
0000,
2Department of Biological Sciences, Seton Hall
University , South Orange, NJ 07097
Toll-like receptors (TLRs) are key immune receptors that
mediate inflammation. Although nicotine dampens TLR
S22 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59signaling and exerts anti-inflammatory effects in macro-
phages, the underlying molecular mechanism is not fully
understood. We investigated gene expression patterns in
RAW264.7 macrophages treated with 5 μM nicotine and
stimulated with lipopolysaccharide (LPS) or poly(I:C)
using a custom-designed pathway-focused RT-PCR array
containing 50 genes in the TLR signaling pathway.
Nicotine significantly suppressed expression of various
key adaptors of two signaling pathways downstream of
the TLR: the myeloid differentiation primary response gene
88 (MyD88)-dependent pathway and the TIR domain-
containing adaptor inducing interferon-gamma (TRIF)-
dependent pathway. Because more genes in the TLR3 than
the TLR4 pathway were changed by nicotine, we hypoth-
esized that the TRIF-dependent TLR3 pathway is more
sensitive to nicotine than is TLR4, which triggers both
TRIF-and MyD88-dependent pathways. To test this hy-
pothesis, we examined nicotine’s effects on LPS-induced
phosphorylation of P38, the early phase of which is
controlled by the MyD88 pathway whereas the late phase
is controlled by the TRIF pathway. We found that nicotine
suppressed the late but not the early phase of P38
activation. This indicates that the suppressive effect of
nicotine on TLR signaling is more dependent on the TRIF
than the MyD88 pathway. Supported by NIH grant DA
DA-013783 to MDL and DA-026356 to SCL and MDL
Valproic acid (VPA) as a Potential Adjunct Therapy
for Human Immunodeficiency Virus (HIV)-Associated
Neurocognitive Disorders (HAND). DC Davidson
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2,AC a s e y
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4Department of Neurology, University of Rochester, Rochester,
NY 14642
HIV-1 enters the CNS in the early stages of infection and
can lead to the development of neurocognitive impairments,
referred to as HAND. Infiltration of the CNS by activated
macrophage is believed to be one of the largest contributing
factors in the pathogenesis of HAND due to the induction
of an excessive inflammatory state that leads to neuronal
death. In this context, we have previously shown that levels
of the inflammatory mediator soluble CD40L (sCD40L) are
elevated in the plasma and CSF of HIV-1-infected,
cognitively impaired individuals. Here, we demonstrate
that the mood-stabilizing drug VPA reduces sCD40L levels
in both plasma samples of HIV-1-infected individuals and
cultured human platelets, which are the main source of
circulating sCD40L. Additionally, previous reports indicate
that VPA acts as an inhibitor of glycogen synthase kinase 3
beta (GSK3b), a kinase known to be activated by the HIV-1
neurotoxin platelet-activating factor (PAF). We hypothesize
that GSK3b may play a role in the release of sCD40L from
platelets, a mechanism that may be blocked with VPA
treatment. Consistent with this notion, here, we show that
treatment of human platelets with VPA is able to reverse
PAF-induced GSK3b activation. Furthermore, over-
expression experiments using GSK3b mutants in human
megakaryocytes suggest that GSK3b is involved in CD40L
surface expression, which occurs prior to its release, in
platelets. These findings offer insight into the possible
mechanism of VPA in the context of neuroprotection and
emphasize the potential of VPA as an adjunct therapy for
HAND.
Greater CNS Penetration of Antiretroviral Medications
May Contribute to Neurotoxicity in HIV Patients. FF
Duennebier
1,UF e g e r
1,HE r n s t
1,SN a k a m a
1,LC h a n g
1;
1Neurscience and MR Research Program, University of HI
John A. Burns School of Medicine, Honolulu, HI 96813
HIV-associated neurological disorder (HAND) remains a
significant burden for HIV-infected individuals even in the
era of readily available antiretroviral therapy (ART). We
evaluated whether the central nervous system-penetrating
effectiveness (CPE) of ART may affect brain metabolites
[using localized in vivo proton magnetic resonance spec-
troscopy (
1H MRS)] and cognitive function (with a battery
of neuropsychological tests) in 46 HIV+ individuals known
to be stable on antiretroviral therapy for at least 6 months.
We categorized HIV groups into those taking ARVs with
lower (CPE < 1.5, n = 19) and higher (CPE ≥ 1.5, n = 27)
CPEs. The two groups were matched by age, education,
CD4 count, viral load, and Karnofsky scores. HIV subjects
taking higher CPE ARVs showed trends for lower brain
myoinositol in all four brain regions than those taking
lower CPE ARVs (p=0.11), with a significantly lower level
in the parietal gray matter (p=0.03). The parietal glutamate
was also lower in those taking the higher CPE ARVs than
those taking lower CPE ARVs (p=0.05). Furthermore,
those taking high CPE were slower on the Grooved
Pegboard task (non-dominant: p=0.04) and tended to score
lower on HIV dementia scales (p=0.12). These findings
suggest that HIV patients taking high CPE ARVs have less
glial activation or neuroinflammation throughout the brain.
However, the lower parietal glutamate and slower fine
motor function in those taking high CPE ARVs suggest that
higher concentrations of ARVs in the brain may contribute
to greater neurotoxicity through other mechanisms. Sup-
ported by NIMH (R01 MH61427); NIDA (K24-DA16170);
NINDS & NIDA (U54NS56883)
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Streptococcus pneumonia infection is common in immune-
compromised human immunodeficiency virus (HIV)-
infected patients and also in opiate drug users. The cellular
mechanisms involved in the acceleration of this co-
infection among morphine drug abusers are largely unde-
fined. In the present study, we explore the extent and
kinetics of specific myeloid subsets that proliferate in the
peripheral blood and their trafficking into the spleen of
Streptococcus pneumoniae (serotype 3)-infected wild-type
(WT) and Tat-transgenic mice following chronic morphine
exposure. Flow cytometry analysis revealed a significant
increase in myeloid subpopulation of CD45
+CD11b
+
Ly6CintLy6G
+ (granulocytes) and CD45
+CD11b
+Ly6G-
Ly6Chigh (inflammatory monocytes) in the blood of Tat-
transgenic mice when compared to the WT mice. Morphine
(25 mg) treatment decreased the polymorphonuclear gran-
ulocytes and inflammatory monocytes in the blood of both
WT and Tat-transgenic mice. However, when leukocyte
trafficking into the spleen was investigated in the presence
of morphine, a significant increase in T lymphocytes
(CD45
+CD11b
−CD3
+) and inflammatory monocytes we
observed in both WT and Tat-transgenic mice. Interestingly,
the trafficking of inflammatory monocytes in the morphine-
treated Tat-transgenic mice was tenfold higher than WT
mice. Results implicate that the morphine exposure follow-
ing infection increases the migration property of the
monocytes at the early stage of infection. Studies are in
progress in identifying the mechanism underlying the
differential migration pattern of leukocyte. Supported by
RO1 DA12104, RO1 DA022935, KO2 DA015349, P50
DA11806 (to S.R.) and T32 DA07097
Association of Pro-inflammatory Cytokines in CSF
with MRS Glial Markers Differs with HIV Status
and Cognitive Function. UF e g e r
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HIV-1 brain infection can lead to the development of HIV-
associated neurocognitive disorders (HAND). To elucidate
the role of an ongoing immune response in the brain and
onset and progression of cognitive impairment, we con-
ducted localized in vivo proton magnetic resonance
spectroscopy (
1H MRS) in four brain regions, and measure-
ments of a set of cytokines in the cerebrospinal fluid (CSF),
in HIV-subjects with HAND (HIV-HAND) and without
HAND (HIV-NC) and in seronegative controls (SN). The
pro-inflammatory markers IP-10, IL-8, and IL-1 alpha were
all elevated in the CSF of HIV subjects with HAND when
compared to controls (<0.00001 to p=0.01) or to HIV-NC
(p=0.003 to n.s.). In addition, elevated MRS myoinositol
(mI), a surrogate marker for glial activation, was seen in the
frontal white (fwM) and grey (fgM) matter in HIV-HAND
subjects when compared to SN (p=0.03 to n.s) and to HIV-
NC (p=0.07 to n.s). Furthermore, SN controls showed a
positive correlation for all three CSF cytokines with mI in
the fgM and fwM (p=0.008 to n.s). In contrast, HIV-NC
subjects showed an inverse relationships between mI in the
fgM and fwM and these CSF cytokines (p=0.02 to n.s). No
clear trend was seen for the HIV-HAND group. Conse-
quently, several interactions were found for the three
groups’ CSF cytokines levels in relation to brain mI. These
findings suggest altered mechanism of immune regulation
in the brains of HIV patients and a potential influence of
immune status on cognitive function. Supported by NIMH
(R01 MH61427); NIDA (K24-DA16170); NINDS and
NIDA (U54NS56883)
Cannabinoids Inhibit the Migration of Microglial-Like
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The HIV-transcriptional trans-activator protein (Tat) has
been implicated as playing a major role in HIVencephalitis
since it elicits chemokines and cytokines from microglia as
well as a chemotactic response. Since cannabinoids can be
anti-inflammatory, the aim of this study was to investigate
the effects of exogenous and endogenous cannabinoids on
the migration of microglia in response to Tat using an
immortalized mouse BV-2 microglial-like cell model. The
exogenous cannabinoid partial agonist Δ
9-tetrahydrocan-
nabinol (THC; 10
−6–10
−9M) exerted a concentration-
related reduction in the migration of BV-2 cells induced
by Tat (50 nM). A similar inhibitory response was obtained
using the endogenous cannabinoid 2-arachidonoylglycerol
(2-AG; 10
−5–10
−7M). The monoacyl glycerol lipase inhib-
itor (URB602, 10
−6M) also reduced the migration of BV-2
cells induced by Tat (50 nM). The CB2 receptor antagonist
SR144528 (10
−6M), but not the CB1 receptor antagonist
SR141716A (10
−6M), blocked the reduction of migration
produced by THC (10
−6M), 2-AG (10
−5M), and URB602
(10
−6M), consistent with a functional linkage of
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receptor. Collectively, the results suggest that the CB2
receptor has potential to serve as a molecular target for the
therapeutic manipulation of untoward CNS inflammatory
effects elicited by the HIV protein Tat. Supported by NIDA/
NIH 005832
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As HIV-infected individuals live longer with the success of
combinatorial antiretroviral therapy, neurological complica-
tions are emerging as a major health issue, especially
among HIV-infected drug abusers. HIV-positive individuals
who abuse drugs such as cocaine and methamphetamine
show significant increases in the incidence and severity of
neuropathology and in the development of HIV-associated
neurological disorders (HAND). The mechanism(s) by
which drug abuse accelerates the development of neuro-
logical disease remains unclear, but cocaine, methamphet-
amine, and other drugs of abuse mediate their effects by
increasing extracellular dopamine in the CNS. We hypoth-
esize that dopamine alters HIV infection in macrophages
through dopamine receptors, resulting in the exacerbation
of HIV-induced neuropathology in HIV-infected drug
abusers. Our findings demonstrate that dopamine increases
HIV replication in primary human macrophages by increas-
ing the number of macrophages infected with HIV, at least
in part, through the activation of D2-like dopamine
receptors. Preliminary data indicate that increased infection
is due to enhanced HIV entry into macrophages in the
presence of dopamine. Our data also demonstrate that
dopamine activates macrophage dopamine receptors and
alters cytokine production. These data indicate a significant
role for dopamine in the response of the CNS to HIV
infection and suggest that drug-induced increases in
dopamine may be a common mechanism by which drugs
of abuse exacerbate the development of HAND in HIV-
infected drug-abusing individuals. Supported by NIDA
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HIV infection of the CNS occurs early in the disease, and
despite successful therapy, significant inflammation and
neurocognitive dysfunction persists. Cells of the monocyte/
macrophage lineage are key mediators of HIV-associated
neuropathogenesis. Connexin43 (Cx43) is a primary com-
ponent of gap junctions in the CNS, facilitating rapid
communication between cells that regulates CNS homeo-
stasis. A role for Cx43 in the immune system has also been
described. Cx43 is expressed in a variety of immune cells
including macrophages. Connexin hemichannels facilitate
inflammation as well as phagocytosis, although their
function is not completely characterized. Our previous data
indicate that gap junctions mediate transfer of an apoptotic
signal from HIV-infected astrocytes to neighboring cells. In
the current study, we demonstrate that Cx43 is expressed in
primary human macrophages at low levels. HIV infection of
macrophages enhances hyperphosphorylation of Cx43,
which correlates with a decrease in the surface expression
of Cx43. Other groups showed that HIV-infected macro-
phages have impaired phagocytosis. We propose that this
effect may be mediated by down-regulation of Cx43 on the
surface of infected cells. Cx36, primarily found in neurons,
has not been demonstrated in macrophages. We find high
levels of Cx36 expression in primary human macrophages.
Expression of both Cx43 and Cx36 is enhanced in CD68
+
cells in HIV encephalitic tissue. Our findings suggest a
novel mechanism of communication in macrophages that
may contribute to the pathogenesis of HIV CNS disease.
HIV-1 Tat Protein and Morphine Alter Proliferation
and Motility in Neuronal/Glial Progenitors and Attract
Microglia by Secreting Chemokines. Y Hahn
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Myelin pallor is commonly detected by MRI in opiate-
abusing HIV patients even in those treated with HAART.
These neurological disturbances are known to be especially
aggressive in pediatric patients. Myelin pallor had been
thought to result from edema due to alterations in the
blood–brain barrier, but our previous work suggests that
oligodendroglia may be directly affected by the HIV-1 Tat
protein. We have hypothesized that neuronal/glial progen-
itors (NPC/GPCs), and especially those that form oligoden-
drocytes, may be targets of HIV proteins ± opioid drugs of
abuse. Based on our hypothesis, we examined the survival,
proliferation, and other cell functions in NPC/GPCs. We
also examined whether the effects of HIV proteins on
progenitors might be exacerbated by opioid drugs of abuse,
as we have observed in mature glia. Our results showed that
NPC/GPCs are direct targets of HIV viral proteins ±
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increased, NPC/GPCs exhibit reduced motility, migration
rate, and proliferation. We are presently confirming these
results on NPC/GPCs in vivo using transgenic mice
exposed to Tat from uterus to early postnatal stages.
Bioplex analysis also showed that Tat exposure significant-
ly enhanced the secretion of specific chemokines (RANTES
and MIP-1a/b) from NPC/GPCs. We demonstrated that
these chemokines could attract microglia using mAb
neutralization of CCR5/CXCR4 (2D7/12G5) and the
specific inhibitors Anibamine/Maraviroc. In summary,
these data support our hypothesis that both HIV protein
and opioids can affect the function of NPC/GPCs. Sup-
ported by NIDA: R01 DA024461 & P01 DA19398
The Cannabinoids JWH-015 and O-1966 Inhibit the Mixed
Lymphocyte Reaction Via the Cannabinoid Receptor 2
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There is a robust literature showing that cannabinoids
modulate immune responses. Our laboratory has previously
shown that delta9-tetrahydrocannabinol (THC) and anan-
damide, added in vitro, suppress antibody responses by
mouse spleen cells in the primary and secondary plaque-
forming cell assays via CB2. The present study tested the
possibility that CB2 agonists, through their immunosup-
pressive capacity, might lessen graft rejection in transplant
patients. The mixed lymphocyte reaction (MLR) is consid-
ered to be an in vitro correlate of transplant rejection. In this
assay, spleen cells from two mouse strains are incubated
together and T cells of one strain respond to the foreign
cells by proliferating. The capacity of CB2 selective
cannabinoids to suppress proliferation in the MLR was
tested. Two CB2 selective cannabinoids, JWH-015 and O-
1966, were added to MLR cultures. Both inhibited the
MLR in a dose-dependent fashion. To verify that these
effects were through the CB2 receptor, splenocytes were
incubated with either CB1 or CB2 selective antagonists
prior to the addition of the agonists. The CB1 selective
antagonist had no effect on the suppression induced by
JWH-015 or O-1966, while the CB2 selective antagonist
blocked the suppressive capacity of both compounds.
Furthermore, treatment of splenocytes from CB2 receptor-
deficient mice with JWH-015 showed no suppression of the
MLR. These results support the hypothesis that cannabi-
noids, acting through the CB2 receptor, can inhibit the
MLR and suggest that CB2 agonists may be useful adjunct
therapies to block graft rejection. Supported by NIH
Training grant 2T32A1007101-30 and NIH grants
DA13429 and DA06650
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Macrophages orchestrate immune responses that include
microbial clearance, presentation of antigens, and secretion
of bioactive molecules. Paradoxically, they also act as
reservoirs and vehicles for microbial pathogen dissemina-
tion including HIV. Moreover, macrophages, as biological
response modifiers, as such influence disease progression.
We demonstrated that both effector T cells (Teff) and
regulatory T cells (Treg) affect neuroAIDS. Treg inhibits
macrophage activation, enhances apoptosis, and reduces
viral production. Teff showed contrary effects except for
killing infected macrophages. To elucidate the molecular
mechanisms for these effects, we used iTRAQ to study the
quantitative changes in the proteome of virus-infected
macrophages during cell–cell interactions with Teff or
Treg. In these studies, HIV-1/VSV pseudotypes were used
to infect murine bone marrow macrophages. Expectedly,
both Teff and Treg modulated virus-infected macrophage
proteins associated with cell structure, metabolism, and
redox biology. Surprisingly, they enhanced virus-specific
immune response by upregulation of interferon-inducible
proteins (GBP2, STAT1, and ISG15). HIV-1 infection
triggered caspase-1 activation. This response was enhanced
by Teff and attenuated by Treg, resulting in pyroptosis and
apoptosis, respectively. Taken together, we posit that Treg
possesses regulatory and effector functions for virus-
infected macrophages. Our results challenge the dogma
that Treg functions exclusively as suppressor and provides
undisclosed mechanisms of adaptive immune surveillance
during HIV-1 infection.
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Alcohol consumption is highly prevalent in HIV patients,
which leads to a decrease in the response to anti-retroviral
therapy (ART) and an increase in oxidative stress (OS)-
mediated toxicity. Therefore, we studied the effect of
alcohol on the genetic and functional expressions of
cytochrome P450 (CYP) that are known to metabolize
ART drugs (such as 2B6, 2D6, and 3A4) and OS (such as
S26 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S592A6, 2E1, and 3A4) in the liver. This study was performed
in U937, a human leukemic monocyte lymphoma cell line
that differentiates into macrophages and is an in vitro model
for HIV-related research. Compared with housekeeping
gene GAPDH, the mRNA expression of CYP2A6 (1%),
CYP2E1 and CYP3A4 (0.1%), and CYP2B6 (∼0.01%) was
measurable in both U937 monocytes and macrophages.
Alcohol showed up-regulation of CYP2A6 (3-fold),
CYP2B6 (2.5-fold), CYP2E1 (5-fold), and CYP3A4 (2.4-
fold) compared with the control in the early time points (6
and 12 h). Thus, the results suggest that alcohol could lead
to a decrease in response to ART drugs as a result of their
increased metabolism by CYP2B6 and CYP3A4. Similarly,
alcohol could lead to an increase in OS by increasing the
expression of CYP2A6, CYP2E1, and CYP3A4. Synergis-
tic effect of alcohol and ART drugs on the expression of
CYP in U937 and primary cells is underway. Supported by
start-up funds KBE78
HIV-1 Hijacks the Endocytic Trafficking Networks
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Tunneling nanotubes (TNT) are bridging conduits that
support intercellular exchanges of receptors, lysosomes,
and mitochondria. HIV-1 transmission by intercellular
connections is 1,000 times more efficient than the cell-
free dissemination. Therefore, mechanisms of TNT-
mediated HIV-1 escape from humoral immunity have
generated intense interest following failure of vaccine
strategies. To determine the mechanisms underlying intra-
and intercellular viral trafficking, still and live confocal
imaging, transmission, and scanning electron microscopy
were utilized. HIV-1 enhances the frequency of TNT in
infected macrophages, and these structures were observed
to extend over 600 μm. These support seamless intercellu-
lar bidirectional flow of endocytic vesicles at an average
velocity of 1.5 μm/s propelled primarily by myosin II.
Confocal imaging and proteomic analysis of TNT showed
that viral constituents (proteins and RNA) are transferred to
the uninfected target cells by early (Rab5/EEA1), recycling
endosomes (Rab11a), multivesicular bodies (ESCRT III),
and lysosomes. Inhibition of myosins by blebbistatin and
butandiene monoxime and disruption of actin filaments and
microtubules by cytochalasin D and nocodasole perturbed
trafficking of HIV-1 constituents through the TNT. These
data provide new evidence that HIV-1 can escape immune
surveillance by inducing TNT formation and increased
vesicle sorting in human macrophages and uses such
processes for direct transport from infected to the uninfect-
ed target cells. Supported by P01 NS43985
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HIV-1-associated neurocognitive disorders (HAND) occur,
in part, due to the inflammatory response to viral proteins,
such as Tat, in the central nervous system (CNS). Ibudilast
(AV411) is a non-selective cyclic AMP phosphodiesterase
inhibitor that is currently used to treat neuropathic pain. It
has previously been shown that phosphodiesterase inhibi-
tion decreases TNF-alpha synthesis via modulation of NF-
KB signaling and that AV411 can specifically inhibit LPS-
induced TNF-alpha production by murine microglial cells.
Based on this information, we hypothesized that AV411
would inhibit Tat-induced TNF-alpha release from micro-
glial cells. Here, we demonstrate that TNF-alpha production
in Tat-exposed microglial cells is dose-dependently
inhibited by AV411 pretreatment and that this inhibition is
dependent on protein phosphatase activity as it was
reversed by okadaic acid. Also, it appears that AV411 does
not affect Tat-induced NF-KB activation in microglial cells,
as shown by IKB-alpha immunoblot and RelA nuclear
localization. Our data suggest that AV411 inhibits Tat-
induced cytokine synthesis in a manner that does not
modulate activation of NF-KB and that this inhibition is
reversed by okadaic acid, which is an inhibitor of serine/
threonine protein phosphatase. Our findings shed light on
the mechanism of AV411 inhibition of Tat-induced TNF-
alpha production and may have important therapeutic
implications for the management of HAND. Supported by
National Institutes of Health
HIV-1 Deactivates Oxidative Stress-Induced Antioxidant
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Background: T cell depletion below a threshold often leads
to recurrent infection in patients with HIV-1 infection.
Recently, pivotal roles of p66ShcA proteins have been
identified in the generation of oxidative stress and induction
of T cell apoptosis. HIV-1 activates p66ShCA pathway
leading to the deactivation of Foxo3A-dependent stress
response program, resulting into the accumulation of ROS
and thus promoting T cell apoptosis. We evaluated the
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phospho-Akt, phospho-FoxO3a, MnSOD, and catalase (by
Western blotting) as well as T cell ROS generation (T cells
probed with DCFDA). Moreover, we studied the relation-
ship of HIV-1-induced ROS generation and induction of T
cell apoptosis. HIV-1 promoted ROS generation in a time-
and dose-dependent manner. HIV-1 also enhanced phspho-
p66ShcA expression by T cells; interestingly, T cells
lacking p66ShcA showed not only attenuated generation
of ROS but also reduced occurrence of apoptosis in
response to HIV-1. Moreover, HIV-1-treated T cells showed
increased phosphorylation of FoxO3A as well as dimin-
ished production of superoxide (SOD) and catalase. HIV-1
stimulates p66ShCA pathway which induces deactivation
of Foxo3A-dependent stress response program, resulting
into the accumulation of ROS and entry into apoptotic
phenotype.
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Methamphetamine (METH) has been shown to induce
oxidative stress in SH-SY5Y, a neuroblastic, dopaminergic
cell line model. In neuronal cells, oxidation of dopamine by
auto-oxidative or enzymatic events leads to the production
of reactive oxygen species (ROS). Neuronal cells treated
with METH accumulate dopamine which can ultimately
lead to increased levels of ROS. ROS has been shown to
mediate expression of mu-opioid receptor (MOR). The goal
of this in vitro study using SH-SY5Y cells was to examine
how treatment with METH affects the accumulation of
intracellular ROS, which may in turn modulate MOR
expression. Laser scanning confocal microscopy indicated
that METH-induced intracellular accumulation of ROS,
detected as the increased fluorescence of dihydrorhodamine
123, occurred in a dose- and time-dependent manner. In
addition, accumulation of ROS preceded METH-induced
expression on MOR. METH-induced MOR expression was
attenuated with the free radical chelator, vitamin E. Addi-
tional evidence supporting a role for ROS in METH
modulation of MOR expression includes an observed
increase in MOR expression following hydrogen peroxide
treatment. Our data show that the effect of METH on MOR
expression appears to be dependent upon the intracellular
accumulation of ROS. This study suggests a possible
coupling of METH- and opiate-mediated intracellular sig-
naling. Supported by NIH/NIDA K02 (DA016149) to SLC
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Human immunodeficiency virus (HIV) infection in the
CNS causes neurocognitive disorders. Impairment of adult
neurogenesis in the hippocampus contributes to cognitive
dysfunction. The effects of paroxetine on the proliferation
and generation of neurons in the hippocampus in HIV-gp120
transgenic mouse model were determined. Paroxetine was
administered by subcutaneous osmotic mini-pump in adult
mice at a dose of 10 mg kg
−1day
−1 for 4 weeks. To assess
neural progenitor cell (NPC) proliferation, a single dose of
200 mg/kg of BrdU was given and euthanized 2 h later. For
the study of maturation of NPCs, after 2 weeks of
paroxetine infusion, 50 mg/kg BrdU was injected once
daily for 7 days and all mice were euthanized 3 weeks after
the first BrdU injection. There was a 37% reduction in the
number of newborn cells labeled with BrdU+ in the dentate
gyrus of the gp120 transgenic mice as compared to wt
mice, suggesting a defect of NPC proliferation. Subcutane-
ous administration of paroxetine led to a 21% increase in
NPC proliferation in gp120 transgenic mice, thereby
resulting in a partial rescue of NPC proliferation. Double-
label immunohistochemistry analysis showed a 47% reduc-
tion in the number of newly generated neurons, which are
labeled as BrdU+NeuN+ cells in the dentate gyrus of gp120
transgenic mice as compared to littermate wt mice.
Paroxetine administration led to a significant increase in
BrdU+NeuN+ cells in the dentate gyrus. Thus, the
paroxetine rescues both NPC proliferation and generation
of new neurons in gp120 transgenic mice. Supported by
NINDS, NIMH
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Bowman–Birk inhibitor (BBI) is a soybean-derived serine
protease inhibitor which has been shown to exert potent
anti-inflammatory effects. We thus investigated the effect of
BBI as a neuroprotective agent against neurocytotoxicity of
LPS-activated macrophages. Although LPS, when directly
added to the rat cortical neuron culture, had little
S28 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59cytotoxicity effect, supernatant from LPS-stimulated mac-
rophage culture induced neurotoxicity as evidenced by the
loss of cortical neurons. In contrast, supernatant from BBI-
treated and LPS-activated macrophage culture resulted in a
significant reduction of neurocytotoxicity. In addition, BBI-
treated neuronal cells became less susceptible to toxicity of
LPS-activated macrophages. This BBI-mediated neuropro-
tection was independent to NMDA receptor as BBI
treatment could not protect rat cortical neuron from
NMDA-mediated cytotoxicity. Investigation of the mecha-
nism responsible for the BBI action revealed that BBI
treatment of macrophages inhibited LPS-induced produc-
tion of pro-inflammatory cytokines, TNF-alpha and IL-6,
two known neurotoxins. BBI treatment also induced the
expression of IL-10, a known anti-inflammatory cytokine in
macrophages. These findings provided scientific evidence
to support the use of BBI as a supplementary treatment for
microglia/macrophage-mediated neuronal injury. Supported
by NIH Grants DA12815 and DA22177 (to WZH)
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Very little is known about the impact of methamphetamine
(METH), a highly abused psychostimulant, on host cell
innate immunity. This study examined whether METH has
the ability to impair toll-like receptor-9 (TLR-9)-mediated
anti-HIV immunity in macrophages. TLR-9 activation by
CpG oligodeoxynucleotides (CpG ODN) induced the
expression of endogenous IFN-alpha and inhibited HIV-1
replication in macrophages. However, METH treatment of
macrophages compromised the anti-HIV ability of TLR-9
activation. Dopamine D1 receptor antagonist (SCH23390)
could block the METH action. Investigation of the
mechanisms revealed that METH selectively inhibited
endogenous TLR-9 expression as well as ODN-induced
TLR-9/IFN-alpha expression in macrophages, leading to
the downregulation of multiple key elements (MyD88, IRF-
7, MxA, and ISG56) in TLR-9/IFN-alpha signaling
pathway. These findings provide an additional novel
mechanism for METH-mediated enhancement of HIV
replication in macrophages. Supported by National Insti-
tutes of Health Grant DA25477
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Methamphetamine (METH), a potent stimulant with strong
euphoric properties, has been shown to alter the permeabil-
ity of the blood–brain barrier (BBB). However, the
mechanisms by which METH directly affects endothelial
cells and causes endothelial injury, leading to BBB
dysfunction, are not completely understood. In some
cellular settings, autophagy can serve as a cell survival
pathway, suppressing apoptosis, and in others, it can lead to
death itself, either in collaboration with apoptosis or as a
backup mechanism when the former is defective. In this
study, we found that METH treatment evoked an autopha-
gic response in primary human umbilical vein endothelial
cells (HUVECs). Endothelial cells exposed to 10 µm
METH did not reduce cell viability, however up-regulated
the autophagy-related gene Beclin 1 expression in a time-
dependent manner with a concurrent inhibition of the
antiapoptotic gene Bcl-2 expression. Confocal microscopy
revealed an up-regulation in the vesicular localization of
LC-3-GFP, and Western blot analysis shows an increased
LC-3II. Studies are in progress to determine if inhibition of
autophagy by siRNA-mediated silencing of Beclin 1 can
prevent METH-induced apoptosis, demonstrating an im-
portant role of autophagy in METH-induced cell death. The
role of sigma-1 and dopamine D1/D2 receptors will also be
investigated as potential mechanisms underlying METH-
induced autophagy using receptor-specific antagonists. Our
studies suggest that METH induces autophagy in endothe-
lial cells as an initial survival response, but chronic
exposure may lead to apoptotic events. Supported by RO1
DA12104, RO1 DA 022935, KO2 DA015349, P50
DA11806 (to S.R.)
Marijuana Use Worsens Cognitive Function But Does Not
Change CSF Immune Markers in Patients Without HIV-
Associated Neurocognitive Disorder (HAND). SM
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Marijuana is the leading drug abused by HIV-infected
individuals and is often prescribed to them for medical
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tive ingredient in marijuana, may lead to cognitive deficits
and may shift the balance of cytokine or chemokine
expression from TH1 to TH2. We studied 20 HIV subjects
with normal cognition and had current (within last
6 months) or without current (last use >1 year) daily
marijuana use. Each was administered a battery of
neuropsychological tests that had been used in numerous
HIV studies, localized brain proton MR spectroscopy in
four brain regions, and had lumbar punctures to collect
cerebrospinal fluid (CSF) for measurements of a set of
cytokines using Luminex. No significant group difference
was observed between HIV current and non-current
marijuana smokers in the 11 measurable cytokines and
chemokines (IL-1-beta, IL-6, IL-8, FLT-3L, IP-10, MCP-1,
MDC, PDGF-AA, and TGF-beta) in their CSF. Yet, current
HIV+ marijuana users had significantly lower z-scores in
cognitive domains for learning (p=0.040), memory (p=
0.050), and motor function (p=0.023), as well as lower
glutamate in the basal ganglia (p=0.05) and higher
glutamate+glutamine in frontal white matter (p=0.03).
These findings suggest that poorer cognitive functions in
the HIV+ marijuana users is not related to the THC-
mediated alteration of expression of these cytokines and
chemokines, but may be due to other mechanisms such as
oxidative stress or changes in neurotransmitter function.
Supported by NIMH (R01 MH61427); NIDA (K24-
DA16170); NINDS and NIDA (U54NS56883)
Morphine Modulation of Neutrophil Chemotaxis
and Function. T Muppavarapu
1, R Charboneau
1,R A
Barke
2,SR o y
1;
1Department of Pharmacology, University
of Minnesota, Minneapolis, MN 55455,
2Department of
Surgery, Veterans affairs medical center, Minneapolis, MN
55455
Patients prescribed morphine for the management of
chronic pain often present complications like increased
susceptibility to opportunistic infections and inadequate
healing of wounds. Neutrophils are important cells of the
innate immune system and are among the first responders
that are recruited to the site of infection or inflammation.
Neutrophil chemotaxis occurs by the binding of the
chemokine (MIP2) to a chemokine receptor (CXCR2). A
delay in neutrophil chemotaxis and function would result in
impaired clearance of infection or improper wound healing.
However, effects of morphine on neutrophil chemotaxis,
function, and the mechanisms underlying this phenomenon
have not yet been characterized. Our lab has standardized a
modified model for chemotaxis—under agar migration
assay—to observe the effects of morphine on neutrophil
chemotaxis. Our findings show a marked decrease in
chemotaxis towards MIP2 when neutrophils were treated
with morphine. Furthermore, morphine treatment signifi-
cantly altered neutrophil function as observed by an in vitro
phagocytosis assay. To delineate the mechanism, we show
that chronic morphine treatment increases intracellular
cAMP which concurrently activates PKA. PKA has been
shown to modulate downstream effectors of the Rho family
GTPases Rac/cdc42, leading to actin polymerization. Actin
polymerization is important for neutrophil chemotaxis and
function. Taken together, these results establish the detri-
mental effects of morphine on neutrophils. The mechanisms
underlying this phenomenon will be identified using
specific antagonists. Supported by RO1 DA12104, RO1
DA022935, KO2 DA015349, P50 DA11806 (to S.R.)
Cytomegalovirus Preferentially Infects Neuronal
Precursors in the Developing Brain. MB Mutnal
1,M C
Cheeran
1,SH u
1, M Little
1, JR Lokensgard
1;
1CIDMTR,
University of Minnesota, Minneapolis, MN 55455
Cytomegalovirus (CMV) is the most frequent infectious
cause of developmental disorders of the central nervous
system (CNS) in humans. It has been shown that neural
stem cells are specifically targeted by this virus, which
appears to be responsible for the generation of brain
abnormalities. In this study, we hypothesized that CMV
preferentially infects neuronal precursors in the developing
brain and alters subsequent neurogenesis. In our first set of
experiments, we evaluated which specific cell types
supported viral infection. One-day-old neonatal mice were
infected with a recombinant virus that expresses green
fluorescent protein (GFP). At 7 days p.i., CMV-infected
brains were dissociated and incubated with antibodies
identifying distinct CNS precursor subtypes, including
CD133, CD24, CD44, A2B5, and nestin. Previous studies
have shown that CD133 (Prominin-1)-expressing cells have
the highest frequency of initiating clones, as measured by
neurosphere formation. CD24 expression has been used to
identify transit-amplifying cells as well-differentiated neu-
rons, and expression of this marker has been found to be
required for terminal differentiation of neuronal progeni-
tors. At 7 days p.i., we found that the majority of CD24-
positive cells were infected, while only a small proportion
of glial precursor cells were found to be infected. We also
observed that Prominin-1-positive cells were found to be
less numerous in infected brains when compared to sham
controls. These findings suggest that neuronal precursor
cells are at the highest risk of viral infection and damage.
Experiments are currently supported by R01 NS-038836
from NINDS.
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of the NMDA Receptors NR2B Subunit through
a Histone Deacetylase-Dependent Pathway Contributing
to Neuronal Survival. JN i c o l a i
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1,JR u b i n
2,
O Meucci
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1Pharmacology and Physiology, Drexel
University College of Medicine, Philadelphia, PA 19102,
2Department of Pediatrics, Washington University School of
Medicine, St. Louis, MS 63110
Constitutive expression of the chemokine CXCL12 and its
receptor CXCR4 on neuronal and glial cells suggests a
homeostatic role of this chemokine/receptor pair in the
CNS. Our previous studies show CXCL12 protects cortical
neurons from excitotoxicity by promoting the function of
the gene repressor protein Rb, which is involved in the
recruitment of chromatin modifiers (e.g., histone deacety-
lases) to gene promoters. In neurons, Rb controls activity-
dependent genes essential to neuronal plasticity and
survival, such as the NMDA receptors subunit NR2B.
NMDA receptor kinetics is determined by the combination
of regulatory subunits, and receptor subtype/localization
may contribute differently to survival. Some data suggest
that synaptically located NR2A-containing receptors facil-
itate neuronal survival, while NR2B-containing receptors
are involved in neurotoxicity. We report that CXCL12
differentially modulates intracellular responses following
stimulation of synaptic and extrasynaptic NMDA receptors
via a regulation of the NR2B gene that involves histone
deacetylases. Our results show that CXCL12 selectively
inhibits NR2B expression in vitro and in vivo, altering
NMDA-induced calcium responses associated with neuro-
nal death while promoting pro-survival pathways associated
with synaptic receptor activation. Along with previous
studies, these findings underline the role of CXCL12/
CXCR4 in the regulation of crucial components of
glutamatergic transmission. These novel effects of CXCL12
may be involved in the physiological function of the
chemokine in both the developing and mature brain.
Supported by DA15014, DA19808, CA118389
Morphine Modulation of Mechanisms Involved
in Macrophage Bactericidal Activity. J. Ninkovic
1,S .R o y
2;
1Department of Pharmacology, University of Minnesota,
Minneapolis, MN 55455,
2Department of Surgery, Depart-
ment of Pharmacology, University of Minnesota, Minneapolis,
MN 55455
Morphine-induced immune suppression has been well
explored in scientific literature as well as anecdotally.
Clinically, opioid users and abusers show a greater
susceptibility to opportunistic bacterial infections. It has
been shown by our group and others that morphine leads to
increased bacterial dissemination and bacterial loads. The
increased susceptibility to infection and higher bacterial
loads are detrimental for the host’s survival. An important
component of bacterial clearance is bacterial killing.
Following phagocytosis, bacterial pathogens are cleared
by a series of mechanisms. The focus of this research is to
determine mechanisms by which morphine inhibits bacte-
rial killing in macrophages. Our data show that morphine
inhibits bacterial killing by primary peritoneal macrophages
and macrophage cell line. We examine the effects of
morphine on macrophage bactericidal ability by measuring
bacterial loads of GFP-tagged Escherichia coli via fluo-
rometry and by culturing cell homogenates following
macrophage phagocytosis of bacteria. Our data show that
morphine inhibits activation of Rac-GTPase, which is
essential in function and recruitment of the NADPH
complex, a key mechanisms for bacterial killing. In order
to identify other mechanisms involved in morphine-induced
inhibition of bactericidal functions, our studies focus on
how morphine modulates release of reactive oxygen
intermediates such as hydrogen peroxide (H2O2) as well
as release of nitric oxide (NO) and iNOS expression.
Supported by RO1DA12104, RO1 DA022935, KO2
DA015349, P50DA11806 (to S.R.) and T32 DA07097,
F31DA026264-01A1 (to J.N.)
Laboratory Macrophage Screening Assays Predict
Pharmacokinetics of Controlled Release of Nano-
formulated Antiretroviral Drugs In Vivo. A Nowacek
1,
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1, J Mcmillan
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Backgruond: Factors that limit the efficacy of conventional
antiretroviral therapy (ART) for HIV-1 infection include
pharmacokinetics (PK) and penetration into viral sanctua-
ries. These affect rates of viral mutation and drug
resistance. In attempts to bypass these limitations, nano-
particles containing ritonavir (RTV), indinavir (IDV), and
efavirenz (EFV; described collectively as nanoART) were
screened in human monocyte-derived macrophages (MDM)
for measures of drug uptake, release, and cytotoxicity.
NanoART were manufactured by wet-milling of crystalline
drug with various surfactant coatings. Size, charge, and
shape of the nanoparticles were assessed. MDM nanoART
uptake and drug release, cell migration, and cytotoxicity
were determined. NanoART that performed best and worst
in vitro were then tested in mice for in vivo PK and
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S31biodistribution following a single intravenous dose. Drug
levels in serum, liver, and spleen were determined by LC-
MS/MS and RP-HPLC. Parallels between in vitro drug
uptake and in vivo PK were assessed. Efficient MDM
uptake was seen in <30 min based on size, charge, and
coating. Antiretroviral drugs were released over 14 days
and showed dose-dependent reduction in virion production.
Cytotoxicities resulting from nanoART carriage were
limited. Sustained IDV and RTV levels in serum (2–
10 ng/ml) were present >7 days without toxicity. These
results demonstrate that MDM nanoART drug screening in
vitro can predict in vivo PK. The data support the
establishment of cell depots of nanoART for long-term
drug release. Supported by NIH Grant: 34-5160-2028-012
Transcriptional Regulation of the HIV-1 Chemokine
Co-receptor CCR5 by the CAMP/PKA/CREB Pathway
in Bone Marrow Progenitor Cells. NP a r i k h
1,AB a n e r j e e
1,
V Pirrone
1,BW i g d a h l
1, MR Nonnemacher
1;
1Department of
Microbiology and Immunology, Drexel University College of
Medicine, Philadelphia, PA 19102
The cyclic adenosine monophosphate (cAMP)-dependent
signaling pathway directs the expression of several genes.
The primary effectors of this pathway are members of the
cAMP response element binding (CREB) family of
transcription factors, in particular CREB-1 and cAMP
response element modulator (CREM). Although the beta-
chemokine receptor CCR5 has been identified on progen-
itor cells in the bone marrow, the regulatory mechanisms
orchestrating its expression are not fully understood.
Previous reports have identified putative cAMP response
elements in the CCR5 promoter and have described a
suppressive role for cAMP in CCR5 expression. In this
study, the CD34
+CD4
+CCR5
+ human bone marrow pro-
genitor cell line TF-1 was used to investigate the detailed
kinetics of CCR5 transcription in response to the elevation
of intracellular cAMP levels and the underlying molecular
events. We demonstrate that CCR5 transcription follows an
asymmetrical sinusoidal pattern in TF-1 cells that parallels
a protein kinase A-dependent alternating change in the ratio
of activator pCREB-1-alpha,delta to repressor pCREM-
alpha,beta isoforms. However, elevated CCR5 mRNA
levels do not correlate with enhancement in infectivity with
respect to the R5 human immunodeficiency virus type 1
(HIV-1) strain, although there is an increase in X4-utilizing
virus. These results lend critical insight into the precise
mechanism governing the cAMP-CCR5 axis in progenitor
cells and pose interesting questions regarding its functional
role in HIV-1 infection. Supported by NIDA
Human Immunodeficiency Virus-1 NEF
and Methamphetamine Increase the Expression
of Interleukin-6 in Astrocytes: Implication in HIV-
Associated Dementia. KP a t e l
1,AK u m a r
1;
1Division of
Pharmacology, University of Missouri-Kansas City, Kansas
City, MO 64112
Methamphetamine use has been shown to be associated with
increased HIV-1 infection and also known to be associated
with increased neurological abnormalities in HIV-infected
individuals. Patients with AIDS dementia complex have been
reported to show a detectable concentration of IL-6 when
compared with patients with neurological diseases. HIV-1
gp120 and Tathavebeenwidely implicated inHIV-associated
neurological abnormalities, but very little is known about
HIV-1 nef, its effect on astrocytes, and how it works in
conjunction with methamphetamine. In this study, we asked
whether methamphetamine and HIV-1 nef individually affect
IL-6expressioninhumanastrocytesandwhether there willbe
synergybetweenHIV-1nef andmethamphetamine.Ourstudy
shows thatmethamphetamine and HIV-1nef increasedthe IL-
6 expression in SVGA astrocytes by 5.3±0.2- and 11.7 ± 1.9-
fold, respectively. We also observed synergy between these
two, and IL-6 expression was found to be elevated by 28.8±
7.2-fold. We also observed that the NF-kB pathway was
involved in Nef-mediated IL-6 over-expression as NF-kB-
specific siRNA inhibited IL-6 production. Moreover, Nef-
specific siRNA inhibited the IL-6 induction too. These
results indicate that HIV+ individuals and methamphet-
amine users are at a higher risk of neurological abnormal-
ities compared to those who are infected with HIV but do
not use methamphetamine.
Glycogen Synthase Kinase 3-Beta in the Basolateral
Amygdala Mediates the Reconsolidation of Drug-Related
Memory. WU Ping
1;
1National Institute on Drug
Dependence, Peking University, Beijing, P.R. China 100191
Exposure to drug-associated conditioned stimuli elicits
craving and increases the probability of drug relapse in
cocaine users evenafter extendedperiods ofabstinence, while
drug seeking can be inhibited by disrupting the reconsolida-
tion of drug-related memory. Previous studies have demon-
strated a role for glycogen synthase kinase 3-beta (GSK-3-
beta) in the synaptic plasticity underlying dopamine-
associated behaviors and diseases, as well as the reconsolida-
tion of fear memory. In the present study, we examined the
role of GSK-3-beta in the basolateral amygdala (BLA) in
reconsolidation of drug-related memory using an animal
model of cocaine-conditioned place preference (CPP). We
foundthat:(1)GSK-3-betaactivityintheBLA,butnotcentral
S32 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59amygdala (CeA) of rats that acquired cocaine CPP, increased
after re-exposure to a previously cocaine-paired chamber (a
retrieval procedure). (2) Lithium chloride, a non-selective
inhibitor of GSK-3-beta, systemically administered after
retrievalinhibitedreconsolidationofthedrug-relatedmemory.
(3)MicroinjectionofSB216763,a selectiveinhibitorofGSK-
3-beta, into the BLA, but not into the CeA, immediately after
re-exposure to the previously cocaine-paired chamber
inhibited reconsolidation of the drug-related memory. The
disruption of the memory lasted at least 1 week and did not
reinstate following a cocaine priming injection. These results
suggest that the activity of GSK-3-beta in the BLA mediates
the reconsolidation of drug-related memory.
Comorbid Effect of HIV-1 GP120 and Methamphetamine
on Synaptic Transmission and Plasticity in Rat
Hippocampal Slices. BC Reiner
1,HX i o n g
1;
1Department
of Pharmacology and Experimental Neuroscience, University
of Nebraska Medical Center, Omaha, NE 68198
Methamphetamine (Meth) abuse and human immunodefi-
ciency virus 1 (HIV-1) infection are major public health
issues today, and infection of HIV-1 is often associated with
Meth use. While many investigations have focused on the
individual effects of Meth and HIV-1 in the brain, far less has
been done on their intersecting influences. We hypothesize
that Meth and HIV-1gp120 might have synergistic detrimen-
tal effects in the brain. To test this hypothesis, we studied the
effects of HIV-1gp120 (200 pM) and Meth (100 μM) on
synaptic transmission and plasticity in rat hippocampal slices
using an electrophysiological approach. Electrical-evoked
field excitatory postsynaptic potentials (fEPSPs) were
recorded in the CA1 region of untreated (control) slices and
slices treated with HIV-1gp120 or Meth alone or in
combination. Our results showed that incubation (1 h) of
brain slices with HIV-1gp120 or Meth alone impaired input–
output responses and long-term potentiation (LTP) induced
by high-frequency stimulation of Schaffer collateral fibers,
and these impairments were significantly strengthened when
brain slices were incubated with both HIV-1gp120 and Meth.
Our data demonstrated that HIV-1gp120 and Meth exert a
comorbid effect on synaptic transmission and plasticity in the
brain. Supported by NIH grant R01 NS063878
Synaptic Protein Degradation Plays Critical Roles
in Reconsolidation of Cocaine-Rewarding Memory. ZY
Ren
1,M ML i u
1,LL u
1;
1National Institute on Drug
Dependence, Peking University, Beijing , P.R. China 100191
The process of drug addiction shares striking commonali-
ties in neural plasticity associated with natural reward
learning and memory. A fundamental mechanism for
learning and memory is the remodeling of synapses, arising
by the degradation of proteins or by the incorporation of
new proteins. Drug memories are dynamic in nature. The
reactivation of a drug memory through re-exposure to drug-
related cues results in its destabilization, necessitating a
restabilization process known as reconsolidation, a disrup-
tion of which leads to amnesia. Memory reconsolidation
consists of two phases, a reactivation-dependent destabili-
zation process followed by the protein synthesis-dependent
restabilization phase. Although it has been shown that
protein synthesis inhibition can disrupt the morphine-
conditioned place preference (CPP) memory, it still remains
unknown what is the role of synaptic protein degradation in
drug-rewarding memory. Using cocaine CPP model, we
demonstrated that synaptic protein degradation was in-
creased by memory reactivation in the nucleus accumbens
(NAc) core, a critical region in mediating drug-seeking
behavior. Synaptic protein degradation is critical in reconso-
lidation and extinction, but not consolidation of cocaine-
rewarding memory. Infusion of lactacystin into the NAc core
rescued anisomycin-induced reconsolidation impairment and
blocked memory extinction. This suggests that protein
degradation is as crucial as protein synthesis in the updating
process of cocaine-rewarding memory, which provides a
novel strategy for drug addiction treatment. Supported by the
National High Technology Research and Development
Program of China (863 Program, 2006AA02Z4D1)
Cystatin B Associates with Proteins Related to HIV
Replication. L Rivera Rivera
1,JP é r e zl a s p i u r
1, M Plaud
Valentín
1,LM e l é n d e z
1;
1Department of Microbiology and
NeuroAIDS Program, University of Puerto Rico, School of
Medicine, San Juan, PR 00936-5067
HIV persistence in monocyte-derived macrophages (MDM)
has been associated with cystatin B, a cysteine protease
inhibitor. High levels of cystatin B in MDM are associated
with HIV replication, whereas low levels in placental
macrophages (PM) and microglia are associated with HIV
restriction. Furthermore, studies with MDM demonstrate
that levels of cystatin B correlate with lower level of
tyrosine-phosphorylated STAT-1 (STAT-1PY). We used a
proteomics approach consisting of immunoprecipitation
followed by LC-MS/MS to identify the proteins interacting
with cystatin B in order to elucidate the relationship
between cystatin B, STAT-1 phosphorylation, and HIV
persistence in MDM. We hypothesize that cystatin B may
interact with proteins that regulate the phosphorylation of
STAT-1 and contribute to additional functions besides being
an active cysteine protease inhibitor. We found that cystatin
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S33B associates with two distinct regulatory proteins, one of
these associated with the STAT-JAK signaling pathway. Six
enzymes were associated with the glycolytic pathway,
including pyruvate kinase M2 isoform, previously associ-
ated with HIV replication. These results demonstrate that
cystatin B interacts with proteins related to the regulation of
STAT-1 phosphorylation and HIV replication. The elucida-
tion of how cystatin B regulates STAT-1 phosphorylation
and HIV infection can prove important for the development
of inhibitory factors against macrophage reservoirs. Sup-
ported by RO1 MH08316-01, NINDS 1 U54NS430,
RCMI-G12RR03051
Effect of Buprenorphine and Methadone on Human Cd4
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T Lymphocytes and Glial Cells. M Rodriguez
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Background: Buprenorphine (BUP) and methadone (MTD)
are mu-opioid receptor agonists widely used for detoxifi-
cation and short- and long-term maintenance treatment of
opiate addiction. Since the emerging and frequent use of
these drugs in the HIV-1 population, it is significant to
appreciate how these drugs impact the HIV-1 replication at
the cellular and molecular level. Previous studies indicated
that MTD enhances HIV-1 replication and suppresses
cellular function, raising a major concern that MTD and
perhaps BUP could play a role in the pathogenesis of HIV-
associated neurocognitive disorders (HAND). In this study,
we investigated whether MTD or BUP potentiates HIV-1
replication in human CD4
+ T lymphocytes and glial cells
using quantitative RT-PCR. In addition, we also measured
the production of pro-inflammatory cytokines using cyto-
metric bead array (CBA). We have shown that both MTD
and BUP enhanced HIV-1 replication in both CD4
+ T cells
and microglial cells. This enhancement effect was associ-
ated with alterations in the production of pro-inflammatory
cytokines in CD4
+ T lymphocytes and the expression of
HIV-1 co-receptor CCR5 on microglial cells. Following
pre-exposure with mu-opioid receptor antagonists such as
nalthrexone (NALT) and naloxone (NALX), HIV-1 repli-
cation was not affected, suggesting that MTD and BUP
may be eliciting their cellular and molecular mechanisms
through the mu-opioid receptor. These findings provide a
cellular mechanism that supports the notion that both MTD
and BUP may have a co-factor role in the development of
HAND. Supported by NIH-RCMI grant #2G12RR03035
Human Immunodeficiency Virus-1 GP120 Increases
the Expression of Interleukin-6 in Astrocytes: Implication
in HIV-Associated NeuroAIDS. A Shah
1, A Kumar
1;
1Division of Pharmacology and Toxicology, University of
Missouri-Kansas City, Kansas City, MO 64112
HIV-1 protein gp120 is a surface glycoprotein which
enables viral attachment/entry to the host cells. Among
various complications associated with HIV-1, the mech-
anism of HIV-associated dementia (HAD) remains under-
developed. HIV-1 Tat and gp120 have been largely
implicated in neuroinflammation in HIV-infected individ-
uals. However, it is not known with certainty whether
gp120 causes IL-6 over-expression in the central nervous
system. It has also been reported that HIV-infected
patients with neuroinflammation show elevated levels of
interleukin-6 (IL-6). In our study, we sought to address
whether gp120 is involved in IL-6 over-expression in
astrocytes. Our study shows that HIV-1 gp120 increases
the IL-6 expression at both mRNA and protein levels by
51.3±2.1- and 17.9±3.7-fold, respectively, which could
be abrogated by the use of gp120-specific siRNA. We
have also confirmed that the NFkB pathway is involved
in gp120-mediated IL-6 over-expression as IKK-2 and
IKKb inhibitors inhibited the gp120-mediated IL-6
expression by 55% and 65%, respectively. These results
were also confirmed with the use of NFkB-specific
siRNA. The results indicate that HIV-1 gp120-mediated
over-expression of IL-6 in astrocytes may be at least one
mechanism responsible for neuroinflammation in HIV-
infected individuals and that this over-expression was
mediated by the NF-kB pathway.
Vaccine Strategy for Parkinson’s Disease Protects Against
TH17 Cell-Mediated Nigrostriatal Neurodegeneration
in MPTP Mouse Model. DK Stone
1, AR Reynolds
1,J A
Hutter
1,R LM o s l e y
1,H EG e n d e l m a n
1;
1Department of
Pharmacology and Experimental Neuroscience, University
of Nebraska Medical Center, Omaha, NE 68198-5880
Nitration (N) and aggregation of alpha-synuclein (a-syn)
are associated with a broad range of immune and neural
activities in Parkinson’s disease (PD). N-a-syn drains to
cervical lymph nodes and induces a robust antigen-specific
T cell effector (Teff) response that exacerbates microglial
neurotoxic responses and consequent nigrostriatal neuro-
degeneration in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyri-
dine (MPTP)-intoxicated mice. We show that such
neuroimmune degenerative activities, in significant mea-
sure, are Th17 cell-mediated. Indeed, adoptive transfer of
CD4
+ T cells polarized to Th1 and Th17 N-4Ysyn (nitrated
C-terminus of a-syn) Teff exacerbates MPTP-induced
S34 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59nigrostriatal degeneration, whereas Th2 Teff did not, and,
importantly, CD4
+CD25
+ regulatory T cells (Treg) were
protective. Tregs from N-4Ysyn-immunized mice showed
diminished antiproliferative responses and, as such, con-
tribute to Teff-associated neurodegeneration. In contrast,
natural and vasoactive intestinal peptide (VIP)-induced
Treg reversed N-4Ysyn T cell nigrostriatal degeneration.
Combinations of adoptively transferred N-4Ysyn and VIP
immunocytes attenuated MPTP-induced microglial inflam-
mation and led to robust protection of the nigrostriatum.
Taken together, these results demonstrate the ability to
utilize immunopharmacologic means to reverse the patho-
biology of in vitro and in vivo PD models. This work is
transformative as it provides a distinct direction in neuro-
immune pharmacology to slow the progression of nigros-
triatal degeneration reflective of PD. Supported by Frances
and Louie Blumkin Foundation and the Community
Neuroscience Pride of Nebraska Research Initiative
Alterations in the Expression of the HIV-1 Coreceptor
CXCR4 in Response to the Mu-Opioid Agonist DAMGO
Decreases HIV-1 Replication in TF-1 Human Bone
Marrow Progenitor Cells. M Strazza
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About one third of the cases of acquired immunodefi-
ciency syndrome in the USA have been attributed to the
use of injected drugs, frequently involving abuse of
opioids. Previous in vitro and in vivo studies addressing
the role of mu-opioid agonists in altering levels of co-
receptor CXCR4 and consequent HIV-1 replication have
yielded contrasting results. The bone marrow (BM) is
believed to be a potential anatomical sanctuary for HIV-
1. In this study, the CD34
+CD38
+ human BM progenitor
cell line TF-1 was used as a model to investigate the
effects of the mu-opioid receptor-specific peptide
DAMGO on CXCR4 expression as well as infection of
undifferentiated hematopoietic progenitor cells. The
results revealed the presence of the mu-opioid receptor-1
isoform (MOR-1) in TF-1 cells. Immunofluorescence
microscopic analyses demonstrated a bipolar co-
localization pattern for MOR-1 and CXCR4 in a subpop-
ulation of cells positive for both receptors. TF-1 cells were
subdivided into two subpopulations comprising low and
high surface CXCR4 expressors. Flow cytometry experi-
ments indicated that treatment with DAMGO resulted in a
shift in the relative proportion of CXCR4
+ cells to the
low-expressing phenotype. This result is correlated with a
>3-fold reduction in replication of X4 HIV-1 strain IIIB,
indicating a potential role for the CXCR4 high expressors
in sustaining infection within these cells. These experi-
ments provide insight into the role of MOR-1-mediated
signaling with respect to inhibition of viral replication in
BM progenitor cells. Supported by NIDA
Effects of Acute Tyrosine, Tryptophan, and Phenylalanine
Depletion Treatment on Cue-Induced Alcohol Urging
in Patients with Alcohol Dependence in China. HQ Sun
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The capacity of alcohol cues to precipitate the desire to drink
may be an important determinant of relapse to alcohol use in
recovering alcohol-dependent patients. The serotonin and/or
dopamine may play a role in the craving induced by alcohol
cues. Tryptophan (Trp) and phenylalanine/tyrosine (Phe/Tyr),
precursors of serotonin and dopamine synthesis, acute
depletion canmakethe attenuation ofserotonin and dopamine
synthesis in the human brain. Some studies showed that there
were no significant changes in the magnitude of cue-induced
craving with active tryptophan depletion compared with
placebo in abstinent alcoholic patients. However, compared
to the balance mixture, Phe/Tyr-free, but not Trp-free,
significantly decreased the ingestion of alcohol in healthy
women. Up to date, the effect of acute tyrosine, tryptophan,
and phenylalanine depletion on the cue-induced alcohol
craving in patients with alcohol dependence is not entirely
clear. This study evaluated whether attenuation of serotonin
and dopamine synthesis via depletion of their precursors
tryptophan, tyrosine, and phenylalanine can change the
magnitude of cue-induced alcohol urging for alcohol in
recently abstinent alcoholic male individuals in China. This
is a double-blind, randomized, placebo-controlled, crossover
design. Twelve male patients with alcohol dependence in
China who met the criteria of DSM-IV completed the
experiment under two acute treatment conditions. Supported
by The National Basic Research Program of China (973
Program, 2007CB512302)
Functional Disconnection of the Ventral Tegmental Area–
Basolateral Amygdala–Nucleus Accumbens Circuit
Disrupts Heroin-Induced Conditioned Immunomodulation.
JL Szczytkowski
1, DT Lysle
1;
1Psychology Department,
University of North Carolina, Chapel Hill, NC 27703
Heroin-induced suppression of pro-inflammatory mediators
such as inducible nitric oxide synthase (iNOS), TNF-alpha,
and IL-1 beta can be conditioned to environmental stimuli
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S35associated with drug administration. Recently, our labora-
tory has shown that both the basolateral amygdala (BLA)
and the nucleus accumbens (NAC) independently play
critical roles in the expression of these conditioned effects.
The present investigations sought to determine whether a
circuit exists between the ventral tegmental area (VTA), the
BLA, and the NAC which mediates the expression of
heroin-induced conditioned immunomodulation by utilizing
the functional disconnection procedure. Rats were given
five conditioning trials in which they received an injection
of heroin immediately upon placement into a conditioning
chamber. Rats were then re-exposed to the conditioning
chamber 6 days later without further drug administration.
Prior to re-exposure, rats received unilateral intra-BLA
microinfusions of the dopamine D1 antagonist, SCH23390,
to block the dopaminergic input from the VTA to the BLA.
Concomitantly, the glutamate antagonist, AP-5, was infused
into the contralateral NAC shell to disrupt the glutamatergic
input to the NAC from the BLA. Analyses using real-time
RT-PCR indicate that disconnection of this circuit attenu-
ates the suppressive effects of heroin-associated environ-
mental stimuli on pro-inflammatory mediators. This study
is important because it is the first to define a specific circuit
involved in neural immune interactions. Supported by
NIDA
Opiates Modulate T Cell Stress Response Program.
D Torri
1, D Saran
1,DK u m a r
1,P CS i n g h a l
1;
1Feinstein
Institute for Medical Research, North Shore-LIJ Health
System, New Hyde Park, NY 11040
Oxidative stress has been demonstrated to be an important
mediator of cell death in a variety of cells including T cells.
Recently, pivotal roles of p66ShcA proteins have been
identified in the generation of oxidative stress and induction
of T cell apoptosis. We hypothesize that opiates stimulate
the p66ShCA pathway which induces deactivation of
Foxo3A-dependent stress response program, resulting into
the accumulation of ROS and entry into apoptotic pheno-
type. We studied the effect of morphine on T cell oxidative
stress, associated downstream signaling, and the outcome.
Morphine promoted ROS generation which was associated
with T cell apoptosis. These effects of morphine were
inhibited both by opiate receptor antagonists as well as by
antioxidants. Interestingly, morphine enhanced T cell
phspho-p66ShcA and phospho-Foxo3A expression which
led to the diminished production of superoxide dismutase
(SOD) and catalase. Similarly, mice receiving morphine not
only showed enhanced splenic tissue ROS generation,
apoptosis, and expression of p66ShcA, and Foxo3A but
also displayed diminished production of SOD and catalase;
however, these effects of morphine were attenuated by
naloxone. These findings indicate that opiates stimulate the
p66ShCA pathway which induces deactivation of Foxo3A-
dependent stress response program, resulting into the
accumulation of ROS (by attenuating antioxidant genera-
tion) and entry into apoptotic phenotype.
Heroin-Induced Suppression of Sickness Behavior
and Pro-inflammatory Mediators in Associated Brain
Regions. AF Wagner
1,L JJ a n n a c h
1, RL Bigler
1,D TL y s l e
1;
1Department of Psychology, University of North Carolina at
Chapel Hill, Chapel Hill, NC 27599-3270
Central pro-inflammatory mediators are essential for inducing
sickness behaviors that improve infection outcome. Opiates
are known to be peripherally immunosuppressive; however,
little is known regarding the immune effects of opiates within
the brain and subsequent consequences on these adaptive
sickness behaviors. In the present experiments, the effects of
heroin on pro-inflammatory mediators in the brain and
sickness behaviors (behavioral depression and fever) were
evaluated. Biotelemetry devices conveying activity levels and
body temperature were surgically implanted in Lewis rats.
Groups consisted of saline/saline, heroin (1 mg/kg, s.c.)/
saline, saline/LPS (1 mg/kg, s.c.), or heroin/LPS treatments.
Brains were removed 8 h post-treatment, and the hippocam-
pus and the hypothalamus, which are associated with
behavioral depression and fever, respectively, were processed
for mRNA analysis via RT-PCR. In the saline/LPS-treated
group, TNF-alpha, IL-1beta, iNOS, MCP-1, and IL-6 mRNA
levels were significantly increased in the hippocampus and
hypothalamus, and behavioral depression and fever were
exhibited. However, in the heroin/LPS-treated group, mRNA
levels of TNF-alpha and IL-6 in the hippocampus and in
TNF-alpha, IL-1beta, IL-6, and iNOS in the hypothalamus
were significantly suppressed compared to the saline/LPS-
treated group. The heroin/LPS group also displayed inhibited
behavioral depression and fever production. These results
indicate that heroin has immunosuppressive effects in the
brain and on sickness behaviors, which may be detrimental to
infection outcome. Supported by NIDA
Pro-inflammatory Mediators Increased Selectively
in the Hippocampus of HIV-1 Transgenic Rats. AF
Wagner
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Neurological complications in HIV-1 infection are associ-
ated with increased levels of pro-inflammatory mediators,
including interleukin-1beta (IL-1beta), tumor necrosis
factor-alpha (TNF-alpha), and inducible nitric oxide syn-
thase (iNOS) in the central nervous system. These pro-
S36 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59inflammatory mediators are believed to be produced in
response to the presence of HIV proteins and contribute to
neurological symptoms by creating a chronic inflammatory
state in the central nervous system. The present study
examined pro-inflammatory mediator mRNA present in
specific brain regions in the HIV-1 transgenic rat which
expresses HIV proteins. Brains from HIV-1 transgenic rats
were dissected and processed for real-time reverse tran-
scriptase polymerase chain reaction (RT-PCR) analysis.
Results indicated that the HIV-1 transgenic rats expressed
increased levels IL-1beta, TNF-alpha, and iNOS mRNA in
the hippocampus compared to wild-type controls; in the
cortex, striatum, and hypothalamus, there were no differ-
ences in mRNA between the two groups. However, control
experiments utilizing lipopolysaccharide (LPS) treatment as
a general immune stimulus in non-HIV-1 transgenic rats
induced elevations in IL-1beta, TNF-alpha, and iNOS
mRNA in all regions examined. The specificity of pro-
inflammatory responses to the hippocampus of HIV-1
transgenic rats versus the general pro-inflammatory re-
sponse produced by LPS suggests a particular susceptibility
of the hippocampus to HIV protein-induced alterations.
Supported by National Institute on Drug Abuse
Chronic Delta9-Tetrahydrocannabinol Treatment Lowers
Markers of Inflammation and Oxidative Stress in Lymph
Nodes of Rhesus Macaques Infected with Simian
Immunodeficiency Virus. EM Walker
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Ongoing studies indicate that chronic Delta9-THC (THC)-
treated, simian immunodeficiency virus (SIV)-infected rhesus
macaques have increased survival and tend to have lower
plasma viral loads during infection. Cannabinoids have been
reported to exert anti-inflammatory and anti-oxidative effects;
both mechanisms could impact on viral replication particular-
ly at lymphoid sites. Lymph nodes serve as a viral reservoir,
contributing to plasma viral load throughout infection, and
could be a site of cannabinoid immunomodulation. We
examined the effects of chronic THC (0.32 mg/kg; twice
daily, i.m.) administration on viral load, cytokine expression,
and oxidative stress in plasma and lymph nodes of SIV-
infectedrhesusmacaquescollectedatnecropsy.Animals were
necropsied at various time points post-infection. Chronic
THC-treated animals had lower plasma viral load (5.28 vs.
6.11 log copies of gagRNA/ml), lymph node proviral DNA
(1.57 vs. 1.99 log copies/10,000 cells), and viral gagRNA
(1.14 vs. 2.08 log copies/total RNA) as compared to vehicle-
treated animals, yet failed to reach statistical significance.
Survival time post-infection showed a negative correlation
with levels of IFNgamma in lymph nodes (r=−0.853, p=
0.007). Levels of IFNgamma and protein carbonylation, a
marker of oxidative stress, were lower in THC-treated
compared to vehicle-treated animals, but these values failed
to reach statistical significance. These data suggest that small
changes in inflammatory or oxidative states in lymphoid
tissues may contribute to the THC treatment effects on
survival and viral load. Supported by NIDA-020419-011
Morphine Differentially Modulates TLR-4-Induced
Autophagy and Phagolysomal Maturation in Macrophages.
JW a n
1,H DY u
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Autophagy is an important player in many critical biolog-
ical processes and involves the sequestration of regions of
the cytosol within double-membrane-bound compartments
and delivery of the contents to the lysosomes for degrada-
tion. Activation of TLR-4 by LPS leads to the redistribution
of LC3 from diffuse to punctate staining, typical of
autophagosomes. As maturation proceeds, autophagosomes
fuse with endosomal vesicles and acquire lysosome-
associated membrane proteins (LAMP1 and LAMP2), thus
becoming late autophagosomes that subsequently fuse with
lysosomes. Phagolysosomal fusion then facilitates killing of
ingested pathogens. We investigated the effect of morphine
on TLR-4-induced autophagy and phagolysosomal fusion
in bone marrow-derived macrophages (BMDM). Our
results show that morphine treatment resulted in a signif-
icant increase in LPS-induced vesicular translocation of
LC3-1-GFP with a concurrent increase in the lipidated form
of LC3-II (Western blot). In addition, morphine treatment
of BMDM resulted in the up regulation of LPS-induced
Beclin 1 and down-regulation of Bcl-2. In contrast,
morphine inhibited LPS-induced phagosome maturation
and phagolysosomal fusion, as indicated by the failure to
recruit the late phagosomal marker LAMP-1 into phag-
osomes. These observations imply that although morphine
treatment facilitates LPS-induced autophagy leading to
increased survival of infected macrophages, it inhibits
phagosome maturation and phagolysosomal fusion which
is essential for the efficient removal of internalized
pathogens, thereby potentiating bacterial survival. Sup-
ported by RO1 DA12104, RO1 DA022935, KO2
DA015349, P50 DA11806 (to S.R.) and T32 DA07097
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Many facets of transcriptional and translation regulation
contribute to the proper functioning of the nervous system.
miRNAs are small RNA molecules that serve as checkpoints
in transcription and translation processes. However, the
molecular basis for neuronal dysfunction found in the HIV-
associated neurocognitive disorder (HAND) and its associat-
ed neuropathology, HIV encephalitis (HIVE), remains un-
known. This study focused on identifying the regulation of
miRNAs in the brains of monkeys and humans with SIVE/
HIVE. Strikingly, a number of miRNAs were significantly
increased in the infected brains and, when assessed by in situ
hybridization, were abnormally expressed in neurons. Given
the ability of miRNAs to modulate cellular mRNAs and
proteins and thus cellular physiology, we identified for the
first time that a critical neuronal transcription factor is a target
of one of these miRNAs, miR-21. Functionally, miR-21
expression in neurons prolongs the opening of voltage-gated
K
+ channels. These findings further underscore the regulatory
loop in which miRNAs function and highlights their
importance in neurodegenerative research. Supported by
NIH grants P30 MH062261 and R01 MH073490 in addition
to Nebraska Tobacco Settlement Biomedical Research
A Cannabinoid CB2 Agonist Attenuates Leukocyte–Brain
Endothelial Interactions and Blood–Brain Barrier
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Lipopolysaccharide (LPS), released from Gram-negative
bacteria, induces an inflammation-mediated endothelial and
vascular dysfunction in various organs. Our previous
studies indicated that selective CB2 receptor activation
was neuroprotective through its anti-inflammatory proper-
ties. In this study, the role of a selective CB2 receptor
agonist (O-1966) in LPS-induced cerebral microvascular
inflammation and blood–brain barrier (BBB) function was
investigated. Cranial window and intravital microscopy
were used to directly observe leukocyte/endothelial inter-
actions in mouse brain after LPS (6 mg/kg) injection. O-
1966 (5 mg/kg) was given at the same time as LPS. BBB
function was tested by Evans blue extravasations in vivo.
Transendothelial electrical resistance (TEER) was used to
test the effects of O-1966 on compromised barrier integrity
of human brain endothelial cells (BMVEC) after LPS
stimulation in vitro. The results showed that LPS induced
a dramatic increase in leukocyte rolling and adhesion (p<
0.05) on brain microvascular endothelial cells after LPS
inoculation, which were significantly reduced by O-1966
(p<0.05). Permeability of BBB (measured by Evans blue
extravasations) was increased at 24 h after LPS injection
(p<0.05), and these changes were prevented by treatment
with O-1966. Our preliminary data also indicate that O-
1966 enhances and protects barrier function when the
TEER is monitored on BMVEC. Our studies demonstrated
that selective CB2 activation diminished leukocyte engage-
ment by brain endothelium under inflammatory conditions
and protected the BBB.
Depressive-Like Behaviors are Associated with Increased
Membrane Fraction of P35 Level in the Hippocampal
Dentate Gyrus After Chronic Mild Stress in Rats. WL
Zhu
1,LL u
1;
1National Institute on Drug Dependence, Peking
University, Beijing, P.R. China 100191
Cyclin-dependent kinase 5 (Cdk5) has been implicated in
learning and synaptic plasticity. Previous evidence suggests
that neuronal plasticity and neurotrophins are involved in
depression and bipolar disorder. Here, we explored if Cdk5
participates in the depressive-like behaviors in chronic mild
stress (CMS)-treated rats. We found here that CMS caused
a significant increase of Cdk5 activity and an upregulation
of membrane fraction of p35 protein as well as a reduction
of cytosolic p35, a Cdk5 activator, in the dentate gyrus
(DG) of the hippocampus. Conversely, microinjection of a
Cdk5 inhibitor, butyrolactone (Buty), in DG subregion, but
not in CA1 or CA3 hippocampal subfields, reversed these
depressive-like symptoms without affecting the symptoms
of control rats. Furthermore, treatment with Buty in DG,
but not in CA1 or CA3 of the hippocampus, increased the
cytosolic p35 level as well as decreased the membrane p35
level in CMS-administrated rats. The current results
proposed that the development of depressive-like behaviors
were regulated by increased Cdk5 activity through the p35
translocation from the cytosol to the membrane in the DG
subregion of the hippocampus. These findings indicated
that the depressive-like behaviors induced by chronic mild
stress were mediated by the activation of Cdk5 in DG and
that the Cdk5/p35 complex could provide a potential target
for development as a novel therapeutic for the treatment of
depressive disorders. Supported by the National Basic
Research Program of China (973 Program,
2007CB512302) and National Natural Science Foundation
(no. 30800362)
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High HIV DNA in Brain CD14
+/16
+ Cells in Necropsy
Cases Diagnosed with Neurocognitive Disorders. MA
Agsalda
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1;
1Hawaii Center for
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0000
In HIV-associated neurocognitive disorder (HAND), acti-
vated monocytes (CD14
+/16
+) are hypothesized to traffic
HIV into the CNS and initiate inflammation. We hypoth-
esize that HIV encephalitis (HIVE) brains will have higher
HIV DNA copies in CD14
+/16
+, which could be targeted
by polyamine analogs in new therapeutic strategies.
Matched cryostat sections from the basal ganglia (BG)
and the frontal cortex (FC) from HIVE and HIV-infected
cases with normal cognition (NC) were obtained from the
UCSF ACSR. Dual-labeled regions (CD14
+/16
+)w e r e
extracted by laser-capture microdissection. CD14 regions
were extracted separately. Quantitative multiplex PCR
determined HIV DNA copies/cell. HIVE individuals (n =
4) contained higher CD14
+/16
+ HIV DNA levels (0.9 HIV
DNA copies/cell±0.9; 0.7 copies/cell±0.5) compared to
CD14-cells (0.3 copies/cell±0.1; 0.09 copies/cell±0.09) in
the BG and FC, respectively. In contrast, individuals with
NC (n=3) had higher HIV DNA levels in CD14 cells (2
copies/cell±3; 0.8 copies/cell±0.5) compared to CD14
+/
16
+ cells (1.3 copies/cell±0.5; 0.02 copies/cell±0.04) in the
BG and FC, respectively. Higher HIV DNA copies are
found in CNS targeted regions in CD14
+/16
+ cells from
HIVE cases, suggesting that these cells traffic and target the
basal ganglia and frontal cortex, possibly establishing an
inflammatory environment. This further suggests that
specific polyamine analogs that target CD14
+/16
+ cells
peripherally, such as MGBG, could potentially be used to
prevent CNS inflammation. Supported by AI081450;
NS053345
Effects of Alcohol on Cannabinoid (CB2) and Serotonin
(5-HT3) Receptors in the Human Neuroblastoma
Cell Line, SK-N-MC, and the Role of Histone Deacetylase
2 (HDAC2). M Agudelo
1,ZS a i y e d
1, N Gandhi
1,
T Samikkannu
1, P Khatavkar
1, M Nair
1;
1Institute of
NeuroImmune Pharmacology, Florida International
University, Miami, FL 33199-0000
Alcohol dependence (AD) is a complex addiction regulated
by multiple mechanisms including the serotonin and
cannabinoid systems. The serotonin (5-hydroxytryptamine,
5HT) and cannabinoid receptor (CBR) genes are known to
be involved in AD, and 5-HT3 and CB1 antagonists have
been shown to reduce alcohol self-administration. However,
most studies were done in animals, and the expression and
alcohol-mediated mechanism of 5-HT3 and CB2 in human
neuronal cells is not clear. CB2 is known as the peripheral
receptor, and its expression in brain cells is controversial.
Recent reports have implicated histone deacetylases
(HDACs) in drug abuse through their ability to regulate
gene expression, and HDAC inhibitors modulate genes
involved in drug addiction such as the µ-opioid receptor
gene. Therefore, we hypothesize that HDACs play a role in
AD via modulation of CB2 and 5-HT3 receptors. The
levels of CB2, 5-HT3, and HDAC 2 mRNAwere measured
in the human neuroblastoma cell line, SK-N-MC, by qRT-
PCR. The effects of acute EtOH treatment on gene and
protein expression were assessed at different time points.
The HDAC effect was studied using an HDAC inhibitor,
Trichostatin A (TSA). Results show that SK-N-MC
expresses CB2 and 5-HT3 receptors and EtOH increases
CB2, 5-HT3, and HDAC2 mRNA in a dose-dependent
manner. Inhibition of HDAC with TSA shows modulation
of ethanol effects on CB2 and 5-HT3 mRNA. These results
suggest that HDAC2 is involved in the alcohol-mediated
effects on CB2 and 5-HT3 receptors and the use of HDAC
inhibitors may be of therapeutic significance for the
treatment of AD. Supported by National Institute on Drug
Abuse grants R37DA025576, R01DA01DA2366, and
R01DA021537
HIV-1-Induced Amyloid Beta Accumulation in Brain
Endothelial Cells is Attenuated by Simvastatin. IE
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HIV-1-infected brains are characterized by increased amy-
loid deposition. To study the influence of HIV-1 on amyloid
beta (Abeta) homeostasis at the blood–brain barrier (BBB)
level, we employed a model of brain microvascular
endothelial cells exposed to HIV-1 in the presence or
absence of Abeta. HIV-1 markedly increased endogenous
Abeta levels and elevated accumulation of exogenous
Abeta. Simvastatin, the HMG-CoA reductase inhibitor,
blocked these effects. We next evaluated the effects of
HIV-1 and/or simvastatin on the expression of the receptor
for lipoprotein-related protein (LRP1) and the receptor for
advanced glycation end products (RAGE) known to
regulate Abeta transport across the BBB. LRP1 expression
was not affected by HIV-1; however, it was increased by
simvastatin. Importantly, simvastatin attenuated HIV-1-
induced RAGE expression. These results suggest that
HIV-1 may directly contribute to Abeta accumulation at
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S39the BBB level. In addition, statins may protect against
increased Abeta levels associated with HIV-1 infection in
the brain.
Lower CSF ApoE in HIV-infected Individuals Without
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ApoE gene polymorphism is implicated to play a signifi-
cant role in the progression of the HIV disease. Of the three
possible ApoE alleles (E2, E3, and E4) in humans, E4
renders HIV-infected individuals more susceptible to
neurological impairments and to dysregulated lipid, sterol,
and sphingolipid metabolism, increasing susceptibility to
oxidative stress. Since ApoEprotein transports cholesterol
to growing and regenerating neurons in the CNS, adequate
delivery of lipids and cholesterol by ApoEprotein may be a
critical factor in repair processes in the brain. This study
evaluated possible interactions between HIV infection and
ApoE4 status on CSF ApoEprotein levels and cognitive
function. We genotyped 32 HIV-infected subjects and 29
age- and education-matched seronegative controls and
measured their CSF [ApoEprotein]. HIV-infected subjects
have significantly lower levels of CSF ApoEprotein than
the healthy controls (−20%, p = 0.048). Although no
differences in CSF [ApoEprotein] were observed between
E4+ and E4− seronegative controls (p=0.20), E4-HIV
subjects had even lower CSF [ApoEprotein] compared to
E4+ carriers with HIV (−33%, p=0.026). Those with lower
CSF [ApoEprotein] actually performed better on the HIV
dementia scale. These findings suggest that the metabolism
of ApoEprotein in the CNS is affected by HIV infection,
but the alteration may not be due to the E4 allele. Ongoing
analyses will further correlate these findings with detailed
cognitive assessments. Supported by NIH (2R01MH61427,
5R25MH080661 2K24DA016170 and 1U54-NS056883)
Morphine Induces the Release of CCL5 from Astrocytes:
Potential Neuroprotective Mechanism Against the HIV
Protein GP120. V Avdoshina
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A number of HIV-positive subjects are also opiate abusers.
These individuals are at high risk to develop neurological
complications from HIV infection. However, little is still
known about the molecular mechanism(s) linking opiates
and HIV neurotoxicity. To learn more, we exposed rat
mixed neuronal/glial cultures from the cerebellum to opiate
agonists and the HIV envelope glycoprotein gp120, which
has been shown to cause neuronal loss. Gp120IIIB and
gp120BaL, which bind to CXCR4 and CCR5 chemokine
receptors, respectively, promoted cell death. Morphine did
not change the toxic effect of gp120IIIB but inhibited the
cytotoxic property of gp120BaL. This effect was blocked
by naloxone and reproduced by the μ-opioid receptor
agonist DAMGO. To examine the potential mechanism(s)
of neuroprotection, we determined the effect of morphine
on the release of chemokines CCL5 and CXCL12. CCL5
has been shown to prevent gp120BaL neurotoxicity, while
CXCL12 decreases neuronal survival. Morphine failed to
affect the release of CXCL12. However, morphine elicited
a time-dependent release of CCL5, which was seen only in
primary cultures of astrocytes. To examine the role of
endogenous CCL5 in the neuroprotective activity of
morphine, mixed cerebellar neurons/glial cells were immu-
noneutralized against CCL5 prior to morphine and gp120s.
In these cells, the neuroprotective effect of opiate agonists
was blocked. Our data suggest that morphine may exhibit a
neuroprotective activity against M-tropic gp120 through the
release of CCL5 from astrocytes. Supported by NIDA
Unfolded Protein Response in Human Monocyte-Derived
Dendritic Cells Exposed to Alcohol Revealed by Proteomics.
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Dendritic cells (DC) are responsible for the activation of T
and B cells. There is accumulating evidence showing that
alcohol can significantly affect various immune responses.
We hypothesize that this occurs by modulating changes in
specific key proteins triggering a process known as the
unfolded protein response (UPR). This process typically
protects cells from the toxic effects of accumulated
misfolded proteins causing endoplasmic reticulum (ER)
stress. Although much is known about ER stress, much less
is understood about the consequences of the disruption of
these interactions due to alcohol treatment. In the present
study, we investigated alterations in DCs proteins treated
with 0.1% of alcohol by 2D gel electrophoresis, protein
identification using mass spectrometry, and confirmation at
the gene expression level by qRT-PCR. DCs proteome
induced with alcohol demonstrated 32 differentially
expressed proteins. Alcohol significantly changed the
expression of the key components of the UPR-ER stress-
induced pathway that include chaperones, ER stress
S40 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59antioxidant enzymes, protein degradation proteins, and
enzymes related to alcohol metabolism. qRT-PCR analyses
highlighted enhanced expression of important UPR and
antioxidant genes that increased rapidly with alcohol
treatment. Results of these analyses provide insights into
alcohol mechanisms of regulating DC and suggest that
alcohol induced a UPR transcriptional program in DC. We
speculate that activation of a UPR by alcohol may protect
the DC from oxidant injury that may lead to the
development of alcohol-related diseases.
Psychostimulants and the Female Genital Mucosa:
Norepinephrine (NE) Delays Epithelial Wound Healing.
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Abuse of sympathomimetic psychostimulants like cocaine,
which increase synaptic NE concentrations, is associated
with increased susceptibility to HIV infection. The epithelia
of the vagina and cervix are the first sites exposed to HIV
and are damaged during coitus. Immunohistochemistry
revealed that nerve fibers immunoreactive for NE synthetic
enzymes terminate under the human cervical epithelium.
We hypothesized that NE alters wound repair in cervical
and vaginal epithelial cells. Wound repair was measured
using continuous impedance sensing combined with phase
contrast imaging to characterize the time course for wound
closure. Circular wounds (250-μm diameter) were produced
by electroporation of confluent vaginal (hVE) and cervical
(hCE) cell monolayers. Complete restitution occurred at 4 h
for control hVE cells and at 5.5 h for hCE cells. NE
(10 μM) significantly slowed the initial rate of wound
closure by 3.5-fold in hVE and hCE cells, and complete
restitution was delayed by 4–6 h after wounding. The
inhibitory effect of NE on wound healing appears to be
mediated by alpha2-adrenergic receptors in hVE cells.
These results suggest that NE disrupts intrinsic barrier
function and repair processes in vaginal and cervical
epithelial cells. Cocaine and other abused sympathomimetic
drugs could enhance pathogen penetration in the female
genital mucosa. Supported by NIH DA-10200
Reversal of gp120 Inhibition of the Antinociception
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In a previous study, both the chemokine CXCL12/SDF-
1alpha and the human immunodeficiency virus type 1 coat
protein, glycoprotein 120 (gp120), were reported to reduce
the antinociception induced by subcutaneous (s.c.) injection
of the cannabinoid agonist WIN55,212-2 in the cold water
tail-flick test (CWT). Because gp120 binds to the same
receptor, CXCR4, as CXCL12/SDF-1alpha, the present
experiments were designed to use the CXCR4-selective
antagonist, AMD3100, to investigate the receptor involve-
ment in the effect of gp120 on the cannabinoid-induced
antinociception. Adult male Sprague–Dawley rats (200–
250 g, Ace Animals, Inc.) were housed individually after
surgical implantation of cannulae into the periaqueductal
grey (PAG). Experiments began 1 week postoperatively.
The CWT was used as an antinociceptive index. A cutoff
time was set at 60 s. The percent of maximum possible
antinociception (%MPA) for each animal at each time was
calculated using the following formula: %MPA=[(test
latency−baseline latency)/(60−baseline latency)] × 100.
The results showed that (1) AMD 3100 (100 pg, 10 ng,
100 ng, and 500 ng, PAG) itself had no effect in this range;
(2) gp120 (100 ng, PAG, t=−30) can reduce the anti-
nociception induced by WIN55,212-2 (1 mg/kg, s.c., t=0);
and (3) AMD3100 (100 ng, PAG, t=−45) can reverse the
gp120 (100 ng, PAG, t=−30) antagonism of this antinoci-
ception. These results suggest that CXCR4, expressed in
the brain of rats, is involved in the gp120 antagonism of
antinociception induced by cannabinoids. Supported by
NIDA Grants DA 06650 and DA13429
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Obstructive Pulmonary Disease (AECOPD). WD
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Long-term inhalation of tobacco smoke can result in the
development of chronic obstructive pulmonary disease
(COPD) which is characterized by remodeling and destruc-
tion of the lung tissue and a significant reduction of lung
function. These patients can also experience periods of
acute exacerbation in which lung function is further
reduced and hospitalization may be required. In an effort
to understand the immune system status of these patients,
we examined the gene expression profile of PBMCs of
patients during AECOPD. Twenty-two patients hospitalized
for AECOPD were enrolled. Blood samples were collected
during hospitalization and 11±8 weeks following resolution
of AECOPD. PBMCs were isolated and microarray
analysis performed. Data were analyzed using Scoregene,
Genomica, and Ingenuity. Of probes, 4.8% and 3.4%
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S41detected significant gene expression changes >40% up or
down, respectively. Several genes with higher expression,
including fibronectin, scavenger receptors, arginase1, IL1R
type II, IL13Ra1, IGF1, C5aR1, MMPs, and TLR6, suggest
an elevation of circulating alternatively activated macro-
phages. In contrast, there were T cell-specific genes
reduced, including CD3, CD8, LFA1, IL2Rg, and TCR
Vb alleles, but not CD4. Interestingly, the expression of
these genes is not normally regulated in mature cells, which
suggest that there is a significant reduction in circulating
CD8 cells during AECOPD. These results suggest that the
development of AECOPD involves a change in the
composition of the circulating immune system which may
contribute to the ongoing immunopathology in the lung.
Supported by NIH-NIDA P30DA-13429; DA25532;
DA14230
LPS-Induced miR-155 Upregulation Modulates MOR
Expression by Inhibiting PU.1. SD a s
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Mammalian microRNAs (miRNAs) have recently emerged
as potent regulators of gene expression in activated
acquired and innate immune responses including develop-
ment, differentiation, and homeostasis. In addition, mech-
anistic studies have suggested that these processes are
crucially dependent upon the interaction between miRNAs
and transcription factors. The current study was aimed at
investigating the role of miR155 in modulating LPS-
induced mu opioid receptor (MOR) expression. Our
preliminary miRNA array data suggested miRNA-155 as
one of the miRNAs being upregulated when stimulated
with LPS. Our findings suggested that LPS upregulated
miR-155 expression in murine J774 cells. Morphine alone
did not have any effect, while morphine in combination
with LPS decreased LPS-induced miR-155 overexpression.
We also tested the target genes for miR-155. The two major
target genes we found were PU.1 and C/EBPb. In our
studies, both transcription factors were negatively regulated
by miR155, confirming them as its target. Since PU.1 has
also been shown to interact with MOR gene in sequence-
specific manner, thereby negatively regulating MOR gene
expression, we tested the same in our model. LPS
stimulation also increased MOR gene expression. There-
fore, in our model, LPS by inducing miR-155 negatively
regulates PU.1, thereby upregulating MOR gene expres-
sion. We are further investigating the roles of other
transcription factors like NFkB and how they regulate
LPS-mediated miR155 upregulation and MOR gene ex-
pression. Supported by RO1 DA12104, RO1 DA022935,
KO2 DA015349, P50 DA11806 (to S.R.)
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The objective of this study was to determine the time-
dependent functional central nervous system (CNS) alter-
ations following HIV-1 infection in humanized mice. NOD/
SCID-IL-2R g
−/− mice were reconstituted with human cord
blood CD34
+ cells. Mice were infected with the laboratory-
adapted HIV-1ADA strain and CNS deficits assessed
during progressive viral infection using quantitative
1H
magnetic resonance spectroscopy (
1H MRS) acquired at 4
and 8 weeks after viral infection. Mice were bled once
every 2 weeks and the sera analyzed for HIV-1 viral RNA
by the COBAS AMPLICOR test. Blood cells were stained
for human CD45, CD3, CD4, CD8, CD19, and CD14 and
analyzed by flow cytometry. Viral load in peripheral blood
increased from 2 to 8 weeks after virus exposure. Flow
cytometric analyses clearly demonstrated reductions in
CD4
+ T cells by 8 weeks after HIV infection. Immunohis-
tochemical analysis of infected brains demonstrated human
cell infiltration into the CNS with activation of microglia
and astrocytes. While
1H MRS showed no significant
alterations in the hippocampus or the brainstem/pons
regions, diminished N-acetyl aspartate levels at 8 weeks
were seen in the cerebellum and the cerebral cortex,
demonstrating early neurodegeneration. This multiplex
study of HIV-1-infected of humanized mice provides a
model system to assess in vivo functional changes in the
brain following progressive viral infection. Future studies
will determine the time course of neurodegeneration and
the effectiveness of therapeutic interventions for CNS
disease following HIV-1 infection.
Role of NFkB in IL-1beta-Mediated C3 Gene Regulation.
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Uncontrolled complement component C3 synthesis as a
result of excessive IL-1beta synthesis as observed in
patients with acute (stroke, trauma) and chronic (HIV
dementia, Alzheimer’s disease) neurodegenerative diseases
S42 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59can be injurious to host tissue. Our previous studies have
demonstrated that IL-1beta induces C3 expression in a
CAAT/enhancer-binding protein (C/EBP)-dependent man-
ner. In this study, we investigated the role of NFkB in IL-
1beta-mediated regulation of C3 expression in astrocytic
cells. Our results demonstrate that overexpression of NFkB
subunits p65, p50, and c-rel induces C3 promoter activity.
Furthermore, pre-incubation of astrocytic cells with SC-
514, an inhibitor of NFkB signaling, or overexpression of a
dominant negative mutant of IkBalpha inhibits IL-1beta-
mediated C3 expression. Our studies also demonstrate that
overexpression of NIK activated C3 expression, and this
expression was inhibited by co-transfection of a wild-type
IKK-gamma expression plasmid. Our results suggest that
overexpression of IKK-gamma inhibits activation of NFKB
by NIK by competing with NIK for interaction with IKK-
gamma. Supported by NIDA
Anti-inflammatory Actions of the Opioid Receptor
Antagonist, β-Funaltrexamine: Implications
in Neuroinflammation. RL Davis
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Increasing evidence suggests that astroglial-mediated in-
flammation is instrumental in the neuronal damage ob-
served in neuroinflammatory pathologies. For instance,
astrocyte-derived chemokines, such as CCL2 and CXCL10,
seem to contribute to the pathology of neuroAIDS. We have
modeled an integral component of neuroinflammation
associated with HIV-1 infection by exposing human
astroglial cells to tumor necrosis factor (TNF)α, HIV-1
Tat1-72, and bacterial lipopolysaccharide (LPS). These pro-
inflammatory mediators induce NF-κB activation and
subsequent CCL2 and CXCL10 induction. We have
discovered that the opioid receptor antagonist, β-
funaltrexamine (β-FNA) inhibits pro-inflammatory-
induced astroglial chemokine expression. Furthermore, we
have utilized HEK-293 reporter cells (HEK-Blue4) to
assess signaling through the toll-like receptor (TLR)4-NF-
κB pathway. Initial findings demonstrate that TLR4
signaling is also inhibited by β-FNA. To date, our data
suggest that modulation of NF-κB activation may be
involved in the anti-inflammatory actions of β-FNA.
Studies are ongoing to further elucidate the mechanism by
which β-FNA inhibits inflammatory signaling, particularly
in human astroglia. Insights gained are expected to be
instrumental in the development of therapeutic strategies to
prevent and/or treat neuroinflammation. Supported by NIH/
NINDS R15 NS 062664
Cannabinoid Modulation of Matrix Metalloproteinase
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The dysregulation of matrix metalloproteinases (MMPs) is
thought to play an important role in the dissemination of HIV-
1 and associated neuropathies. Secreted MMPs cleave
components of the extracellular matrix, facilitating the
migration of cells through the blood–brain barrier into the
central nervous system (CNS) and altering trafficking of
chronically activated immune cells. Macrophages and micro-
glia are important targets of HIV-1 which, upon infection,
release a plethora of factors including the viral regulatory
protein Tat. In response to Tat, activated cells secrete
inflammatory mediators and proteases such as MMPs. In the
present study, human monocytic U937 cells and primary
neonatal rat microglia were employed using an in vitro
invasion model to assess the effects of the cannabinoid partial
agonist delta-9-tetrahydrocannabinol (THC) on MMP activity
and cell migration in response to Tat. Using gel zymography
and Western immunoblotting to MMP-2 and MMP-9, it was
demonstrated that Tat-induced increase in the production of
MMPsbythesecellswasinhibitedbyTHC.Inaddition,itwas
shown that Tat-induced increase in cell migration was
inhibited by the metalloproteinase inhibitor 1,10-phenantro-
line and by THC. These results suggest that select cannabi-
noids have the potential to alter migration of cells through
extracellular matrices in response to the HIV protein Tat by
inhibiting the expression of MMPs. Supported by NIH/NIDA
DA005832
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Rationale: The clinical syndrome of HIV-associated pulmo-
nary arterial hypertension (HIV-PAH) is a serious complica-
tion of HIV infection. While the prevalence of clinical HIV-
PAHis0.5%,recentreports shedsomeinsight intosubclinical
arteriopathic phenomena through their report of elevated
pulmonary arterial systolic pressures in 35% of asymptomatic
individuals with known HIV infection. The possible identifi-
cation of early changes within the pulmonary vascular bed
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S43may offer preemptive therapeutic opportunities and deserves
attention. In this study, we have used HIV-transgenic (Tg) rat
model as a biological tool to explore the association of
pulmonary arteriopathy and HIV-1.The lungs from 4- to 5-
month-oldHIV-Tgratandwild-typecontrolswereassessedfor
pulmonary arteriopathy, right ventricular hypertrophy (RVH),
andfor the expression of mediators associated with PAH. HIV-
Tg rats demonstrated significant medial hypertrophy of
pulmonaryvesselsandincreasedrightventricularhypertrophy.
The real-time RT-PCR analysis suggested an increase in the
expressionofHIF-1alpha,IL-18,andPDGF-BmRNAinlung
extracts from HIV-TG rat compared with wild-type controls.
The increase in the expression of these mediators was linearly
correlated with the increase in RVH as measured by RV/LV
+septum ratio. Our report of pulmonary arteriopathy with right
heart hypertrophy in a HIV-Tg rat model may warrant an
increased focus on the screening and monitoring of HIV-
infected patients for HIV-PAH and offer therapeutic targets.
Supported by Parker B. Francis Fellowship (ND), NIH-
AI080280-01(ND), Joseph A.Cates Foundation (AOL)
Role of Gap Junction and Maxi Channels in Astrocytes
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HIVentry into the central nervous system (CNS) is an early
event after infection, resulting in neurological dysfunction
in a significant number of individuals. As people with
AIDS live longer, the prevalence of cognitive impairment is
increasing despite antiretroviral therapy. The mechanisms
that mediate CNS dysfunction are still not well understood
and include inflammation, viral presence, and/or replica-
tion. Our laboratory demonstrated that gap junction,
electrical synapses, and maxi channels, hemichannels of
connexin and pannexin-1, as well as ATP receptors in
astrocytes play a key role in the amplification of inflam-
mation and toxicity within the CNS, BBB integrity, and
neuronal function. Our findings describe a novel mecha-
nism of toxicity within the brain triggered by low numbers
of HIV-infected astrocytes and amplified by gap junction
and maxi channels, contributing to the pathogenesis of
NeuroAIDS. Supported by NIH MH076679
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The cerebral vascular endothelium provides the protective
blood–brain barrier (BBB) interface. By restricting the
entry of blood components, including immune cells, the
BBB regulates the delicate milieu optimal for neuronal
communication. Inflammatory responses diminish BBB
integrity, leading to neuronal dysfunction. Therefore,
pharmacological strategies that feature anti-inflammatory
and barrier-enhancing properties may prevent BBB break-
down under inflammatory conditions. To this end, we
sought to evaluate whether CB2 stimulation (1) down-
regulate pro-inflammatory genes in TNFa stimulated
primary human microvascular endothelial cells (BMVEC)
and (2) enhance barrier function. Using the Taqman Gene
Signature Array for human immune responses, the expres-
sion of 92 pro-inflammatory genes was evaluated in
BMVEC exposed to CB2 agonist alone (O-1966 or JWH-
133), TNFa, or TNFa with CB2 agonist. Analysis of fold
regulation revealed that the following genes were markedly
inhibited by either of the CB2 agonists: CCL2, CSF1, IP10,
CXCL11, ICAM-1, and NOS2A. In addition, agonist O-
1966 attenuated the expression of many genes that were not
decreased by JWH-133 (such as CCL5 and CCL19),
suggesting a differential potency of the CB2 agonist.
Evaluation of barrier function showed that CB2 agonists
increased transendothelial electrical resistance and up-
regulated membranous expression of tight junction pro-
teins, occludin and claudin-5. These results indicate that
CB2 agonist may benefit the BBB by dampening inflam-
matory response and strengthening barrier function. Sup-
ported by NIDA and NIAAA
C/EBPbeta Regulates Astrocyte TIMP-1 During
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Human immunodeficiency virus (HIV)-associated neuro-
cognitive disorders comprise several complications of
which HIV-associated dementia (HAD) is the most devas-
tating. The disease is characterized by an accumulation of
infected macrophages/microglia in the central nervous
system (CNS) which causes neuroinflammation. Astrocytes
are the most numerous cell type of the CNS and are
essential to maintaining homeostasis and proper neural
function. Neuroinflammation activates astrocytes, causing
astrogliosis and affecting their gene expression. One
important multifunctional molecule expressed predominant-
ly by astrocytes is tissue inhibitor of metalloprotease-1
(TIMP), the inducible form of a family of four TIMPs that
are the natural antagonists of matrix metalloproteases
(MMP). An altered MMP/TIMP ratio is believed to
contribute to several diseases of the CNS including HAD.
TIMP-1 levels are decreased in HAD patients. In vitro,
immune-stimulated astrocytes initially increase TIMP-1
expression, but over time, levels decrease. The mechanism
S44 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59for this switch is unknown. We identified a novel CAAT
site at -310 of the promoter that when deleted increases
promoter activity. Treating astrocytes with HAD-relevant
stimuli robustly increases C/EBPbeta expression, and the
transcription factor is localized to the nucleus. Knockdown
of C/EBPbeta increases TIMP-1 mRNA levels after 3 days
of stimulation. Overexpressing C/EBPbeta in astrocytes
decreases TIMP-1 promoter activity. This work begins to
unravel the mechanism causing the decrease in astrocyte
TIMP-1 in neuroinflammation. Supported by NIH-
Neurobiology of Aging
Molecular Basis for Kappa-Opioid Regulation
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We report here that activation of the kappa opioid receptor
(KOR) down-regulates transcription of the chemokine
receptors CCR5 and CXCR4. Transcription factor array
analysis revealed a possible involvement of the signal
transducers and activators of transcription (STATs) and
interferon regulatory factor (IRF) pathways in this process.
STAT activation following KOR stimulation by the KOR-
specific agonist, U50,488H, resulted in Janus kinase (JAK)-
dependent phosphorylation of STAT3. Increased mRNA
and protein production of interferon regulatory factors
(IRF) 1 and 2 have been detected by real-time PCR. Using
a bioinformatic approach to search for potential transcrip-
tion elements, IRF elements have been identified in both
the CCR5 and CXCR4 promoters. In addition, chromatin
immunoprecipitation assays have demonstrated binding of
IRFs within the promoter region of CXCR4. This suggests
a direct mechanism of IRF suppression of CXCR4
transcription. Characterization of this novel pathway link-
ing opioid and interferon signaling pathways will have
several benefits, including the potential use of KOR
agonists as therapeutic tools for the treatment of HIV-1
infection or certain inflammatory diseases. Supported by
NIH grants: DA14230, DA16544, and P30 DA13429
Sublethal Changes of Synaptic Organization and Function
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HIV-associated cognitive impairment, including memory
dysfunction, continues to be a major clinical manifestation
of advanced HIV infection. To assess whether HIV Tat is
responsible for disrupting neuronal plasticity and cognitive
impairment, we used a GFAP-driven, doxycycline (DOX)-
inducible Tat transgenic mouse model and examined
structure–activity relationships in hippocampal pyramidal
CA1 neurons using morphologic (Golgi impregnations) and
electrophysiological approaches. First, we examined the
effects of Tat induction on structural changes by assessing
the number of dendritic spines and neuronal TUNEL
reactivity in CA1 neurons. Second, we examined the effects
of Tat induction on synaptic function by assessing long-
term potentiation (LTP) of field excitatory postsynaptic
potential (fEPSP) at Schaffer collateral/commissural fiber-
CA1 synapses. Third, we examined the effects of Tat
induction on spatial learning in the Morris water maze.
Data showed a Tat-induced disruption of spatial learning as
well as a suppression of LTP in hippocampal CA1
pyramidal neurons. Additionally, the loss of function
coincided with increased dendritic pathology with signifi-
cantly reduced numbers of spines but without overt
neuronal death. Collectively, our data indicate that non-
lethal pathologic structural and functional changes in
dendrites and synapses caused by Tat were sufficient to
disrupt spatial memory. Based on the present findings, we
speculate that Tat-induced structural and functional deficits
in neurons underlie the cognitive dysfunction seen in
patients infected with HIV-1. Supported by NIDA
DA19398 and DA27374
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HIV-1-infected individuals who abuse opiates show an
increased risk of CNS complications compared to either
affliction alone. To assess whether morphine interacts with
HIV Tat to increase CNS inflammation and disrupt
neuronal synaptic organization, a GFAP-driven, doxycy-
cline (DOX)-inducible Tat transgenic mice model was used
to explore alterations in Golgi-impregnated striatal spiny
neurons. Tat induction caused detectable Tat expression
throughout the brain as assessed by immunoblotting and
immunohistochemistry. Morphine exposure caused syner-
gistic increases in Tat-induced MCP-1/CCL2 production,
astrogliosis, and microgliosis at 2 or 7 days. Sustained Tat
induction with morphine co-exposure significantly reduced
J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59 S45spine density while causing synergistic dendritic pathology,
including the formation of bead-like varicosities and/or
fragmentation. Morphine effects were typically antagonized
by naltrexone. Collectively, Tat induction caused increased
cytokine production (RANTES/CCL5, IL-6), dendritic
pathology, and spine losses, while morphine co-exposure
potentiated MCP-1/CCL2 production and dendritic pathol-
ogy. Because similar types of degenerative changes in
dendrites can be reversible in other systems, we speculate
that the neurocognitive defects accompanying chronic HIV-
opioid abuse comorbidity may involve reversible alterations
in neuronal organization. Supported by NIDA DA19398
and DA27374
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Histone deacetylases (HDACs) play a pivotal role in
epigenetic regulation of transcription and homeostasis of
protein acetylation in histones and other proteins involved
in chromatin remodeling. Previous studies report histone
hypoacetylation and transcriptional dysfunction in a variety
of neurodegenerative disorders. More recently, neuron-
specific overexpression of HDAC2 has been shown to
modulate synaptic plasticity and learning behavior in mice.
However, the role of HDAC2 in the development of HIV-1-
associated neurocognitive disorders (HAND) is not
reported. We hypothesize that HIV-1 tat protein may
upregulate HDAC2 leading to transcriptional repression of
neuroprotective genes in neuronal cells, thereby contribut-
ing to the progression of HAND. We evaluated the effect of
HIV-1 Tat protein on HDAC2 gene expression by qRT-PCR
and protein expression by flow cytometry in neuroblastoma
cells, SKNMC, and primary neuronal cultures. Results
indicate upregulation of HDAC2 by Tat treatment in a dose-
and time-dependant manner. Furthermore, HDAC2 over-
expression was associated with concomitant downregula-
tion in Camk2a, BDNF, and CREB gene expression which
are known to regulate neuronal functions. The observed
effects were specifically reversed by treatment with HDAC
inhibitor trichostatin A. Thus, our results for the first time
indicate the possible role of HDAC2 in the development of
HAND. Therefore, the use of HDAC2-specific inhibitor in
combination with HAART may be of therapeutic value in
the treatment of neurocognitive disorders observed in HIV-
1-infected individuals. Supported by NIDA
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Immediate sign of alcohol abuse include impaired coordi-
nation of movement, balance, vision, and cognitive func-
tion, indicating cerebellum as a key target. Clinical
symptoms and pathology of Wernickes encephalopathy
support the evidence that cerebellum is a target organ of
chronic alcohol abuse. We identify the putative underlying
molecular, biochemical, and cellular mechanisms of how
the cerebellum possibly regulates the CNS response to
alcohol intoxication and the aftermath neurological effects.
Aldehyde dehydrogenases (ALDH2, ALDH1A1) mostly
localized in cerebellar astrocytes control the mechanism.
ALDHs protein reduction in mice cerebellum from chronic
alcohol or thiamine deficiency diets correlated with
increased gliosis and neuronal loss, whereas co-
administration of acetyl-L-carnitine (ALC) with alcohol
diet stabilized the cerebellar astrocytic ALDHs, reduced the
sign of astroglial activation, and neuronal loss. ALC
significantly delayed the onset of muscle atrophy and
prolonged the life span of mice in thiamine-deficient diets.
Co-culture of primary human neurons with astrocytes,
endothelial cells, or microglia with/without ALC confirmed
the neuroprotective effects of astrocytes from ethanol
toxicity by stabilizing ALDHs protein. These findings
suggest that inherent cerebellum ALDHs activity controls
the underlying switch mechanism of beneficial or deleteri-
ous effects of alcohol in the brain. Furthermore, stabiliza-
tion of ALDHs protein and preventive effects on thiamine
deficiency warrant dietary supplementation of ALC for
chronic alcohol abusers. Supported by NIH/NIAAA grants
AA017398-01, AA016403-01A2
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Delta-9-THC (THC) has immunoregulatory effects on
human immune cells. While it has been hypothesized
that the CB2 receptor mediates these effects, immune
cells also express mRNA for CB1 and could be
susceptible to receptor-independent effects. We are
S46 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59therefore developing an expanded toolkit of reagents for
analyzing CB2 receptor expression and function in
human cells. Adenoviral and lentiviral vectors capable
of expressing full-length human CB2 in a transient or
stable fashion, respectively, were constructed. CB2
expression by cell lines and primary human cells can
be manipulated with these reagents. Corresponding
shRNA sequences are being screened to produce
knockdown vectors capable of down-regulating CB2
expression. In a test cell line, biologic responses to
THC correlated with CB2 receptor modulation. The
final toolkit reagents are for characterizing CB2 expres-
sion. A monoclonal anti-CB2 receptor antibody was
optimized for detecting CB2 receptor on the surface of
human cells by FACS analysis. Using this reagent, fresh
human peripheral blood B cells and monocytes from
normal donors were found to express cell surface CB2.
In contrast, CB2 expression by CD8 cells was found to
be low and variable, while CD4 cells were not stained.
Modulation of CB2 receptor protein on immune cells by
different activation and differentiation signals is under
study and will be correlated to mRNA expression by
real-time RT-PCR. This toolkit should allow the immu-
nobiology of human CB2 receptor to be studied in
greater detail. Supported by NIDA/NIH R21-DA021813
and R01-DA03018
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There is consensus that older age is associated with an
increased likelihood of HIV-associated dementia; however,
studies correlating age with mild neurocognitive disorder
and asymptomatic neurocognitive impairment in HIV-
seropositive individuals are less compelling. We have
undertaken a longitudinal study to determine the extent to
which aging affects the progression of HIV-1 infection in
terms of neuropsychological test performance and impair-
ment, HIV-1-associated neurocognitive disorder (HAND),
functional status in activities of daily living, immunologic
measures, and virologic measures. In terms of virologic
biomarkers of disease, we have developed a standardized
microchip assay to measure HIV gene expression in
PBMCs derived from our study cohort, which includes
older and younger HIV-seropositive individuals at varying
stages of neurocognitive impairment and disorder. The first-
generation custom gene array includes structural and
regulatory HIV genes as well as inflammatory and anti-
inflammatory cytokines, chemokines, and chemokine re-
ceptor genes. The samples remain blinded as to age and
neurocognitive status; however, HIV-1 serostatus is known.
In the HIV-1-seropositive subjects, preliminary results
indicate up-regulation of IL-5 and CCR5 (5-fold) and
down-regulation of CCL2 (4-fold), relative to samples from
HIV-1-seronegative subjects. Although our results are
preliminary, we have established an experimental frame-
work that will allow us to determine if virologic biomarkers
of HIV disease correlate with an age-associated decline in
neurocognitive function. Supported by NIH/NIMH R01
MH058532
Natural Killer T Cells Inhibit HIV Infection of Macrophages.
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Natural killer T (NKT) cells are a crucial component of the
host innate immune system and play an important role in
defense against viral infections. However, the role of NKT
cells in the control of HIV infection remains to be
determined. We investigated the non-cytolytic anti-HIV-1
activity of primary NKT cells in human macrophages.
Supernatants (SN) collected from NKT cell cultures
inhibited HIV infection and replication. This NKT SN-
mediated anti-HIV-1 activity is broad as NKT SN could
inhibit infection by both laboratory-adapted and clinical
strains of HIV. The antibody to interferon (IFN)-γ could
block NKT SN-mediated anti-HIV effect. Investigation of
mechanism(s) responsible for the NKT action showed that
NKT SN upregulated the expression of signal transducer
and activator of transcription-1 (STAT-1) and STAT-2 and
enhanced the expression of IFN regulatory factors (IRFs) 1,
7, and 9, resulting in the induction of endogenous IFN-γ/γ
expression in macrophages. Moreover, NKT SN induced
the expression of CC-chemokines, the ligands for CCR5.
The antibodies to CC-chemokines (MIP-1α, MIP-1β, and
RANTES) significantly blocked NKT SN-mediated anti-
HIV activity. These findings indicate that NKT cells have a
critical role in innate immune cell-mediated defense against
HIV-1 infection. Supported by DA 12815, DA 25477 and
DA 22177 (to WZ Ho); China National Natural Science
Foundation grants 30972754 (to W Hou)
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Human immunodeficiency virus (HIV)-1 gp120 has been
implicated in HIV neuropathogenesis. Reports have shown
that gp120 is neurotoxic and the toxicity is partially
mediated by enhanced glutamate release and activation of
glutamate receptors. Using high-affinity radiolabeled 3H-
glutamate receptor binding assay, we found in this study
that treatment of highly enriched human cortical neuronal
cultures with gp120 for 3 days increased glutamate receptor
activity. Furthermore, in the presence of glutamate, gp120
pretreatment potentiated neurotoxicity of human cortical
neuronal cultures. Cannabinoids have been shown to have
anti-inflammatory and neuroprotective properties. There-
fore, we sought to investigate the effects of cannabinoid
agonists on the gp120-treated human cortical neuronal
cultures. Our preliminary results showed that pretreatment
with synthetic cannabinoid agonist WIN55,212-2 (300 nM)
downregulated gp120-induced glutamate receptor activity,
suggesting a possible neuroprotective mechanism. We will
continue to study the effects of cannabinoids on gp120 and
glutamate-treated neuronal cultures to delineate their mech-
anisms involved in the neuroprotection. Supported by NIH/
DA025525
Methamphetamine Alters Fundamental Relationships
Between Immune, Viral, and Blood–Brain Barrier
Measures in Simian Immunodeficiency Virus-Infected
Rhesus Macaques (Macaca mulatta). JJ i a n g
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Methamphetamine (METH) has been associated with
alterations in cognition and blood–brain barrier function
in HIV infection, but the extent of METHs influence is
unclear. We tested the hypothesis that METH exerts its
effects by altering the relationships between blood–brain
barrier (BBB), immune, and viral measures. Adult male
rhesus monkeys were randomly assigned to groups,
received twice daily i.m. injections of either METH
(0.75 mg/kg, n=11) or saline (n=10), and were inoculated
with SIVmac251. Among saline-treated animals, we found
expected relationships among variables that were strong
and significant: a stronger SIV-specific IgG response at
week8 post-inoculation (p.i.) was associated with fewer
activated monocytes (CD14
+CD16
+; r=−0.89) at week8 p.
i., lower viral set point at week10 p.i. (r=−0.603), and a
lower ratio of CSF/serum albumin (r=−0.81), a measure of
BBB integrity. Similarly, the number of activated mono-
cytes was positively correlated with viral load (r=0.71) and
albumin ratio (r=0.78). There were no significant differ-
ences between METH and saline animals for any measures
(all p>0.16), but the correlation coefficients among the four
measures for the METH animals were all non-significant.
Moreover, four of the five correlation coefficients for saline
animals were significantly (or nearly significant) different
from the corresponding coefficients for the METH animals.
These results indicate that METH leads to major disrup-
tions in immune control of the virus and suggest examina-
tion of lymphoid tissue to understand the mechanisms of
this alteration. Supported by NIDA/DA024441
Mechanisms by Which Cannabidiol Enhances T Cell
Function. BK a p l a n
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While cannabinoid compounds have been historically
characterized as immunosuppressive, there are conditions
under which cannabinoids enhance immune function. For
instance, the non-psychoactive cannabinoid, cannabidiol
(CBD), differentially modulates IL-2 and IFN-γ production
depending on the magnitude to which T cells are activated.
Using phorbol ester plus calcium ionophore (P/I) to
stimulate cytokine production, CBD suppressed or en-
hanced cytokine production in response to optimal P/I
(40 nM/0.5 µM) or suboptimal P/I (4 nM/0.05 µM),
respectively. Thus, the objectives of these studies were to
characterize the mechanisms by which CBD enhances
immune function in primary murine T cells. CBD increases
intracellular calcium in resting lymphocytes, which is
exacerbated by P/I regardless of the concentration of P/I
used, suggesting that the differential regulation of cytokine
production might be mediated by the concentration of
intracellular calcium. Moreover, the trend of cytokine
production was similar to that of nuclear protein expression
of nuclear factor of activated T cells (NFAT), a calcium-
dependent transcription factor important for IL-2 and IFN-γ
production. Finally, using FACS analysis, CBD induced IL-
2 from CD4
+ T cells, whereas CBD induced IFN-γ from
CD8
+ T cells. Overall, these results demonstrate that
cannabinoids enhance cytokine production in response to
suboptimal T cell activation and suggest that cannabinoids
should be classified as immunomodulatory. Supported by
NIDA DA007908
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in HIV-1 Transgenic Rats During Development. MD
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We have recently shown (1) that methamphetamine
(METH) induced greater behavioral sensitization (BS) in
adult HIV-1 transgenic (HIV-1 Tg) rats than in adult
Fischer 344/NHsd (F344) strain background control
animals, (2) that the HIV-1 Tg rat has metabolic
abnormalities, and (3) that environmental modulation of
METH-induced behavior can be differentiated from HIV-
associated biological determinants of behavior. Thus, we
hypothesized that METH-induced disturbances in brain
metabolism and behavior would be affected by both the
persistent presence of viral proteins and developmental
factors. In the present study, we evaluated the effects of
METH on the brains of adolescent versus adult HIV-1
Tg rats using both behavioral (METH-induced stereotypic
head movement) and physiological (rectal body temper-
ature) parameters. We found that both the acute and BS
effects of METH were greater in HIV-1 Tg rats
compared to controls and also in adolescent rats
compared to adult animals regardless of HIV-1 status.
We determined that acute hyperthermic effects of METH
as well as tolerance to METH-induced hyperthermia were
greater in HIV-1 Tg rats than in controls. Taken together,
these results suggest that both the neuroadaptations seen
in HIV infection and the immaturity of the adolescent
brain are associated with increased sensitivity to the
psychoactive and BS properties of METH. Thus, HIV-
infected individuals and adolescents may be more
vulnerable to the development of METH abuse and
dependence than non-infected individuals and adults.
Supported by National Institute on Drug Abuse/
DA016149 to SLC
Activation of CB2 Cannabinoid Receptors Inhibits gp120-
Induced Synapse Loss. HJ Kim
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1;
1Department
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Minneapolis, MN 55455-0000
Human immunodeficiency virus (HIV) infection of the CNS
is associated with dendritic and synaptic damage. Synapse
loss correlates better with cognitive decline than cell loss in
patients with HIV-1 associated dementia (HAD). HAD is due
in part to the release of viral proteins from infected cells.
Because cannabinoids modulate neurotoxicand inflammatory
processes,we investigated theireffects onchanges in synaptic
connections induced by the HIV-1 envelope glycoprotein
gp120. Morphology and synapses between cultured hippo-
campal neurons were visualized by confocal imaging of
neurons expressing DsRed2 and postsynaptic density protein
95 fused to GFP (PSD95-GFP). Twenty-four-hour treatment
with gp120 IIIB decreased the number of PSD95-GFP puncta
by 37±4%. The decrease was time- and concentration-
dependent (EC50 = 195±79 pM). Synapse loss preceded cell
death. Pretreatment with AMD3100, IL-1 ra, or MK801
significantly reduced gp120-induced synapse loss, indicating
that sequential activation of the CXCR4 receptor, the IL-1
receptor, and the NMDA receptor was required. Expression
of ARF, which inhibits the ubiquitin ligase MDM2, protected
synapses, implicating the ubiquitin-proteasome pathway. The
cannabinoid receptor full agonist WIN55,212-2 inhibited
gp120-induced PSD loss in a manner reversed by the CB2
receptor antagonist AM630. These results indicate that
cannabinoids prevent the impairment of network function
produced by gp120 and thus might have therapeutic potential
in HAD. Supported by Grants DA07304 and DA024428
from NIDA.
Effect of Alcohol on Cytochrome P450 in Monocytes/
Macrophages: Implications in Anti-retroviral Therapy
and Oxidative Stress. S. Kumar
1,M .J i n
1, P. Silverstein
1,
A. Kumar
1;
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Cells of the monocyte/macrophage lineage are not only
known to function as an important HIV-1 reservoir but
have also been demonstrated to require higher concen-
trations of antiretroviral therapeutic drugs (ART) for
effective inhibition of viral replication. Alcohol abuse is
known to reduce the therapeutic efficacy of ART that are
metabolized by cytochrome P450 (CYP) system. In
addition, CYP enzymes play an important role in
oxidative stress, which is an important mediator of HIV
pathogenesis. The present study is designed to assess the
effect of alcohol on the CYP enzymes involved in ART
metabolism (CYP2B6, CYP2D6), oxidative stress
(CYP2A6, CYP2E1), and both (CYP3A4). The CYP
expressions in U937 monocytes/macrophages were deter-
mined by mRNA quantification and protein analysis. The
mRNA levels relative to GAPDH (housekeeping gene)
were CYP2A6 (1%), CYP2E1 and CYP3A4 (0.1%), and
CYP2B6 and CYP2D6 (∼0.001%). The protein levels of
these CYP were consistent with their respective mRNA
levels. Alcohol caused upregulation of the mRNA levels
of CYP2A6 (3-fold), CYP2B6 (2.5-fold), CYP2E1 (5-
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The upregulation of these CYP was also confirmed by
protein analysis. Furthermore, the activity of oxidative
stress marker enzymes showed a significant increase in
activity in alcohol-treated samples. Thus, the results
suggest that alcohol leads to: (1) a decrease in response
to ART as a result of their increased metabolism by
CYP2B6 and CYP3A4 and (2) an increase in oxidative
stress by enhanced expression of CYP2A6, CYP2E1, and
CYP3A4. Supported by Start-up funds KBE78
Genome-Wide Association Study of HIV-Associated
Neurocognitive Disorders: Preliminary Report. AJ
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Improved healthcare access and pharmaceutical therapies
have prolonged the lives of HIV+ individuals. However,
this has resulted in an increasing prevalence of HIV-
associated neurocognitive disorders (HAND). Factors
affecting risk for HAND include older age, substance
use, and the presence of certain comorbid medical
conditions. In addition, candidate gene studies have
identified a handful of genes believed to have a role in
the neuropathogenesis of HAND. Unfortunately, the
results of such candidate gene studies have been difficult
to replicate. More recently, genome-wide association
studies (GWAS) have become the method of choice for
identifying genetic factors associated with disease. For
example, a recent GWA identified novel genes associated
with disease progression in HIV/AIDS. The success of
this method in identifying genetic markers associated
with HIV disease progression suggests that it will help
clarify the neuropathogenesis of HAND. Towards this
goal, we describe here the preliminary results of a GWA
study of HAND. Over 350,000 single nucleotide poly-
morphisms (SNPs) were genotyped in a well-
characterized sample of 1,230 HIV+ individuals from
the Multicenter AIDS Cohort Study. We examined two
phenotypes: (1) progression of neurocognitive deficits
and (2) time to dementia using Cox proportional hazards
model. This preliminary report will evolve into a much
larger study involving over 4,000 HIV+ individuals.
Ultimately, this investigation may lead to the identifica-
tion of pharmaceutical targets for those with or at risk
for HAND. Supported by UCLA-AIDS Institute and the
UCLA Center for AIDS Research-AI28697 and National
Institute of Drug Abuse-1R03DA026099-01
Involvement of KV1.3 Channel in Microglia-Induced
Neurotoxicity. JL i u
1,CX u
1,LC h e n
1, B Katafoasz
1,
H Xiong
1;
1Dept. Pharmacol. & Exp. Neurosci., University
of Nebraska Medical Center, Omaha, NE 68198-5880
Inflammatory responses mediated by activated microglia
play a pivotal role in the pathogenesis of HIV-1-associated
neurocognitive disorders (HAND). As such, studies on the
identification of specific targets to control microglia
activation and resultant neurotoxic activity are imperative.
Increasing evidence indicates that voltage-gated K
+ (Kv)
channels are involved in the regulation of microglia
functionality. In this study, we investigated role of Kv1.3
channels in gp120-induced neurotoxic activity in primary
rat microglia cultures. Our results showed that incubation of
microglia with gp120 increased the expression levels of
Kv1.3 mRNA and protein, which were significantly
blocked by Kv channel blockers 4-aminopyridine (4-AP)
and tetraethylammonium (TEA). In parallel, whole cell
patch-clamp studies revealed that gp120 enhanced Kv1.3
currents in microglia. The association of gp120-induced
enhancement of Kv1.3 current with microglia neurotoxic
activity was demonstrated by experimental results that
blockade of microglia Kv channels markedly inhibited
microglia-induced neuronal injury, cytokine secretion, and
NO production. TUNEL assay revealed that 4-AP and TEA
reduced the numbers of apoptotic neurons induced by
gp120-activated microglia from 33.8 ± 2.3% to 11.9±4.5%,
and 12.5±5.0%, respectively. In addition, knockdown of
Kv1.3 gene by transfection of Kv1.3-siRNA abrogated
neurotoxicity mediated by gp120-activated microglia. Our
data indicate that Kv1.3 channels regulate microglial
neurotoxic activity and may function as the potential targets
for the development of therapeutic strategies. Supported by
NIH R01 NS041862
HIV-1 Pr55gag/env Virus-Like Particles (HIV VLPS)
Induce Robust Pro-inflammatory Responses by Human
Microglia. A Nettles
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Virus-like particles (VLPs) have been shown to be potent
inducers of both innate and adaptive immune responses
and have been widely used in vaccine studies. However,
they may also be used to induce neuroinflammatory
responses, including production of reactive oxygen
species (ROS). In this study, we produced HIV-1 VLPs
expressing surface gp120 using co-transfection of Pr55
gag-yellow fluorescent protein (YFP), Tat, and env
plasmids: p3NL4-3env and p3NL(AD8)env. These HIV
VLPs were quantified by p24 Ag ELISA as well as by
their intrinsic Gag-YFP expression. HIV VLPs were also
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Results obtained from this study demonstrated that
CCR5- and CXCR4-utilizing HIV VLPs induced strong
pro-inflammatory cytokine and chemokine responses from
primary human microglial cells. Currently, we are
investigating the interaction of HIV VLP surface gp120
with the CXCR4, CCR5, and CD4 receptors. In addition,
we are examining the mechanisms of stimulation by
blocking this interaction with antibodies and dissociating
HIV VLPs with detergent or sonication. We are also
currently assessing the induction of ROS and determining
the extent of oxidative damage in murine brains after the
administration of HIV VLPs. Supported by NIH/NIDA
5T32DA007097-27
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The human immunodeficiency virus type 1 (HIV-1) long
terminal repeat (LTR) serves a number of critical functions
in viral replication, one of which involves regulating the
transcriptional activity of the integrated provirus. We have
previously demonstrated that sequence variation at HIV-1
LTR C/EBP site I and Sp site III revealed sequence
configurations that were found to increase in prevalence
with disease severity and correlate with HIV-associated
dementia (HAD). In contrast, LTR NF-κB sites I and II
were highly conserved regardless of disease severity.
Previous studies have demonstrated that substances of
abuse modify HIV disease by altering the activation state
of infected cells, resulting in a compromise of the immune
system, thereby affecting viral replication. This in turn
impacts the selection of viral quasispecies within a given
patient. In conjunction with our ongoing analysis of the
HIV-1 LTR transcription factor binding sites for specific
genotypic variants that correlate with disease progression in
the DREXELMED HIV-1 cohort, we have also character-
ized these sequence variations to determine if the use of
drugs of abuse (specifically cocaine and cannabinoids)
impacts the genotypic variants observed within these sites
in LTRs isolated from patients in late stages of disease. To
date, results have shown that the use of either substance
results in an overall decreased binding site conservation;
however, each binding site revealed a unique pattern of
conservation relevant to the subtype B consensus sequence.
Supported by NIDA R01 DA19807
Methamphetamine Alters Tight Junction Integrity Via
NADPH Oxidase-Induced Oxidative Stress in Human
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The blood–brain barrier (BBB) is formed by specialized brain
endothelial cells interconnected by tight junctions (TJ) whose
main function is to maintain the homeostasis of the CNS.
Methamphetamine (METH) is an abused drug whose neuro-
t o x i ce f f e c t sm a yb em e d i a t e di np a r tb yr e a c t i v eo x y g e n
species (ROS). Because generation of ROS may induce BBB
dysfunction and neuroinflammatory responses in the brain,
the present study focused on the role of NAD(P)H oxidase
(NOX) as a possible source of METH-induced ROS gener-
ation in brain endothelial cells. NOX activity was markedly
activated by a 30-min exposure to 10 μMM E T Hi nt h e
human cerebral microvascular endothelial cell line (hCMEC/
D3). These effects were associated with an increase in
phosphorylation of p47 and bindings between p47 and gp91
or p22 NOX subunits. Importantly, treatment of hCMEC/D3
with METH resulted in a significant increase in ROS levels
that was significantly attenuated by the NOX-specific
inhibitor NSC 23766. Inhibition of NOX also protected
against METH-induced alteration of expression of tight
junction proteins, occludin and ZO-1, and transendothelial
migration of monocytes. The present findings indicate the
importance of NOX as a source ofROS generation in METH-
mediated dysfunction of brain endothelial cells. In addition,
they suggest that NOX may be a promising target in
therapeutic strategies to protect against METH-induced
disruption of the BBB and the development of neuroinflam-
mation. Supported by DA027569, MH63022, MH072567,
and NS39254
Quantitative Proteomic Profiling of the Caudate Nucleus
During Chronic SIV/METH and SIV/Morphine-
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Despite substantive research efforts, the mechanisms
underlying cognitive impairment resulting from HIV
infection and drugs of abuse (DOA) are far from under-
stood. While profiling of biofluids such as cerebrospinal
fluid (CSF) and plasma have been useful to a certain extent,
the real clues that can divulge CNS changes are by
analyzing the brain itself. Our working hypothesis is that
in the presence of a DOA, the harmful effects of SIVon the
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synaptic proteome. Using isobaric tag for relative and
absolute quantitation (iTRAQ)-based quantitative proteo-
mics approach, we analyzed the caudate, a target of both
SIV/HIV and drugs of abuse such as methamphetamine
(METH) and morphine for differential protein expression.
Employing classical biochemical fractionation, we isolated
purified synaptosomes that are subcellular structures con-
taining the pre- and postsynaptic components and identified
several membrane proteins including transporters, ion
channels, and receptors to be differentially regulated.
Amongst these, we found Na
+/K
+ ATPase alpha 3
(ATP1A3), a member of the Na
+/K
+ family of ATPases,
to be upregulated in SIV-infected monkeys that were treated
with METH or morphine. Given its role in establishing and
maintaining the electrochemical gradients of Na
+ and K
+
ions across the plasma membrane and also for electrical
excitability, we are currently performing validation studies.
Future studies focus on using in vitro approaches to
elucidate associated mechanistic clues during SIV/HIV
and drugs of abuse comorbidity. Supported by NIH grants
MH073490, MH062261 and DA026146
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Methamphetamine (METH), a potent stimulant with strong
euphoric properties, has a high abuse liability and long-
lasting neurotoxic effects. Recent studies in animal models
have indicated that METH can induce impairment of the
blood–brain barrier (BBB), thus suggesting that some of the
neurotoxic effects resulting from METH abuse could be the
outcome of barrier disruption. Here, we provide evidence
that METH alters BBB function via direct effects on
endothelial cells and explore possible underlying mecha-
nisms leading to endothelial injury. We report that METH
increases BBB permeability in vivo, and exposure of
primary human microvascular endothelial cells (BMVEC)
to METH diminishes tightness of BMVEC monolayers in a
dose- and time-dependent manner by decreasing expression
of cell membrane-associated tight junction (TJ) proteins.
These changes were accompanied by enhanced production
of reactive oxygen species, increased monocyte adhesion to
and migration across METH-treated endothelial mono-
layers, and activation of myosin light chain kinase (MLCK)
in BMVEC. Antioxidant treatment attenuated or completely
reversed all tested aspects of METH-induced BBB dys-
function in vitro and in vivo. Our data suggest that BBB
injury is caused by METH-mediated oxidative stress, which
activates MLCK and negatively affects the TJ complex.
These observations provide a basis for antioxidant protec-
tion against brain endothelial injury caused by METH
exposure. Supported by NIDA.
Meth-Induced Cytosolic Calcium Enhances the Generation
of Mitochondrial ROS in T Cells: Role in Immune
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Methamphetamine (METH) abuse is known to be associ-
ated with an inordinate rate of infections. However, little is
known about the effects of METH on T cells and how it
may lead to compromises in the regulation of immune
homeostasis. Here, in our present study, we show that
METH exposure resulted in mitochondrial oxidative dam-
age and caused dysfunction of primary human T cells.
METH treatment of T cells led to a rise in intracellular Ca
2+
levels that enhanced the generation of reactive oxygen
species (ROS). Exposure to METH induced mitochondrial
dysfunction in the form of marked decrease in mitochon-
drial membrane potential (ΔΨm), increased mitochondrial
mass, enhanced protein nitrosylation, and diminished
protein levels of complexes I, III, and IV of the electron
transport chain. These changes paralleled reduced IL-2
secretion and T cell proliferative responses following TCR-
CD28 stimulation, indicating impaired T cell function.
Furthermore, antioxidants attenuated METH-induced mito-
chondrial damage by preserving the protein levels of
mitochondrial complexes I, III, and IV. Altogether, our
data suggest that METH-induced cytosolic calcium enhan-
ces the generation of mitochondrial ROS. In this context,
the mitochondrial impairment (decrease membrane poten-
tial and increased mitochondrial mass) and T cell dysfunc-
tion ensuing the METH-induced generation of ROS
represents a redox-dependent pathway mediating their
effects. Supported by NIDA/R21 DA0249791
Cannabinoids Inhibit Macrophage Migration to the Tat
Protein of HIV-1: Linkage to the CB2 Cannabinoid
Receptor. ES Raborn
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Macrophages are important targets of human immunodefi-
ciency virus type-1 (HIV-1) infection at peripheral sites and
in the CNS. Infected cells secrete a multitude of toxic
factors, including the viral regulatory protein Tat. This
protein is highly immunogenic and also serves as a potent
chemoattractant for monocytes. We demonstrated that the
exogenous cannabinoids delta-9-tetrahydrocannabinol
S52 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59(THC) and CP55940 significantly inhibited migration of
human U937 macrophage-like cells to the Tat protein in a
concentration-related manner. The CB1 receptor selective
agonist ACEA had no effect on Tat-mediated migration,
whereas the CB2 receptor-selective agonist O-2137 exerted
a concentration-related inhibition of U937 cell migration in
response to Tat. Pharmacological blockage of CB1 receptor
signaling using the antagonist SR141716A had no effect on
CP55940-mediated inhibition of macrophage migration to
Tat, while treatment with the CB2 receptor antagonist
SR1444528 reversed the CP55940-mediated inhibition of
migration. THC had no inhibitory effect on migration to Tat
following siRNA knockdown of the CB2 receptor. Collec-
tively, the pharmacological and biochemical knockdown
data indicate that cannabinoids signal through the CB2
cannabinoid receptor to modulate macrophage migration to
the HIV-1 Tat protein. These results suggest that the CB2
receptor has potential to serve as a therapeutic target for
ablating detrimental inflammatory responses associated
with HIV-1 infection. Supported by NIDA/NIH DA005832
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In the post-HAART era, neuroAIDS remains a great
challenge due to the poor penetrability of antiretroviral
(ARV) drugs across the blood–brain barrier (BBB).
Recently, the advent of nanotechnology-based drug target-
ing strategies has shown tremendous potential for the
delivery of ARVs to the brain. Previous studies have
reported that such nano-sized formulations can directly
transverse the BBB and also be taken up by circulating
mononuclear phagocytes, thereby piggybacking across the
BBB via cell-based carrier system. We report herein the
development of magnetic AZTTP liposomal nanoformula-
tion and its ability to transmigrate across an in vitro BBB
model by the application of an external magnetic field. The
results show that magnetic AZTTP liposomes were suc-
cessfully formulated and were able to transverse across an
in vitro BBB model using direct transport by the applica-
tion of an external magnetic field. The apparent permeabil-
ity of magnetic AZTTP liposomes was significantly higher
than free AZTTP. The magnetic AZTTP liposomes were
also efficiently taken up by monocytes, and these magnetic
monocytes showed enhanced transendothelial migration
compared to non-magnetic monocytes in the presence of
an external magnetic field. Furthermore, we found that
magnetic AZTTP liposome effectively inhibited HIV-1
replication in an in vitro HIV-1 infection model system.
Thus, we anticipate that the developed magnetic nano-
formulation can be used for targeting active NRTIs to the
brain and thereby eliminate the brain HIV reservoir and
help treat neuroAIDS. Supported by NIDA
Neuropathogenic Mechanisms of HIV-1 Clade B and C:
Role of Methamphetamine (METH). T Samikkannu
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Methamphetamine (METH) enhances the HIV viral repli-
cation and disease progression. Previous studies have
demonstrated that infections with HIV-1 clades differential-
ly contribute to the neuropathogenesis of HIV infection.
The dopamine receptor-2 (DRD-2) and tyrosine hydoxylase
(TH) downregulate Ca
2+/CaM-dependent protein kinases
(CaMKs) and are known to play a significant role in
neuropathogenesis of acquired immunodeficiency syn-
drome (AIDS). We hypothesize that clade B and C gp120
proteins exert differential effects on DRD-2 and TH and
METH exacerbates these effects, and the mechanisms may
be mediated by dysregulation of CaMKinases (CaMK II
and IV) gene and protein expression. Astrocytes were
treated with gp120 form HIV-1 clade B- and C-proteins
alone or in combination with METH. RNA was extracted,
reverse-transcribed, and analyzed by quantitative real-time
PCR to determine DRD-2, TH, and CaMK II and CaMK IV
gene expression. Cell lysates were analyzed by Western
blot for protein expression. Our results indicate that HIV-1
clade B gp120 protein significantly downregulated DRD-2,
TH, CaMK II, and CaMK IV genes and their protein
expression compared to gp120 from HIV-1 clade C, and
METH exacerbates these effects. Our studies for the first
time demonstrate that HIV-1 clades B and C differentially
modulate DRD-2, TH, CaMK II, and CaMK IV genes and
their protein expression, and METH exacerbates neuro-
pathogenesis of HIV infection. The present study was
supported by grants from National Institute of Health
(NIH); DA012366, DA 021537, DA 025576
Herpes Simplex Virus Infection of Microglia Triggers
Oxidative Stress Responses and Damage Via Toll-Like
Receptor 2. SJ Schachtele
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Using a murine model of herpes simplex virus (HSV)-1
encephalitis, our laboratory has determined that the induc-
tion of pro-inflammatory mediators in response to viral
brain infection is largely mediated through a Toll-like
receptor-2 (TLR2)-dependent mechanism. Published stud-
ies have shown that like other inflammatory mediators,
reactive oxygen species (ROS) and reactive nitrogen
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present study, oxidation of 2,7-dichlorofluorescin diacetate
(DCFH-DA) was used to measure intracellular ROS
production in microglia isolated from murine brain tissue
and in cultured murine microglia. Intracranial injection of
HSV into C57B/6 mice increased microglial cell-produced
ROS at 4 days post-infection (p.i). Similarly, levels of
intracellular ROS were highly elevated by 48 h p.i. in HSV-
stimulated microglia cultures. Comparison of virus-induced
ROS production in microglia from wild-type and TLR2
−/−
mice indicated that in vivo and in vitro ROS production
was largely mediated through TLR2. It is increasingly clear
that reactive oxygen species are responsible for facilitating
secondary tissue damage, such as lipid peroxidation, during
and subsequent to herpes encephalitis. Using 8-isoprostane
as a marker for lipid peroxidation, we found that HSV-
infected microglia from TLR2
−/− mice produce less
neuronal oxidative damage when added to mixed brain cell
cultures. These effects are associated with insufficient
activation of p38 and p42/44 MAPK and aberrant
production of oxidative stress enzymes (Gpx1, HO-1) in
TLR2
−/− mice.
Regulation of Cannabinoid Receptor Expression
in Human Microglial Cells. WS Sheng
1,SH u
1,P K
Peterson
1, RB Rock
1;
1CIDMTR, University of Minnesota
Medical School, Minneapolis, MN 55455-0000
Cannabinoid receptors (CBs) in the CNS play an important
role in modulating brain development and inflammatory
responses. Expression of CB1 is well documented in the
CNS and CB2 in the immune system. We and others have
found that CB2 is also expressed in microglial cells. While
psychoactive effects resulting from CB1 activation are
undesirable, activation of CB2 has been reported to regulate
many physiological functions, and CB2 is considered a
therapeutic target. CB expression levels could be modulated
by various stimuli depending on the cell activation state. In
this study, we sought to investigate the effects of lipopoly-
saccharide (LPS), HIV proteins gp120 and Tat, cytokines,
and CB agonists WIN55,212-2 and JWH015 on CB
expression in human microglial cells. Using real-time
PCR, we found that CB1 mRNA expression was relatively
unaffected by these treatments (<2-fold change in 24 h).
However, treatment with LPS and Tat markedly down-
regulated CB2 mRNA expression. Treatment with the
cytokines TNF-alpha, IL-1beta, and IL-10 also modestly
inhibited CB2 mRNA expression. In a binding study using
3H-CP55,940, we found that specific binding was approx-
imately 75% and mostly through CB2 when CB-specific
antagonists SR141716A (CB1) and SR144528 (CB2) were
used for competitive binding. Similarly, treatment with LPS
and Tat for 72 h markedly inhibited 3H-CP55,940 binding
mainly through CB2. These findings suggest an interaction
between CB2 and microglial activation and that CB2
expression can be regulated for potential therapeutic
benefit. Supported by NIH/DA025525
Lipopolysaccharide Increases the Expression of Multidrug.
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Multidrug resistance-associated protein 1 (MRP-1) is a
ubiquitously expressed member of the ATP-binding
cassette transporter family. MRP-1 is one of the primary
transporters of glutathione and glutathione conjugates.
This protein also transports antiretroviral therapeutics
such as HIV-1 protease inhibitors (PI). We hypothesized
that inflammatory mediators that activate macrophages
would modify the expression and activity of MRP-1 in
macrophages. Real-time PCR assays, Western blots, and
calcein efflux assays were used to show that exposure of
macrophage cell line RAW 264.7 to lipopolysaccharide
(LPS) increased the expression of MRP-1 at the levels
of mRNA, protein, and functional activity. Treatment of
macrophages with LPS resulted in 2-fold increases of
MRP-1 expression or functional activity. LPS-mediated
increases in calcein efflux were repressed by the MRP-
specific inhibitor MK-571. These results suggest that the
effectiveness of HIV-1 PI therapy may be compromised
by the presence of opportunistic infections. Supported by
NIH
Voluntary Exercise Protects Against Methamphetamine-
Induced Oxidative Stress in Brain Microvasculature
and Disruption of the Blood–Brain Barrier. MT o b o r e k
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Moderate to vigorous exercise is a powerful means to
influence health status and lower the risk of the develop-
ment of chronic diseases. We hypothesize that increased
antioxidant potential by endurance exercise plays a critical
role in the protection against the development of cerebral
toxicity associated with drug abuse. To address this
hypothesis, mice were subjected to voluntary wheel running
for 5 weeks. The control mice did not have access to
running wheels. At the end of exercise training, mice were
injected with methamphetamine (Meth, 10 mg/kg) for 24 h.
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cerebral blood flow and protected against Meth-induced
disruption of the blood–brain barrier as assessed by in situ
brain perfusion. Consistent with these results, exercise
protected against Meth-mediated disruption and localiza-
tions of tight junction protein expression (ZO-1, occludin,
and claudin-5). Importantly, exercise markedly attenuated
Meth-induced oxidative stress in brain microvessels. It
appears that protection against upregulation of NADPH
oxidase may be responsible, at least in part, for these
protective effects. The obtained results indicate that
exercise is an important modifiable behavioral factor that
can protect against Meth-induced CNS toxicity. Supported
by DA027569, MH63022, MH072567, NS39254, and from
the University of Kentucky Center for Muscle Biology
Quiescent CD4
+ T Cells Exhibit Low Levels of HIV
Infection: Impact on Viral Latency and Persistence. DN
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Quiescent CD4
+ T cells have shown resistance to human
immunodeficiency virus (HIV) infection. Interestingly, our
recent studies of HIV infection kinetics in quiescent CD4
+ T
cells found that viral integration occurred in these cells at
essentially the same efficiency as in activated T cells once
reverse transcription was completed. Yet, subsequent stimu-
lation of quiescent cells failed to result in robust viral protein
expression. Recently published work by our group demon-
strated that the integration sites in quiescent CD4
+ Tc e l l s
showed similar patterns to that of stimulated cells. Further-
more, proviral 3 LTR ends at the virus–host junctions, and 2-
LTR circles showed increased levels of abnormal LTR
junctions in quiescent CD4
+ T cells. Treatment of quiescent
CD4 T cells with nucleosides resulted in improved HIV
infection kinetics and an increase of the fraction of normal
LTR ends to the levels seen in stimulated cells (not treated
with nucleosides). This may be due to improved stability of
the viral cDNA or the presence of increased raw materials
needed to successfully complete reverse transcription.
Furthermore, we were able to activate the quiescent cell
reservoir in vitro and establish a spreading infection when
co-culturing with uninfected T cells. Based on the studies
above, quiescent CD4
+ T cells can constitute a stable and
inducible HIV reservoir, a reservoir that may provide new
insights on HIV latency and reactivation in AIDS, especially
in the context of other disease co-factors such as drugs of
abuse. Supported by NIH grants AI36059, AI03059, and
AI070010 and UCLA CFAR (AI28697)
Effects of Nicotine on the Water Maze Performance
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1,
JC a o
3,MK a s s
2,DK r o n e r
1,M DL i
3,S LC h a n g
2;
1Department of Psychology, Seton Hall University, South
Orange, NJ 07079-0000,
2Institute of Neuroimmune Pharma-
cology, Seton Hall University, South Orange, NJ 07079-
0000,
3Dept. of Psychiatry and Neurobehavioral Sciences,
University of Virginia, Charlottesville, VA 22908-0000
Previous studies have demonstrated that HIV-1 transgenic
(HIV-1 Tg) rats show a deficit in learning to locate a
submerged platform in a multiple-trial water maze task
compared to control rats (Vigorito et al. 2008; Lashomb et
al. 2009). The purpose of this study was to determine if the
learning deficit in HIV-1 Tg rats is also observed in a single-
trial-per-day procedure and to investigate the effects of
nicotine on maze performance. We found that the learning
deficit in HIV-1 Tg rats is also observed in a single-trial-per-
day procedure and that daily nicotine (1.0 mg/kg) treatment
disrupted performance of both HIV-1 Tg and F344 control
rats. In addition, we found that nicotine reduced the memory
for the location of the platform in both groups as determined
by a probe test trial at the end of 14 days of training.
Additional tests with the F344 control animals showed that
7 days of pretreatment with nicotine eliminates the disruptive
effects of nicotine during training. Moreover, the lowest of
four tested nicotine doses (0.125, 0.25. 0.5, and 1.0 mg/kg)
improved performance in F344 rats, although this effect was
not observed consistently. Nicotine treatment is known to
have neuroprotective effects and has been observed to
improve performance in a variety of learning tasks. The
effects of nicotine in a HIV-1 Tg rat model will be instructive
in elucidating the learning deficits resulting from the presence
of HIV-1 viral proteins and in defining the genes and
biological pathways associated with those effects. Supported
by NIH DA-026356
Morphine Modulates Dendritic Cell Interleukin 23
Production Through TLR2 and NOD-2 Synergistic
Signaling. J Wang
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IL-23, produced by dendritic cells and macrophages, plays
a critical role in innate immunity against bacterial infection.
To determine the mechanism by which morphine modulates
IL-23 production, bone marrow-derived dendritic cells
(BMDCs) and macrophages (BMDMs) were treated with
morphine and infected with Streptococcus pneumoniae or
stimulated with toll-like receptor (TLR) ligands (pneumo-
lysin, LTA, CpG) and Nod2 ligand (MDP). We found that
an increase in IL-23 protein production was observed in S.
pneumoniae-, LTA-, and PLY-stimulated BMDCs and
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BMDCs secreted approximately 5-fold more IL-23. Mor-
phine treatment significantly inhibited the IL-23 promoter
activity, mRNA expression, and protein production in S.
pneumoniae-infected DCs. Interestingly, LTA in synergy
with MDP induced the same level of IL-23 production as S.
pneumoniae infection, suggesting that IL-23 production in
DCs is through the activation of TLR2 and Nod-2
synergistic signaling. Pretreatment of DCs with MyD88
and IL-1 receptor-associated kinase (IRAK) 1/4 inhibitors
or TLR-2 antibody diminished the S. pneumoniae-induced
IL-23 and abolished morphine inhibitory effects, indicating
that the IL-23 production induced by S. pneumoniae
infection is a downstream event that depends on the
activations of TLR2-MyD88-IRAK1/4 signaling pathway.
Moreover, morphine decreased S. pneumoniae-induced
phosphorylation of IRF3 and ATF2 in DCs. Our study
shows that morphine impairs S. pneumoniae-induced IL-23
production through MyD88-IRAK1/4-dependent TLR2 and
Nod-2 synergistic signaling in DCs. Supported by R03
DA023353 (J. Wang) and R01 DA12104 and K02
DA015349, P50 DA11806 (S. Roy)
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Opioids have a cofactor role in the immunopathogenesis of
HIV disease. However, the mechanism(s) of their actions
remains to be determined. We thus investigated whether
heroin, one of the most widely abused drugs, inhibits
intracellular innate immunity in human blood monocyte-
derived macrophages and facilitates HIV infection/replica-
tion. Heroin treatment was found to suppress the expression
of endogenous IFN-alpha and IFN-beta in macrophages. In
addition, heroin treatment of macrophages impairs the
expression of anti-HIV miRNAs and APOBEC3G, the
newly identified intracellular restriction factors of HIV
replication. The in vitro impact of heroin on the miRNA
expression was supported by the in vivo observation that
the heroin-dependant subjects had significantly lower levels
of anti-HIV miRNAs in macrophages than the normal
subjects. These findings were in parallel with the observa-
tion that heroin treatment enhanced HIV infection of
macrophages. These in vitro and in vivo data indicate that
heroin use impairs intracellular innate anti-HIV mecha-
nisms in macrophages, promoting HIV infection and
replication. Supported by NIH DA12815, DA22177to Dr.
Wenzhe Ho; P30DA13429 to Dr. Martin W. Adler
NMR Metabolic Changes of Human Microglial Cells
Exposed to Lipopolysaccharide or Morphine. GL Wilcox
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Microglial cells play a major role in host defense of the
central nervous system. Once activated, several functional
properties are up-regulated, including migration, phagocy-
tosis, and secretion of inflammatory mediators such as
cytokines and chemokines. Little, if anything, is known
about the metabolic changes that occur during the activa-
tion process. High-resolution
1H nuclear magnetic reso-
nance (NMR) spectra obtained from perchloric acid (PCA)
extracts of human microglial cell cultures exposed to
lipopolysaccharide (LPS) or morphine were used to both
identify and quantify the metabolites. We found that human
microglia exposed to LPS had increased concentrations of
glutamate and lactate, whereas the cells exposed to
morphine had decreased concentrations in creatinine,
taurine, and thymine. Glutamate and creatinine were the
key metabolites differentiating between the two stimuli.
Interestingly, in light of recent data indicating activation of
rodent microglia in situ by morphine, neither the classic
indicators of microglial activation, cytokines, and chemo-
kines nor glutamate, which may be a novel indicator, was
increased by ex vivo treatment of human microglia with
morphine. These results add a new dimension to the
detection of activation in the inflammatory response of
human microglial cells to LPS and morphine. Supported by
Minnesota Medical Foundation, NIH R01 DA 04381 and
Minnesota Supercomputer Institute
IFNβ-Modulating miRNAs in Lentivirus-Associated CNS
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Interferon beta (IFNβ) production is an early innate
immune response to lentiviral infection of the CNS. In
our rapid and consistent SIV/macaque model of HIV
encephalitis, SIVenters the CNS within 4 days of infection,
accompanied by a marked IFNβ response. IFNβ levels
then decline when SIV enters its latent phase. The critical
role of IFNβ in the CNS antiviral response, combined with
the potential for inflammatory damage associated with
long-term activation, suggests that IFNβ is subject to
multiple levels of regulation. Adding to known regulatory
mechanisms, we present evidence that IFNβ expression
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NAs). We identified miRNAs with potential recognition
elements in the 3 UTR of the IFNβ transcript using target
recognition algorithms. Three macrophage-expressed miR-
NAs,-26a,-34a, and let-7b appear to exert direct effects on
the IFNβ 3 UTR in reporter assays and to modulate the
levels of IFNβ protein in primary macrophages, while miR-
145 may have indirect effects. In vivo relevance is
supported by differential expression of these miRNAs
during the course of SIV infection and by IFNβ-mediated
upregulation of several IFNβ-targeting miRNAs. We
further describe the localization of miRNAs and IFNβ
mRNA in macrophages/microglia, astrocytes, and neurons
during SIV infection, discussing the implications of these
expression patterns for miRNA-mediated control of IFNβ.
Our results suggest the regulation of IFNβ by miRNAs and
show that miRNAs may influence HIV-associated CNS
disease progression. Supported by NIH/NS055648
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Occurrenceofcollapsingvariantofglomerulosclerosisbothin
HIV-1 transgenic mice and in HIV-associated nephropathy
(HIVAN) patients highlighted the role of podocytes in the
development of HIVAN. In vitro studies showed that
conditionally immortalized human podocytes (CIHPs) inter-
nalized the primary R5 and X4 HIV-1 strains (JASN, 09). We
have shown that DC-specific ICAM-3-grabbing non-integrin
(DC SIGN) receptor is expressed in CIHPs and mediates the
binding and the entry of HIV-1. The immunochemical studies
in human renal tissue showed the podocyte expression of DC-
SIGN receptors. Drug abuse being an important risk factor in
the development of HIVAN, we asked whether use of cocaine
(Coc) or morphine (Mor) contributes to the entry of HIV-1
intopodocytes.CIHPs were treated in the presenceorabsence
of morphine or cocaine for variable time periods followed by
mRNA isolation and proteins for probing for DC-SIGN. Viral
assay by RT-PCR was done on Mor- and Coc-pretreated
CIHPs incubated with HIV-1 for variable time periods. Drug-
stimulatedCIHPsshowedenhancedDC-SIGNgeneaswellas
protein expression when compared to control cells. Since
drug-stimulated CIHPs showed increased levels of HIV-1-
specificstrong-stopDNAlevels,itappearsthatdrug-mediated
up-regulation of DC-SIGN resulted in the increased internal-
ization of R5 and X4 HIV-1 strains. These findings suggest
that Mor and Coc may act as cofactors in HIVAN by
increasing DC-SIGN expression on human podocytes. A
better understanding of the role of DC-SIGN will help design
novel therapeutic strategies to combat HIVAN.
Cocaine Abuse and HIV-1 Infection: Role of PDGF/
PDGF Receptor Axis in Disruption of Blood–Brain
Barrier. HH Yao
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Cocaine, often abused by HIV-infected patients, has been
suggested to worsen HIV-associated neurological disorders
(HAND) via unknown mechanisms. Blood–brain barrier
(BBB) is critical for the maintenance of CNS homeostasis
and for the regulation of the neural microenvironment. In HIV
disease, however, disruption of this barrier is what leads to the
entry of HIV-infected monocytes into the CNS. In this study,
we demonstrated up-regulation of PDGF-β in monocytes
infected with HIVor exposed to cocaine. Reciprocally, we also
found that exposure of human brain microvascular endothelial
cells (HBMEC) to cocaine resulted in the phosphorylation of
the PDGF-β receptor. Furthermore, PDGF-βR activation was
associated with increased endothelial permeability. Addition-
ally, we have also shown that both exogenous PDGF as well
as cocaine can disrupt the integrity of the BBB in a tissue
culture model, with alterations in expression of tight junction
and adhesion proteins. Dissection of signaling pathways in
PDGF and in cocaine-mediated activation of PDGF-βRi n
HBMECs has implicated the roles of MAPK and FAK/Rho/
PKC kinases. Exposure of mice to either of these agents
resulted in increased BBB permeability and transmigration, as
evidenced by Evans blue extravasation and monocyte
migration assays, respectively. Furthermore, PDGF-βRi n -
hibitor, iminitab was able to abrogate cocaine/PDGF-mediat-
ed enhancement of BBB permeability and transmigration in
vivo. Taken together these findings underpin the role of
PDGF-βR as a potential target in the therapeutical interven-
tion of HAND. Supported by RO1 DA020392, RO1
DA027729
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1,XW a n g
1,J LL i
1,J P
Liu
1,W ZH o
1;
1Department of Pathology and Laboratory
Medicine, Temple University School of Medicine,
Philadelphia, PA 19140-0000
Transmembrane protein tetherin (BST-2, CD317) was
recently discovered as a novel component of the innate
defense against enveloped viruses. Tetherin is an unusu-
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virions from infected cells. This study investigated
whether tetherin has the ability to inhibit hepatitis C
virus (HCV) release from infected human hepatocytes,
impairing HCV infection. Tetherin was found in very low
abundance in primary human hepatocytes and hepatocyte
cell line (Huh 7). Expression of exogenous tetherin in
human hepatocytes, however, did not inhibit HCV release
as it did not affect the levels of intracellular or
extracellular HCV RNA as well as the production of
infectious HCV. Although the exogenous interferon-alpha
treatment could greatly increase tetherin expression by
human hepatocytes, the induced endogenous tetherin had
no role in the anti-HCV activity of interferon-alpha.
These findings do not support the presence of an
association between tetherin and HCV replication/release
in/from human hepatocytes. Supported by National
Institutes of Health grant DA22177
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Tobacco smoking prevalence in the HIV-positive popula-
tion is profoundly higher than that in the non-HIV
population. The current study explored potential neuro-
behavioral mechanisms through which HIV-positive indi-
viduals show increased vulnerability to nicotine
dependence. Rats received bilateral microinjections of
Tat1-86 (50 μg/side) or vehicle directed at ventral tegmen-
tal area (VTA). Subsequently, 24 h after Tat injection, rats
were injected intravenously with nicotine (0.05 mg/kg) or
saline once daily for a total of 14 days. Locomotor activity
was measured every other day in automated chambers for
60 min following nicotine or saline injections. In saline
group, intra-VTA Tat diminished locomotor activity across
treatment days compared to the vehicle injection. Repeated
nicotine administration produced behavioral sensitization
with ∼3-fold higher levels of total activity. Tat attenuated
the locomotor sensitization observed with nicotine admin-
istration alone. Since the transcription factor cyclic AMP-
response element binding protein (CREB) plays a critical
role in rewarding properties of nicotine, we also investigat-
ed whether the phosphorylated form of the CREB (pCREB)
in mesocorticolimbic areas of these rats was changed after
the last nicotine or saline injection. In vehicle group,
pCREB was reduced in prefrontal cortex (PFC) but
increased in nucleus accumbens (Nac) and VTA following
repeated nicotine administration. In contrast, intra-VTA Tat
enhanced the basal levels of pCREB and blocked the
effects of nicotine on CREB phosphorylation in these brain
regions. Supported by NIH/NIDA DA026721
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Dopamine (DA) transporter (DAT) function is strikingly
altered in patients with HIV-1-associated neurocognitive
disorders and a history of chronic drug abuse. The current
study investigated the mechanisms underlying the inhibito-
ry effects of the HIV-1 protein Tat on DAT function.
Kinetic analysis of [
3H]DA uptake and [
3H]WIN35,428
binding in HEK293 cells expressing human DAT revealed
that Tat decreased Vmax and increased the apparent Km in a
concentration-dependent manner. The potency of Tat for
inhibiting [
3H]DA uptake (IC50=3.2 µM) was 4-fold less
than that for inhibiting [
3H]WIN 35,428 binding. In
addition, indatraline and cocaine, two competitive inhib-
itors at DAT, and SoRI-20041, a novel allosteric modulator
of the DAT, were examined. Cocaine-induced inhibition of
[
3H]DA uptake was determined in the presence and absence
of Tat or these drugs. Indatraline (10 nM) decreased
specific [
3H]DA uptake by 33% of the control and
increased the IC50 value of cocaine from 0.52 to 2.0 µM.
SoRI-20041(12.8 µM) reduced specific [
3H]DA uptake to
30% of control and changed the IC50 value of cocaine to
0.71 µM. Tat protein (5 µM) reduced specific [
3H]DA
uptake to 45% of the control and produced a smaller
increase in the IC50 value of cocaine (from 0.52 to
0.95 µM) than did indatraline. Taken together, these results
indicate that the Tat protein may act as an allosteric
modulator of DAT. Such allosterism could represent a
novel therapeutic potential and underlie a neurobiological
mechanism of dysfunction of DAT reported in patients with
HIV infection. Supported by DA026721, HD043680 and
DA013137
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Dendritic cells (DC) are an important reservoir for HIVand
play an essential role in HIV infection of activated T cells.
T cell activation also promotes important changes in
S58 J Neuroimmune Pharmacol (2010) 5 (Suppl 1):S3–S59proliferation and cytokine/chemokine production, which also
may enhance HIV infection. Many of these events are
modulated by cocaine, suggesting a variety of potential
mechanisms by which cocaine could synergize with the
process of DC Ag presentation to enhance HIV infection.
Using in vitro adenoviral and MLR antigen presentation
assays, we determined that both control and cocaine-exposed
DC induced HIV infection in responding T cells. The
frequency and magnitude of HIV infection was, however,
enhancedfollowingexposureofTcellstococaine-treatedDC.
In order to determine the mechanisms underlying these
effects, we used receptor antagonists and/or blocking anti-
bodies to relevant co-stimulatory molecules. We found that
blocking the HIV entry pathway with the HIV co-receptor
(CXCR4) antagonistorinterferingwithDC:Tcellinteractions
(using neutralizing antibodies to CD86/β2M) significantly
decreased HIV infection in DC:T cell co-cultures (±cocaine).
Additionally, co-administration of dopamine or sigma-1
receptor antagonists diminished cocaine-mediated effects on
HIV replication, suggesting that the effects of cocaine are
mediatedinpartbybothdopamineandsigma-1receptors.Our
studies suggest that cocaine influences the immune response
to HIV by impacting the phenotype and function of human
DC, the characteristics of DC-activated T cells, and their
subsequentsusceptibilitytoHIVinfection.SupportedbyNIH/
NIDA R01DA023386
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